 
S A V [ADDRESS_1117063]  N a m e:  A e r o V a n c ( v a n c o m y ci n  h y d r o c hl o ri d e 
i n h al ati o n  p o w d e r), 3 0  m g  t wi c e  d ail y ( B I D) 
I n di c ati o n:  M et hi cilli n -r esi st a nt  St a p h yl o c o c c us  a ur e us  l u n g i nf e cti o n i n  p ati e nts  wit h  c ysti c fi b r osis 
P h as e:  III  
S p o ns o r:  S a v a r a I n c.  
6 8 3 6  B e e  C a v es  R d.,  B uil di n g III  
S uit e  2 0 0 A usti n,  T X  7 8 7 4 6  
D at e  of  P r ot o c ol : 1 8 -A p r -2 0 1 8  
S a v a r a  D o c u m e nt  N u m b e r:  D -0 2 7  
V e rsi o n : [ADDRESS_1117064] u d y  w h o  h a v e  a n e e d t o  k n o w,  wit h t h e  o bli g ati o n  n ot t o f u rt h e r  diss e mi n at e t his i nf o r m ati o n.  
  
Jessica Jackson 
I am the author of this document2018.05.03 16:11:50 -05'00'
Cecilia Ganslandt 
I am approving this document 2018.05.04 07:25:37 +02'00'
Taneli Jouhikainen 
I am approving this document2018.05.04 14:55:31 -05'00'
S a v ar a  P h ar m a c e uti c al s  
Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  3 P R O T O C O L  A G R E E M E N T  
A m e n d m e nt  # [ADDRESS_1117065] es  a n d t o  a bi d e  b y t h e t er ms  of t his  pr ot o c ol. 
P r ot o c ol  N u m b e r:   S A V 0 0 5 -0 4  
P r ot o c ol  Titl e:   A  P h as e III, r a n d o mi z e d,  d o u bl e -bli n d,  pl a c e b o -c o ntr oll e d st u d y  of  A er o V a n c f or t h e 
tr e at m e nt  of  p ersist e nt  m et hi cilli n-r esist a nt St a p h yl o c o c c us  a ur e us  l u n g i nf e cti o n i n  c ysti c fi br osis 
p ati e nts  
Pr ot o c ol  D at e:   1 8 -A pr -2 0 1 8  
 
    
I n v esti g at or  Si g n at ur e    D at e  
 
Pri nt  N a m e  a n d  Titl e  
 
Sit e  #    
PI  N a m e    
Sit e  N a m e    A d dr ess    
  
  
  
P h o n e  N u m b er    
 
  
S a v ar a  P h ar m a c e uti c al s  
Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  4 S Y N O P SI S  
Titl e:  A  P h as e III, r a n d o mi z e d,  d o u bl e -bli n d,  pl a c e b o -c o ntr oll e d st u d y  of  A er o V a n c f or t h e tr e at m e nt  of  p ersist e nt  m et hi cilli n-r esi st a nt St a p h yl o c o c c us  a ur e us  l u n g i nf e cti o n i n  c ysti c fi br osis  p ati e nt s 
St u d y  D r u g:   A er o V a n c ( v a n c o m y ci n  h y dr o c hl ori d e i n h al ati o n  p o w d er),  [ADDRESS_1117066] u d y 
C e nt e rs:  A p pr o xi m at el y  8 5  
P h as e:  III 
N u m b e r  of  S u bj e cts:    2 0 0 s u bj e cts ( 1 5 0 s u bj e cts  ≤  [ADDRESS_1117067] s  >  2 1  y e ars  ol d)  
 
C o o r di n ati n g I n v esti g at o r: P atri c k  Fl u m e,  M D  
St u d y  D esi g n:   R a n d o mi z e d,  m ulti c e nt er,  d o u bl e -bli n d,  pl a c e b o -c o ntr oll e d,  p ar all el -gr o u p 
st u d y t o  e x a mi n e t h e s af et y  a n d  effi c a c y  of  A er o V a n c i n t h e tr e at m e nt  of 
p ersist e nt  M et hi cilli n r esi st a nt  St a p h yl o c o c c us  a ur e us  (M R S A ) l u n g i nf e cti o n 
i n  p ati e nt s  di a g n os e d  wit h  c ysti c fi br osis ( C F). 
Aft er  t h e  Scr e e ni n g  p eri o d ( u p t o  4 2  d a ys)  t o  c o nfir m st u d y  eli gi bilit y, s u bj e cts 
will  b e  r a n d o ml y  assi g n e d i n  a  bli n d e d f as hi o n t o r e c ei v e  eit h er  A er o V a n c  30 
m g t wi c e  d ail y ( BI D ),  or  pl a c e b o BI D  ( 1: [ADDRESS_1117068] a c e b o)  b y i n h al ati o n f or 
2 4  w e e ks  or  3  d osi n g  c y cl es ( P eri o d  1).  U p o n  c o m pl eti o n  of  P eri o d  1, s u bj e cts will r e c ei v e  o p e n -l a b el  A er o V a n c  30  m g  BI D  f or  a n  a d diti o n al  2 4  w e e ks  or 
3  d osi n g  c y cl es ( P eri o d  2), t o  e v al u at e l o n g -t er m s af et y  of  A er o V a n c.  
A  d osi n g  c y cl e is  d efi n e d  as  2 8  d a ys  of tr e at m e nt f oll o w e d  b y  2 8  d a ys  of 
o bs er v ati o n.  S u bj e cts  m e eti n g t h e i n cl usi o n /  e x cl usi o n  crit eri a  will  b e str atifi e d u p o n r a n d o mi z ati o n  o n t h e  b asi s  of  ( a) a g e ( 6 – 2 1 ; >  2 1 ), ( b) B as eli n e  F E V
1 
( ≥ 6 0 %;  < 6 0 %), (c)  pri or  e x a c er b ati o ns tr e at e d  wit h  a nti bi oti cs  d uri n g t h e 
pr e vi o us  1 2  m o nt hs ( 1 -2;  ≥  3)  a n d ( d)  P.  a er u gi n os a  tr e at m e nt (n ot tr e at e d; 
tr e at e d).  
S u bj e cts  o n  a  2 8 -d a y  c y cli c al  o n/ off  a nti -Ps e u d o m o n al  a nti bi oti c r e gi m e n  will 
e nt er t h e  S cr e e ni n g  p eri o d  at  a ti m e s u c h t h at t h e  B as eli n e  visit  c oi n ci d es  wit h 
t h e  e n d  of t h eir  a nti-Ps e u d o m o n as  a nti bi oti c  c y cl e.  St u d y  dr u g  will t h er e b y  b e 
a d mi nist er e d  d uri n g t h e  off -c y cl e,  a n d s u bj e ct s  c a n t h e n r es u m e  a nti -
Ps e u d o m o n al t h er a p y  d uri n g t h e  2 8 -d a y  o bs er v ati o n  p eri o d ( W e e k  5 t hr o u g h 
W e e k  8).  S u bj e ct s  c o nti n ui n g  alt er n ati n g  a nti -Ps e u d o m o n al t h er a p y  c a n 
c o nti n u e t h eir tr e at m e nt  d uri n g t h e st u d y  dr u g  a d mi nistr ati o n,  a n d  o bs er v ati o n 
p eri o d.   
S a v ar a  P h ar m a c e uti c al s  
Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  5  
2 0 0 s u bj e cts ( 1 5 0 s u bj e cts  ≤  [ADDRESS_1117069] s  >  2 1  y e ars  ol d)  
T r e at m e nt:   A er o V a n c is  a  p o w d er f or m  of  v a n c o m y ci n,  d eli v er e d  usi n g  a r el o a d a bl e 
c a ps ul e i n h al er.  T h e i n h al ati o n  p o w d er is  p a c k a g e d i nt o  c a ps ul es  wit h  e a c h 
c a ps ul e  c o nt ai ni n g  1 5  m g  of  v a n c o m y ci n.  T h e  d os e is  A er o V a n c  3 0  m g 
( 2 c a ps ul es)  BI D .  Alt er n ati v el y,  a s u bj e ct  m a y  b e r a n d o mi z e d t o r e c ei v e  a 
m at c hi n g  pl a c e b o,  wit h  e q ui v al e nt  n u m b ers  of  c a ps ul es.   
St u d y  D u r ati o n:  T h e  d ur ati o n  of st u d y  p arti ci p ati o n f or  e a c h s u bj e ct is  5 0 -5 4  w e e ks:  
-  S cr e e ni n g  p eri o d,  u p t o  4 2  d a ys  -  P eri o d  1,  D o u bl e -bli n d ( [ADDRESS_1117070] a c e b o  BI D) f or  3  c y cl es 
or  2 4  w e e ks   
-  P eri o d  2,  O p e n -l a b el ( 3 0  m g  A er o V a n c  BI D) f or  [ADDRESS_1117071] u d y  P o p ul ati o n:
 I n cl usi o n  C rit e ri a  
1.   S u bj e cts  ≥  6  y e ars  of  a g e  at ti m e  of I nf or m e d  C o ns e nt  F or m (I C F)  or 
Ass e nt  F or m si g ni n g.   
2.   C o nfir m e d  di a g n osis  of  C F,  d et er mi n e d  b y  h a vi n g  cli ni c al f e at ur es 
c o nsi st e nt  wit h t h e  C F  p h e n ot y p e,  pl us  o n e  of t h e f oll o wi n g:  
a.   P ositi v e s w e at  c hl ori d e t est ( v al u e  ≥   60  m E q/ L),   b.   G e n ot y p e  wit h  [ADDRESS_1117072] e nt  wit h  C F (i . e.,  a  m ut ati o n 
i n  e a c h  of t h e  c ysti c fi br osis tr a ns m e m br a n e  c o n d u ct a n c e 
r e g ul at or [ C F T R]  g e n es). 
3.   P ositi v e s p ut u m  c ult ur e  or  a t hr o at s w a b  c ult ur e f or  M R S A  at 
S cr e e ni n g.   
4.   I n  a d diti o n t o t h e  S cr e e ni ng s a m pl e,  h a v e  at l e ast  [ADDRESS_1117073]  5 0 %  of  all  M R S A 
c ult ur es (s p ut u m  or t hr o at s w a b  c ult ur e)  c oll e ct e d  fr o m t h e ti m e  of t h e 
first  p ositi v e c ult ur e  (i n t h e  pr e vi o us  1  y e ar) m ust  h a v e t est e d  p ositi v e 
f or  M R S A. ( N ot e:  S cr e e ni n g  s a m pl e  m a y  c o u nt t o w ar ds  5 0 %  p ositi v e c o u nt)  
5.   F or c e d  e x pir at or y  v ol u m e i n  1 s e c o n d ( F E V
1)  ≥ 3 0 %  a n d  ≤  9 0 %  of 
pr e di ct e d t h at is  n or m al f or  a g e,  g e n d er, r a c e,  a n d  h ei g ht,  usi n g t h e Gl o b al  L u n g  F u n cti o n I niti ati v e ( G LI)  e q u ati o n.  
6.   At l e ast  1  e pis o d e  of  a c ut e  p ul m o n ar y i nf e cti o n tr e at e d  wit h  n o n -
m ai nt e n a n c e  a nti bi oti cs  wit hi n  1 2  m o nt hs  pri or t o t h e  B as eli n e  vi sit. (I niti ati o n  of tr e at m e nt  wit h i nt er mitt e nt i n h al e d a nti -Ps e u d o m o n al t h er a p y  will  n ot  q u alif y  as tr e at m e nt  wit h  n o n-m ai nt e n a n c e  a nti bi oti cs).  
S a v ar a  P h ar m a c e uti c al s  
Pr ot o c ol  S A V [ADDRESS_1117074] u d y  P o p ul ati o n:   I n cl usi o n  C rit e ri a  ( c o nt) 
7.   If f e m al e  of  c hil d b e ari n g  p ot e nti al,  a n  a c c e pt a bl e  m et h o d  of 
c o ntr a c e pti o n  m ust  b e  us e d  d uri n g  t h e st u d y  a n d  m ust  b e  c o m bi n e d 
wit h  a  n e g ati v e  pr e g n a n c y t est  o bt ai n e d  d uri n g  S cr e e ni n g;  s e xu all y 
a cti v e  m al e s u bj e ct s  of r e pr o d u cti v e  p ot e nti al  w h o  ar e  n o n -st eril e (i. e., 
m al e  w h o  h as  n ot  b e e n st erili z e d  b y  v as e ct o m y f or  at l e ast  [ADDRESS_1117075] e  a n d/ or  a bs e n c e  of  v as  d ef er e ns t hr o u g h 
ultr as o u n d )  m ust  b e  willi n g t o  us e  a b arri er  m et h o d  of  c o ntr a c e pti o n ,  or 
t h eir f e m al e p art n er  m ust  us e  a n  a c c e pt a bl e  m et h o d  of  c o ntr a c e pti o n , 
d uri n g  t h e st u d y. 
F or  p ur p os es  of t his  st u d y, t h e  S p o ns or  d efi n es  “ a c c e pt a bl e  m et h o ds  of c o ntr a c e pti o n ”  as:  
a.   Or al  birt h  c o ntr ol  pi[INVESTIGATOR_3353]  a d mi nist er e d f or  at l e ast  [ADDRESS_1117076] a nt e d r o d ( e g, I m pl a n o n
®) f or  at l e ast 
[ADDRESS_1117077] u g  a d mi nistr ati o n  b ut  n ot 
b e y o n d t h e  4t h s u c c essi v e  y e ar f oll o wi n g i ns erti o n . 
c.   I ntr a ut eri n e  d e vi c es (I U Ds), i ns ert e d  b y  a  q u alifi e d  cli ni ci a n f or 
at l e ast  [ADDRESS_1117078] er o n e a c et at e ( e g,  D e p o -Pr o v er a®) a d mi nist er e d 
f or  a  mi ni m u m  of  [ADDRESS_1117079] erili z ati o n.  
f.  A bsti n e n c e.  g.   D o u bl e  b arri er  m et h o d ( di a p hr a g m  wit h s p er mi ci d al  g el  or 
c o n d o ms  wit h  c o ntr a c e pti v e f o a m).  
N O T E :  F or s u bj e cts  pr es cri b e d  Or k a m bi:  Or k a m bi  m a y s u bst a nti all y d e cr e as e  h or m o n al  c o ntr a c e pti v e  e x p os ur e, r e d u ci n g t h e  eff e cti v e n ess a n d i n cr e asi n g t h e i n ci d e n c e  of  m e nstr u ati o n -ass o ci at e d  a d v ers e r e a cti o ns.  H or m o n al  c o ntr a c e pti v es, i n cl u di n g  or al, i nj e ct a bl e, 
tr a ns d er m al,  a n d i m pl a nt a bl e, s h o ul d  n ot  b e r eli e d  u p o n  as  a n  eff e cti v e 
m et h o d  of  c o ntr a c e pti o n  w h e n  c o -a d m i ni st er e d  wit h  Or k a m bi. 
 
8.   A bl e  a n d  willi n g t o  c o m pl y  wit h t h e  pr ot o c ol, i n cl u di n g  a v ail a bilit y f or 
all s c h e d ul e d st u d y  vi sits  a n d  a bl e t o  p erf or m  all t e c h ni q u es  n e c ess ar y t o  us e t h e  A er o V a n c i n h al er  a n d  m e as ur e l u n g f u n cti o n. 
9.   A gr e e  n ot t o s m o k e  d uri n g  a n y  p art  of t h e  cli ni c al tri al ( S cr e e ni n g  vi sit 
t hr o u g h  e n d  of st u d y). 
[ADDRESS_1117080] a bl e  d es pit e t h e l a c k  of s u c h tr e at m e nt.  
S a v ar a  P h ar m a c e uti c al s  
Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  7  E x cl usi o n  C rit e ri a  
1.   Us e  of  a nti -M R S A tr e at m e nts  pr es cri b e d  as  m ai nt e n a n c e t h er a p y 
(i ntr a v e n o us [I V]  or i n h al e d tr e at m e nt  wit hi n  2 8  d a ys;  or al tr e at m e nt wit hi n  1 4  d a ys)  pri or t o t h e  B as eli n e  visit.     
2.   Us e  of  n o n -m ai nt e n a n c e  a nti bi oti c  f or  p ul m o n ar y i nf e cti o n  or 
e xtr a p ul m o n ar y  M R S A i nf e cti o n  (I V  or i n h al e d  a nti bi oti c  wit hi n  2 8 d a ys;  or al  a nti bi oti c  wit hi n  1 4  d a ys)  pri or t o t h e  B as eli n e  visit.     
3.   Hist or y  of  pr e vi o us  all er gi es  or s e nsiti vit y t o  v a n c o m y ci n,  or  ot h er 
c o m p o n e nt(s)  of t h e st u d y  dr u g  or  pl a c e b o  e x c e pt f or  a  hist or y  of r e d -m a n s y n dr o m e.  
4.   I n a bilit y t o t ol er at e i n h al e d  pr o d u cts. 
5.   First ti m e  s p ut u m  c ult ur e  or t hr o at s w a b  c ult ur e  yi el di n g  B.  c e p a ci a ,  or 
n o nt u b er c ul o us  M y c o b a ct eri a i n t h e  pr e vi o us  [ADDRESS_1117081] a n c e t o  v a n c o m y ci n  at  S cr e e ni n g ( v a n c o m y ci n r esi st a nt 
St a p h yl o c o c c us  a ur e us  [ V R S A],  or  v a n c o m y ci n i nt er m e di at e r esist a nt 
St a p h yl o c o c c us  a ur e us  [ VI S A],  wit h  mi ni m u m i n hi bit or y  c o n c e ntr ati o n [ MI C]  ≥ 8  µ g/ m L).  
8.   Or al  c orti c ost er oi ds i n  d os es  e x c e e di n g  [ADDRESS_1117082] or y  at 
S cr e e ni n g t h at, i n t h e I n v esti g at or's  o pi [INVESTIGATOR_9384] o n,  w o ul d  c o m pr o mis e t h e s af et y  of t h e s u bj e ct  or t h e  q u alit y  of t h e st u d y  d at a.  
[ADDRESS_1117083] 
1 2.  S p O
2 < 9 0 %  at  S cr e e ni n g.  
[ADDRESS_1117084] r es ult  d uri n g  S cr e e ni n g,  pr e g n a nt 
( or i nt e n ds t o  b e c o m e  pr e g n a nt), l a ct ati n g  or i nt e n ds t o  br e astf e e d 
d uri n g t h e st u d y.  
1 6.  R e n al i ns uffi ci e n c y,  d efi n e d  as  cr e ati ni n e  cl e ar a n c e  <  5 0  m L/ mi n  usi n g 
t h e  C o c k cr oft-G a ult  e q u ati o n f or  a d ults  or  S c h w art z  e q u ati o n f or 
c hil dr e n  at t h e  S cr e e ni n g  visit.  
1 7.  A b n or m al li v er f u n cti o n,  d efi n e d  as  ≥  4 x  u p p er li mit  of  n or m al ( U L N), 
of s er u m  as p art at e  a mi n otr a nsf er as e ( A S T)  or s er u m  al a ni n e a mi n otr a nsf er as e ( A L T),  or  k n o w n  cirr h osi s  at  S cr e e ni n g.  
 
S a v ar a  P h ar m a c e uti c al s  
Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  8  E x cl usi o n  C rit e ri a  ( C o nt.) 
[ADDRESS_1117085] or y  of  p ositi v e r es ult  f or  h u m a n i m m u n o d efi ci e n c y  vir us ( HI V), 
h e p atitis  B  vir us ( H B V)  or  h e p atiti s  C  vir us ( H C V).  
[ADDRESS_1117086] a n n e d  h os pit ali z ati o ns f or  pr o p h yl a xis  a nti bi oti c tr e at m e nt  wit hi n  2 8 
d a ys  pri or t o  B as eli n e  visit  or  d uri n g t h e  d o u bl e -bli n d  p eri o d ( P eri o d 
1).  
P ri m a r y  Effi c a c y 
E n d p oi nt:  T h e  pri m ar y  effi c a c y  e n d p oi nt is t h e  m e a n  a bs ol ut e  c h a n g e fr o m  b as eli n e i n F E V
[ADDRESS_1117087] e d.  T h e  e n d p oi nt  will  b e  a n al y z e d s e q u e nti all y  at  W e e k  4 
( e n d  of  C y cl e  1),  W e e k  1 2 ( e n d  of  C y cl e  2), a n d  at  W e e k  2 0 ( e n d  of  C y cl e  3) . 
•   If  A er o V a n c i s s u p eri or t o  pl a c e b o  aft er  C y cl e  1, t h e n t h e  m e a n  c h a n g e i n 
t h e  F E V [ADDRESS_1117088] e d  aft er  C y cl e  3  will  b e  a n al y z e d.  
•   T h e  pri m ar y  a n al ysis  will  b e  b as e d  o n t h e  I T T  p o p ul ati o n  of all  r a n d o mi z e d 
s u bj e cts ≤  2 1  y e ars  of  a g e .  
S e c o n d a r y  Effi c a c y E n d p oi nt s: T h e f oll o wi n g  p ar a m et ers  will  b e  a n al y z e d  as  s e c o n d ar y  effi c a c y  e n d p oi nts:  
•   T i m e t o first p ul m o n ar y  e x a c er b ati o n  r e q uiri n g us e  of  a n ot h er  a nti bi oti c 
m e di c ati o n ( or al,  I V, a n d/ or i n h al e d) .  
•   C h a n g e fr o m  B as eli n e i n t h e  C ysti c  Fi br osi s  Q u esti o n n air e -R e vis e d ( C F Q -
R) s c or es  at  W e e ks  4 ,  1 2, a n d  2 0.   
•   C h a n g e fr o m  B as eli n e i n t h e  C ysti c  Fi br osi s  R es pir at or y  S y m pt o m  Di ar y -
C hr o ni c  R es pir at or y  S y m pt o m  S c or e ( C F R S D -C RI S S)  s c or es  at  W e e ks  4,  
1 2,  a n d  2 0.  
•   R el ati v e  c h a n g e fr o m  B as eli n e i n  F E V
[ADDRESS_1117089] e d  at  W e e ks  4 ,  1 2, 
a n d  2 0.  
•   T h e  n u m b er  of s u c c essf ul r es p o ns e  c y cl es  a s u bj e ct  a c hi e v es  o v er  P eri o d  1  
( W e e ks 4,  1 2 , a n d  2 0) .  
If  a s u bj e ct  e x p eri e n c es a n  e x a c er b ati o n  a n d  c o n c o mit a nt  a nti bi oti c t h er a p y is  gi v e n, t h e s u bj e ct is  c o nsi d er e d  a f ail ur e i n t h at  c y cl e, b ut t h e 
f ail ur e  d o es  n ot  pr e cl u d e s u c c ess i n f ut ur e  c y cl es. 
N ot e:  A r es p o ns e i n  a  c y cl e i s  d efi n e d  b y  at l e ast  a  5  % r el ati v e 
i m pr o v e m e nt i n  F E V
[ADDRESS_1117090] e d  at t h e  e n d  of t h e r es p e cti v e 
c y cl e ( W e e k  4,  W e e k  1 2,  a n d  W e e k  2 0). If t h e r el ati v e  F E V 1 
i m pr o v e m e nt i s l ess t h a n  5  %, t h e s u bj e ct i s  c o nsi d er e d  a f ail ur e i n t h at 
c y cl e,  b ut t h e f ail ur e  d o es  n ot  pr e cl u d e s u c c ess i n f ut ur e  c y cl es.  
•   Fr e q u e n c y  of  p ul m o n ar y  e x a c er b ati o ns . 
•   Ar e a  u n d er t h e  F E V 1 –  ti m e  pr ofil e, i. e. t h e m e a n tr e at m e nt  diff er e n c e i n 
F E V [ADDRESS_1117091] o r at o r y Effi c a c y  E n d p oi nts:  •   C h a n g es fr o m  B as eli n e i n  E Q -5 D -5 L/ E Q -5 D y s c or es  at  W e e ks  4 ,  1 2, a n d 
2 0 . 
•   C h a n g e fr o m  B as eli n e i n  M R S A s p ut u m  d e nsit y  at  W e e ks  4 ,  1 2, a n d  2 0.  
•   C h a n g e fr o m  B as eli n e i n  b o d y  w ei g ht  at  W e e ks  8 ,  1 6, a n d  2 4.  
•   C h a n g e fr o m  B as eli n e i n  MI C f or  V a n c o m y ci n  a t  W e e ks  4,  1 2  a n d  2 0. 
•   E m er g e n c e  of  a d diti o n al  p at h o g e ns  i n s p ut u m. 
P h a r m a c o ki n eti cs:   P h ar m a c o ki n eti cs  will  b e st u di e d  as  a s u b -st u d y  of  a p pr o xi m at el y  [ADDRESS_1117092] e d  as  p er t h e  S c h e d ul e  of E v e nt s . 
S af et y:  S af et y  ass ess m e nts  will  b e  c o n d u ct e d  o n t h e s af et y  p o p ul ati o n (t h os e r e c ei vi n g at l e ast  [ADDRESS_1117093] u g)  i n cl u d e  a n al ysis  of  all  a d v ers e  e v e nts ( A Es),  as  w ell  as 
st a n d ar d  h e m at ol o g y,  bi o c h e mistr y,  a n d  uri n e  a n al ys es,  vit al si g ns,  p h ysi c al 
e x a mi n ati o n, s pir o m etr y,  p ul m o n ar y f u n cti o n t est s ( P F T)  a n d 
el e ctr o c ar di o gr a m ( E C G).  P ot e nti al  e m er g e n c e  of  a d diti o n al  p a t h o g e ns i n 
s p ut u m will  b e  ass ess e d . 
S a m pl e  Si z e   A t ot al  of  [ADDRESS_1117094] u d y ( [ADDRESS_1117095] s  ≤  2 1  y e ars 
ol d,  5 0 s u bj e cts  >  2 1  y e ars  ol d).  
T h e  pri m ar y  a n al ysis  p o p ul ati o n  will  b e t h e s u bj e cts  ≤  [ADDRESS_1117096] u g  A d mi nistr ati o n ( F D A ),  a 
diff er e n c e i n t h e  m e a n  a bs ol ut e  c h a n g e i n  F E V
[ADDRESS_1117097] e d  of  4. 3  %  a n d 
a r o ot  m e a n s q u ar e  d e vi ati o n  of  6. 3  %  w er e  o bs er v e d  b et w e e n t h e tr e at m e nt 
ar ms i n  s u bj e cts  <  [ADDRESS_1117098] e si z e  of  4 5 s u bj e cts  p er  ar m  w o ul d  pr o vi d e  8 9  %  p o w er t o  d et e ct  a st ati sti c all y si g nifi c a nt 
diff er e n c e  at  al p h a l e v el  of  0. [ADDRESS_1117099] o p  o uts  a n d/ or 
s m all er eff e ct si z e i n  a  3- c y cl e st u d y,  a s a m pl e si z e  of  [ADDRESS_1117100] et e d, w o ul d  pr o vi d e  9 0 %  p o w er t o  d et e ct  a 
diff er e n c e  of  3. 4 %  at  [ADDRESS_1117101] a n d ar d  d e vi ati o n  of  6. 3 %. 
I n a d diti o n,  a p pr o xi m at el y  [ADDRESS_1117102] atisti c al M et h o ds/ A n al ysis:   All st atisti c al  t esti n g  will  b e t w o-si d e d  a n d  will  b e  p erf or m e d  at t h e  0. [ADDRESS_1117103] a n d ar d d e vi ati o ns,  m e di a ns,  mi ni m u m s,  a n d  m a xi m u ms.  
 T h e f oll o wi n g  p o p ul ati o ns  will  b e  us e d f or  effi c a c y  a n al ys es:   
- T h e  I T T  p o p ul ati o n  will i n cl u d e  all r a n d o mi z e d s u bj e cts ≤  2 1  y e ars  of  a g e . 
- T h e  P er -Pr ot o c ol ( P P)  p o p ul ati o n  will i n cl u d e  s u bj e cts  ≤  [ADDRESS_1117104] a n ( S A P).  
S a v ar a  P h ar m a c e uti c al s  
Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  1 0 Effi c a c y  A n al ysis :  A n al ysis  of  P ri m a r y  a n d  S e c o n d a r y  E n d p oi nts   
Pri m ar y  a n d s e c o n d ar y  effi c a c y  a n al ys es, f or  w hi c h f ull  c o ntr ol  of  T y p e I  err or will  b e i m pl e m e nt e d,  will  b e  i n t h e gr o u p  of  p ati e nt s  w h o  ar e  ≤  [ADDRESS_1117105] e d.  T h e  e n d p oi nt  will  b e  a n al y z e d s e q u e nti all y  at  W e e k  4 
( e n d  of  C y cl e  1),  W e e k  1 2 ( e n d  of  C y cl e  2) a n d  at  W e e k  2 0 ( e n d  of  C y cl e  3). If 
a st atisti c all y si g nifi c a nt  diff er e n c e i s  o bs er v e d i n f a v or  of  A er o V a n c  c o m p ar e d 
t o  pl a c e b o  aft er  C y cl e  1, t h e n t h e  m e a n  c h a n g e i n t h e  F E V [ADDRESS_1117106]  a c hi e v es  o v er t h e  3 
c y cl es  of t h er a p y ( 0,  1,  2  or  3)  will  b e  c o m p ar e d  usi n g  a  pr o p orti o n al  o d ds m o d el f o r  or d er e d  c at e g ori es. 
Fr e q u e n c y  of  p ul m o n ar y  e x a c er b ati o ns  will  b e  c o m p ar e d  b et w e e n t h e  gr o u ps 
usi n g  a  n e g ati v e  bi n o mi al  m o d el f or  c o u nt  d at a,  a dj usti n g f or  e a c h  s u bj e ct’s 
l e n gt h  of f oll o w-u p.   T h e r a n d o mi z ati o n str atifi c ati o n f a ct ors  will  b e i n cl u d e d i n t h e  m o d el  as fi x e d  eff e cts. 
Ar e a  u n d er t h e  F E V
1– ti m e  pr ofil e  will  b e  a n al y z e d  usi n g  a n al ysi s  of  c o v ari a n c e 
i n cl u di n g t h e  p ati e nt’s  b as eli n e  F E V [ADDRESS_1117107] ors.  
T y p e I  err or r at e  will  b e  c o ntr oll e d  b y  a s e q u e nti al t esti n g  pr o c e d ur e.  
F or  p ati e nts  w h o  ar e  > [ADDRESS_1117108] e m  or g a n  cl ass es 
usi n g t h e  M e di c al  Di cti o n ar y f or  R e g ul at or y  A cti viti es ( M e d D R A).  T h e 
i n ci d e n c e  of  A Es ( e v er  h a vi n g)  a n d t h e fr e q u e n c y  of  A Es (t ot al  n u m b er) a n d 
9 5 %  c o nfi d e n c e i nt er v al s will  b e t a b ul at e d  b y tr e at m e nt  gr o u p, s yst e m  or g a n 
cl ass,  a n d  pr ef err e d t er m.  S eri o us  a d v ers e  e v e nts ( S A Es)  will  b e s u m m ari z e d i n a si mil ar f as hi o n.  A d v ers e  e v e nt s u m m ari es  b y s e v erit y  a n d r el ati o ns hi p t o 
st u d y  dr u g  will  als o  b e  pr o vi d e d.  T h e  A E s u m m ari es  will  b e  pr es e nt e d f or  all 
s u bj e cts  a n d  b y  t h e t w o a g e  gr o u p s. 
L a b or at or y  p ar a m et ers  will  b e s u m m ari z e d  usi n g  d es cri pti v e st atisti cs  at 
B as eli n e  a n d  at  e a c h  p ost - Bas eli n e  vi sit.  C h a n g es fr o m  B as eli n e  will  als o  b e 
s u m m ari z e d. I n  a d diti o n, s hift t a bl es ( i. e., l o w-n or m al -hi g h  at  B as eli n e  v ers us 
l o w-n or m al -hi g h  at  e a c h  p ost -b as eli n e  vi sit i n  a  3 -b y -3  c o nti n g e n c y t a bl e)  will 
b e  pr o vi d e d t o  ass ess  c h a n g es fr o m  B as eli n e i n l a b or at or y  v al u es.  
Vit al si g ns  will  b e s u m m ari z e d  usi n g  d es cri pti v e st ati sti cs  at  B as eli n e  a n d  at 
e a c h  p ost -B as eli n e  vi sit.  C h a n g es fr o m  B as eli n e  will  als o  b e s u m m ari z e d.  
El e ctr o c ar di o gr a m  p ar a m et ers  will  b e s u m m ari z e d  usi n g  d es cri pti v e st atisti cs  at 
B as eli n e  a n d  at  e a c h  p ost - Bas eli n e  vi sit  w h er e  a n  E C G  ass ess m e nt  w as  m a d e. C h a n g es fr o m  B as eli n e  will  als o  b e s u m m ari z e d. I n  a d diti o n, s hift t a bl es ( i. e., 
n or m al,  n ot  cli ni c all y si g nifi c a nt [ N C S],  cli ni c all y si g nifi c a nt [ C S])  at  B as eli n e v ers us  n or m al,  N C S,  C S  at  e a c h  p ost -b as eli n e  visit i n  a  3 -b y -3  c o nti n g e n c y 
t a bl e)  will  b e  pr o vi d e d t o  ass ess  c h a n g es fr o m  B as eli n e.  
 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117109] u g  at t h e  Sit e  ...................................................................................... 3 9  
       8. 5      D os a g e/ D os a g e  R e gi m e n  .................................................................................................[ADDRESS_1117110] or y  ........................................................................................................ 4 2 
9. 1. 4   P h ysi c al  E x a mi n ati o n  ............................................................................................... 4 2 
9. 1. 5   Vit al  Si g ns  ................................................................................................................ 4 2 
9. 1. 6   1 2 -l e a d  El e ctr o c ar di o gr a m ( E C G) ............................................................................ 4 2 
9. 1. 7   C F R S D -C RI S S  ......................................................................................................... 4 2 
9. 1. 8   C F Q - R ...................................................................................................................... 4 3 
9. 1. 9   E Q -5 D -5 L  &  E Q -[ADDRESS_1117111] s ( P F T)  .............................................................................. [ADDRESS_1117112]  ......................................................................................................... 4 5 
9. 2. 3   Uri n al ysis  ................................................................................................................. 4 5 
9. 3   P h ar m a c o ki n eti c  M e as ur e m e nts  ....................................................................................... 4 5  
9. 4   U ns c h e d ul e d  Visit(s)  ........................................................................................................ [ADDRESS_1117113] u d y  Tr e at m e nt  ...................................................................................... 4 7  
1 2. 4   S eri o us  A d v ers e  E v e nts ( S A E)  ........................................................................................ [ADDRESS_1117114] e d  S eri o us  A d v ers e  R e a cti o ns ( S U S A Rs)  ........................................ [ADDRESS_1117115] eri sti cs  ...................................................................... 5 2  
1 6. 3   A n al ysi s  of  Pri m ar y  E n d p oi nt  .......................................................................................... 5 2  
1 6. 4   A n al ysi s  of  S e c o n d ar y  E n d p oi nts  .................................................................................... 5 2  
1 6. 5   M ulti pli cit y /  C o ntr ol  of  T y p e I  err or r at e  ........................................................................ [ADDRESS_1117116]  C o nfi d e nti alit y  .................................................................................................... 5 6  
1 8   A D MI N I S T R A TI V E,  E T HI C A L,  R E G U L A T O R Y  C O N S I D E R A TI O N S  5 6 
1 8. 1   P rot o c ol  A m e n d m e nts  ...................................................................................................... 5 6  
1 8. 2   I nstit uti o n al  R e vi e w B o ar ds  a n d I n d e p e n d e nt  Et hi cs  C o m mitt e es  ................................... 5 6  
1 8. 3   I nf or m e d  C o ns e nt  F or m ................................................................................................... 5 7  
1 8. 4   P u bli c ati o ns ...................................................................................................................... 5 7  
1 8. 5   I n v esti g at or  R es p o nsi biliti es ............................................................................................ 5 7  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  1 5 1 9.  R E F E R E N C E S  5 9  
A P P E N DI X  1.  S C H E D U L E  O F  E V E N T S  6 0  
A P P E N DI X  2.  B L O O D  V O L U M E  C A L C U L A TI O N  6 1  
A P P E N DI X  3.  C Y S TI C  F I B R O SI S  R E S P I R A T O R Y  S Y M P T O M  DI A R Y ( C F R S D ©)  S E L F -R E P O R T  – 
W E E K L Y  V E R S I O N  2. 0 6 2  
A P P E N DI X  4.  C Y S TI C  F I B R O SI S  Q U E S TI O N N AI R E  - R E VI S E D ( C F Q -R)  S E L F -R E P O R T  –  T W O 
W E E K  R E C A L L;  V E R SI O N   2 6 9  
A P P E N DI X  5.  E Q -5 D -5 L  &  E Q -5 D Y  7 6  
A P P E N DI X  6. I N S T R U C TI O N S  F O R  U S E  O F  A E R O V A N C I N H A L E R  7 8  
 
 
 
LI S TI N G  O F  T A B L E S 
T a bl e  1:  P h as e II  D e m o gr a p hi cs  a n d  C h ar a ct eristi cs  at  B as eli n e ( B L). ..................................................................... 2 3  
T a bl e  2:  Pl as m a  P K  P ar a m et ers.  ............................................................................................................................... 2 6  
T a bl e  3:  S p ut u m  P K  P ar a m et ers.  .............................................................................................................................. 2 7  
T a bl e  4: I n ci d e n c e  of  a d v ers e  e v e nt s  o c c urri n g i n  ≥ [ADDRESS_1117117]  o n e tr e at m e nt  gr o u p  a n d  wit h  a n  o ns et 
d uri n g t h e tr e at m e nt  p eri o d.  ...................................................................................................................................... 2 9  
T a bl e  5:  S u bj e ct  E arl y  Dis c o nti n u ati o ns.  .................................................................................................................. 3 0  
T a bl e  6:  F or m ul ati o n  of  A er o V a n c.  .......................................................................................................................... 3 9  
T a bl e  7:  F or m ul ati o n  of  Pl a c e b o.  .............................................................................................................................. 3 9  
T a bl e  8:  A E  S e v erit y  Gr a di n g.  .................................................................................................................................. 4 7  
T a bl e  9:  R el at e d n ess.  ................................................................................................................................................ 4 7  
 
LI S TI N G  O F  FI G U R E S  
Fi g ur e  1:  S ur vi v al  a c c or di n g t o  M R S A i nf e cti o n st at us i n  C F  p ati e nts ( D as e n br o o k,  et  al.,  2 0 1 0, r e pri nt e d  wit h 
p er missi o n,  C o p yri g ht  © ( 2 0 1 0) J A M A). .................................................................................................................. 1 9  
Fi g ur e  2:  A er o V a n c  a n d i ntr a v e n o us  v a n c o m y ci n  pl as m a  c o n c e ntr ati o n  as  a f u n cti o n  of ti m e (s e mi -l o g)  aft er  a 
si n gl e  d os e  a d mi ni str ati o n.  ........................................................................................................................................ 2 1  
Fi g ur e  3: C h a n g e i n  M R S A  D e nsit y i n  S p ut u m i n  3 2  m g  a n d  6 4  m g  D os e  C o h orts  P o ol e d.  ..................................... 2 4  
Fi g ur e  4:  M e a n  S p ut u m  C o n c e ntr ati o ns  of  V a n c o m y ci n  F oll o wi n g  A er o V a n c  A d mi ni str ati o n  wit h  Visits  O v erl ai d a n d  S e p ar at e d  b y  Tr e at m e nt ( S e mi -l o g  S c al e). ......................................................................................................... 2 5  
Fi g ur e  5:  C h a n g e i n  M R S A  D e nsit y i n  S p ut u m i n  S u bj e cts l ess t h a n  2 1  Y e ars  of  A g e.  ........................................... 3 1  Fi g ur e  6:  A bs ol ut e  C h a n g e fr o m  B as eli n e i n  F E V
[ADDRESS_1117118] s l ess t h a n  2 1  Y e ars  of  A g e.  ......... 3 2  
Fi g ur e  7:  Ti m e t o  Us e  of  Ot h er  A nti bi oti cs f or  R es pir at or y I nf e cti o n i n  S u bj e cts l ess t h a n  2 1  Y e ars  of  A g e.  .......... 3 3  Fi g ur e  8:  St u d y  D esi g n.  ............................................................................................................................................ 3 5  
  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  1 6 LI S T  O F  A B B R E VI A TI O N S 
ß -h C G   H u m a n  c h ori o ni c  g o n a d otr o pi n  b et a -s u b u nit  
A E  A d v ers e  e v e nt  
A L T  A l a ni n e  a mi n otr a nsf er as e 
A N C O V A   A n al ysi s  of  c o v ari a n c e  A PI  A cti v e  p h ar m a c e uti c al i n gr e di e nt  
A S T  A s p art at e  a mi n otr a nsf er as e  
A T S  A m eri c a n  T h or a ci c  S o ci et y  
A U C   A r e a  u n d er t h e  c ur v e B.  c e p a ci a   B ur k h ol d eri a  c e p a ci a  B I D B is i n  di e/t wi c e  d ail y 
B L  B as eli n e  
B MI  B o d y  m ass i n d e x  
B P  B l o o d  pr ess ur e 
B U N   B l o o d  ur e a  nitr o g e n C A T  C o nti n ui n g  alt er n ati n g  a nti -Ps e u d o m o n al t h er a p y  
C F  C ysti c fi br osis  
C F R S D -C RI S S   C ysti c  Fi br osi s  R es pir at or y  S y m pt o m  Di ar y -C hr o ni c  R es pir at or y  S y m pt o m  S c or e  C F T R   C ysti c fi br osis tr a ns m e m br a n e  c o n d u ct a n c e r e g ul at or  C F U  C ol o n y f or mi n g  u nit s  
C F U/ g   C ol o n y f or mi n g  u nit s  p er  gr a m  CI  C o nfi d e n c e i nt er v al  
° C  D e gr e es  C el si us  
C
m a x M a xi m u m  c o n c e ntr ati o n  
C N S  C e ntr al  n er v o us s yst e m  
C P M P   C o m mitt e e f or  Pr o pri et ar y  M e di ci n al  Pr o d u ct s  C R F  C as e r e p ort f or m  
C R O   C o ntr a ct r es e ar c h  or g a ni z ati o n  C V  C o effi ci e nt  of  v ari ati o n  
D L T  D os e  Li miti n g  T o xi cit y  
D M C   D at a  M o nit ori n g  C o m mitt e e  D S M B   D at a  S af et y  M o nit ori n g  B o ar d  E C G  E l e ctr o c ar di o gr a m 
E D C  El e ctr o ni c  D at a  C a pt ur e  
e -Di ar y   E l e ctr o ni c  di ar y E D T A   E t h yl e n e  di a mi n et etr a-a c eti c  a ci d  E L F  E pit h eli al li ni n g fl ui d  
E T  E arl y t er mi n ati o n  
F D A  F o o d  a n d  Dr u g  A d mi nistr ati o n  
F E F  F or c e d  e x pir at or y fl o w  
F E V
[ADDRESS_1117119] uri n g  Pr a cti c e  
h r H o ur(s)  
H B S  A g   H e p atiti s  B s urf a c e  a nti g e n  H C V  A b   H e p atiti s  C  a nti b o d y  H E E N T   H e a d,  e y es,  e ars,  n os e,  a n d t hr o at  HI P A A   H e alt h I ns ur a n c e  P ort a bilit y  a n d  A c c o u nt a bilit y  A ct  HI V  H u m a n  i m m u n o d efi ci e n c y  vir us 
H P L C   H i g h-p erf or m a n c e li q ui d  c hr o m at o gr a p h y  H P M C   ( H y dr o x y pr o p yl) m et h yl  c ell ul os e I C F Inf or m e d  c o ns e nt f or m  
I C H I nt er n ati o n al  C o nf er e n c e  o n  H ar m o ni s ati o n 
I E C I n d e p e n d e nt  Et hi cs  C o m mitt e e 
I R B I nstit uti o n al  R e vi e w  B o ar d 
I T T I nt e nt t o  Tr e at 
I U D Intr a ut eri n e  d e vi c e  
I V Intr a v e n o us  
I W R I nt er a cti v e  W e b  R es p o ns e 
k g  K il o gr a m 
L D H   L a ct at e  d e h y dr o g e n as e  M C H   M e a n  c ell  h e m o gl o bi n  M C H C   M e a n  c ell  h e m o gl o bi n  c o n c e ntr ati o n  M C V   M e a n  c ell  v ol u m e  M D  M e di c al  D o ct or  
M e d D R A   M e di c al  Di cti o n ar y f or  R e g ul at or y  A cti viti es  m g  M illi gr a m 
MI C  M e a n i n hi bit or y  c o n c e ntr ati o n  
µ g   M i cr o gr a m 
mi n  M i n ut e(s) 
mI T T   M o difi e d I nt e nt -t o-Tr e at  m m H g   M illi m et er(s)  of  m er c ur y M R S A   M et hi cilli n  r esist a nt- St a p h yl o c o c c us  a ur e us  n  N u m b er  of  s u bj e cts wit h  a n  o bs er v ati o n  
N  N u m b er  of  s u bj e cts i n t h e  d at as et  or  p o p ul ati o n  
n g  N a n o gr a m  
N O A E L   N o  o bs er v e d  a d v ers e  eff e ct  l e v el P A  P s e u d o m o n as A er u gi n os a  
P E F  P e a k  e x pir at or y fl o w  
P E F R   P e a k  e x pir at or y fl o w r at e  P F R D   P e a k  Fl o w  R e c or di n g  D e vi c e  P F T  P ul m o n ar y f u n cti o n t est  
P K  P h ar m a c o ki n eti c(s)  
P P  P er  pr ot o c ol  
R B C  R e d  bl o o d  c ell  
R E B  R es e ar c h  Et hi cs  B o ar d  
s S e c o n d(s)  
S.  a ur e us   St a p h yl o c o c c us  a ur e us  S A E  S eri o us  a d v ers e  e v e nt  
S A P  St atisti c al  A n al ysis  Pl a n  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117120] e d s eri o us  a d v ers e r e a cti o n  
T D N  T h er a p e uti cs  D e v el o p m e nt  N et w or k  
T E A E   T r e at m e nt-e m er g e nt  a d v ers e  e v e nt(s)  
T O BI   T o br a m y ci n i n h al ati o n  s ol uti o n  U L N   U p p er li mit  of  n or m al  U S  U nit e d  St at es  
U S P  U S  P h ar m a c o p ei al  C o n v e nti o n  
VI S A   V a n c o m y ci n i nt er m e di at e r esist a nt  St a p h yl o c o c c us  a ur e us  V R S A   V a n c o m y ci n r esi st a nt  St a p h yl o c o c c us  a ur e us  W B C   W hit e  bl o o d  c ell  W M A   W orl d  M e di c al  Ass o ci ati o n  
 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  1 9 1   B A C K G R O U N D  
C ysti c fi br osis ( C F) is  a  g e n eti c  dis e as e  c h ar a ct eri z e d, i n  p art,  b y t h e  pr e v al e n c e  of t hi c k, sti c k y  m u c us  pr o d u c e d i n 
t h e l u n g, fr e q u e nt l u n g i nf e cti o ns,  a n d  a r es ult a nt  d e cli n e i n  p ul m o n ar y f u n cti o n.  T h e  c hr o ni c l u n g i nf e cti o ns 
e x p e dit e t h e str u ct ur al  d a m a g e  of t h e l u n gs  c o ntri b uti n g t o t h e  pr e m at ur e  d e at h  of t h e  p ati e nts. I n t h e  p ast  d e c a d e, 
p ersist e nt  M R S A l u n g i nf e cti o n  h as  b e c o m e i n cr e asi n gl y  c o m m o n i n  p ati e nts  wit h  C F,  wit h  a  pr e v al e n c e  of  a b o ut 2 6 % ( a p pr o x.  8, 0 0 0  p ati e nt s) i n t h e  U nit e d  St at es  ( C F F  P ati e nt  R e gistr y,  2 0 1 4).  P ersist e nt  M R S A i nf e cti o n i n p ati e nts  wit h  C F  h as  b e e n  ass o ci at e d  wit h i n cr e as e d  us e  of i ntr a v e n o us (I V)  a nti bi oti cs  ( Mi all  L S,  2 0 0 1) ( Eli z ur  A, 
2 0 0 7) , i n cr e as e d  h os pit ali z ati o ns ( V a n d er h elst  E,  2 0 1 2),  a f ast er  d e cli n e  of l u n g f u n cti o n ( V a n d er h el st  E,  2 0 1 2) 
( D as e n br o o k  E C  M.  C.-W.,  2 0 0 8) ,  as w ell  as  s h ort e n e d lif e- e x p e ct a n c y,  ( D as e n br o o k  E C  C.  W.,  2 0 1 0).  
 
Fi g u r e  1 : S u r vi v al  a c c o r di n g t o  M R S A i nf e cti o n st at us i n  C F  p ati e nts ( D as e n b r o o k,  et  al.,  2 0 1 0,  r e p ri nt e d  wit h 
p e r missi o n,  C o p y ri g ht  © ( 2 0 1 0)  J A M A).  
P ersist e nt  M R S A l u n g i nf e cti o n i n  C F  p ati e nt s is  diffi c ult t o  er a di c at e  or  m a n a g e  usi n g  or al  or I V  a nti bi oti cs,  a n d 
t h er e is  n o st a n d ar d  of  c ar e t o  m a n a g e t h e i nf e cti o n i n  C F  p ati e nts ( Z o b ell J T,  2 0 1 5) d es pit e t h e  hi g h  n e e d. I n  c o ntr ast t o t h e  est a blis h e d tr e at m e nt  of  P.  a er u gi n os a  i nf e cti o n  wit h i n h al e d  a nti bi oti cs, t h er e is  n o  F D A-a p pr o v e d i n h al e d  a nti bi oti c tr e at m e nt  a v ail a bl e f or  M R S A i nf e cti o n. V a n c o m y ci n is t h e  dr u g  of  c h oi c e f or t h e tr e at m e nt  of M R S A i nf e cti o n,  b ut it i s  o nl y  a v ail a bl e i n I V f or m.  W hil e  hi g hl y  eff e cti v e  a g ai nst  gr a m  p ositi v e  b a ct eri a,  c hr o ni c us e  of I V  v a n c o m y ci n  m a y  b e  ass o ci at e d  wit h s yst e mi c t o xi cit y,  es p e ci all y r e n al t o xi cit y  a n d  ot ot o xi cit y.  D u e t o  its I V  us e  a n d  p ot e nti al f or t o xi cit y, I V  v a n c o m y ci n us e i s  g e n er all y li mit e d t o  h os pit al s etti n gs.  As  o bs er v e d  wit h i n h al e d  a nti-Ps e u d o m o n al  dr u gs, t h er e  m a y  b e  si g nifi c a nt  cli ni c al  a d v a nt a g e i n  d eli v eri n g  v a n c o m y ci n  dir e ctl y t o t h e sit e  of i nf e cti o n i n  or d er t o  m a xi mi z e t h e  cli ni c al  effi c a c y, r e d u c e s yst e mi c  e x p os ur e  a n d t h e ri s k  of  a d v ers e eff e cts,  a n d t o  e n a bl e  c o n v e ni e nt  us e  of t h e  pr o d u ct  o utsi d e  of t h e  h os pit al s etti n g.  
S a v ar a  h as  d e v el o p e d  a  hi g h -p erf or m a n c e i n h al ati o n  p o w d er f or m ul ati o n  of  v a n c o m y ci n  h y dr o c hl ori d e,  A er o V a n c, 
utili zi n g  a  c o n v e nti o n al  c a ps ul e i n h al er.  V a n c o m y ci n is  a  gl y c o p e pti d e  a nti bi oti c  eff e cti v e  a g ai nst  m ost  g r a m-p ositi v e  b a ct eri a,  a n d  h as  b e e n  e xt e nsi v el y  us e d f or t h e tr e at m e nt  of  M R S A i nf e cti o ns f or  o v er fi v e  d e c a d es.  T h e pr o p os e d i n di c ati o n  of  A er o V a n c is tr e at m e nt  of  C F  p ati e nts  wit h  p ersist e nt  M R S A i nf e cti o n  of t h e l u n gs.  T h e  ai m  of  A er o V a n c tr e at m e nt is i nf e cti o n s u p pr essi o n i n  or d er t o i m pr o v e  p ati e nts’ r es pir at or y s y m pt o ms,  a n d l u n g f u n cti o n,  a n d t o  pr ol o n g t h e ti m e t o  n e e d  of  ot h er  a nti bi oti cs  a n d  p ul m o n ar y  e x a c er b ati o n.  A er o V a n c  w as  gr a nt e d 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117121]/ F ast  Tr a c k  D esi g n ati o n i n 
N o v e m b er  [ADDRESS_1117122] u di es i n r ats  a n d  d o gs,  as  w ell  as i n t h e I C H/ F D A  pr es cri b e d s af et y  p h ar m a c ol o g y st u di es 
i n v ol vi n g t h e  c ar di o v as c ul ar s yst e m,  p ul m o n ar y s yst e m  a n d  c e ntr al  n er v o us s yst e m ( C N S). A er o V a n c  di d  n ot r es ult 
i n  a n y  a d v ers e  eff e cts i n f u n cti o n alit y  of t h e  c ar di o v as c ul ar s yst e m  a n d  p ul m o n ar y s yst e m  at  a n y  d os e l e v el  u p t o 3 0  m g/ k g i n  b e a gl e  d o gs,  a n d  C N S  at  a n y  d os e l e v el  u p t o  1 0 0  m g/ k g i n  S pr a g u e -D a wl e y r ats.   
T h e  pi v ot al  G o o d  L a b or at or y  Pr a cti c e  ( G L P) t o xi c ol o g y st u di es  c o nsi st e d  of t w o  [ADDRESS_1117123]  L e v el  (N O A E L ) i n t h e r ats  w as  1 8. 6  m g/ k g/ d a y  a n d t h e 
N O A E L i n t h e  d o gs  w as  1 1. 5  m g/ k g/ d a y,  b ot h  N O A E L’s r e pr es e nti n g t h e  mi d  d os e l e v el s  us e d i n t h e r es p e cti v e st u di es.  
F oll o wi n g  [ADDRESS_1117124].  Cli ni c al  p at h ol o g y i n di c es  w er e  c o m p ar a bl e  b et w e e n tr e at e d  gr o u ps  a n d r es p e cti v e  air  a n d  v e hi cl e  c o ntr ol  v al u es.  A d mi nistr ati o n  of t h e  v e hi cl e ( L-L e u ci n e: Tr e h al os e)  a n d t h e t est it e m, A er o V a n c, r es ult e d i n  v e hi cl e -r el at e d  a n d t est it e m-r el at e d  mi cr os c o pi c  c h a n g es i n t h e  n as al  c a vit y,  u p p er 
r es pir at or y tr a ct  a n d l u n gs  of  a ni m als fr o m t h e tr e at e d  gr o u ps,  a n d i n t h e  n as al  c a vit y i n t h e  v e hi cl e tr e at e d  gr o u p. T h e  d os e -r el at e d fi n di n gs i n t h e tr e at e d  gr o u p s i n t h e  n as al  c a vit y i n cl u d e d  d e g e n er ati o n  of t h e  olf a ct or y  e pit h eli al 
c ell/i n cr e as e d  e osi n o p hili c  dr o pl ets . T h e  n as al  c a vit y  of t h e  v e hi cl e tr e at e d  g r o u p s h o w e d  v a c u ol ar  d e g e n er ati o n  of t h e  olf a ct or y  e pit h eli u m.  T h e irrit ati o n/ a d a pti v e  c h a n g es  of t h e  u p p er r es pir at or y tr a ct ( c ari n a, l ar y n x,  n as al  c a vit y a n d  n as o p h ar y n x)  a n d l u n gs  o bs er v e d i n cl u d e d  c h a n g es  s u c h  as s q u a m o us  m et a pl asi a  of t h e r es pir at or y  e pit h eli u m i n t h e  c ari n a  a n d l ar y n x,  er osi o n/ atr o p h y  of t h e  olf a ct or y  e pit h eli u m  a n d  m at eri al/ e x u d at e/ c ell  d e bris i n l u m e n  of t h e n as al  c a vit y  a n d  g o bl et  c ell  h y p er pl asi a  of t h e r es pir at or y  e pit h eli u m  of  n as al  c a v it y/ n as o p h ar y n x, e nl ar g e d/i n cr e as e d  al v e ol ar  histi o c yt es/ al v e ol ar  hi sti o c yt osi s ( c orr el at e d  wit h  d os e -d e p e n d e nt i n cr e as es i n l u n g 
w ei g hts  a n d  m a cr os c o pi c fi n di n g  of  p al e  ar e a/f o c u s i n t h e l u n gs)  a n d  g o bl et  c ell  h y p er pl asi a/ m et a pl asi a wit h/ wit h o ut  c ell  d e bris/ e osi n o p hili c  m at eri al i n  al v e ol ar  d u ct/ b r o n c hi ol ar l u m e n  a n d  p eri v as c ul ar/ p eri br o n c hi ol ar c ell i nfiltr at e i n t h e l u n gs.  A  hi g h er i n ci d e n c e/ s e v erit y  of t h es e fi n di n gs  w as  n ot e d i n t h e  hi g h  d os e  gr o u p  a ni m als.  
Aft er t h e  [ADDRESS_1117125] it e m -r el at e d  c h a n g es ( d e g e n er ati o n  of t h e  olfa ct or y  e pit h eli al 
c ell/i n cr e as e d  e osi n o p hili c  dr o pl ets)  as  w ell  as t h e  v e hi cl e -r el at e d  c h a n g e ( v a c u ol ar  d e g e n er ati o n  of t h e  olf a ct or y e pit h eli u m)  w er e still  pr es e nt i n t h e  n as al  c a vit y  of t h e r e c o v er y  a ni m als i n  t h e  hi g h-d os e  gr o u p  a ni m als ,  b ut  wit h  a l o w er s e v erit y, s u g g esti n g  a n  o n g oi n g r e c o v er y  pr o c ess (r e g e n er ati o n  of t h e  olf a ct or y  e pit h eli u m).  T h e irrit ati o n/ a d a pti v e  c h a n g es  of t h e  u p p er r es pir at or y tr a ct ( c ari n a, l ar y n x,  n as al  c a vit y  a n d  n as o p h ar y n x)  a n d l u n gs s h o w e d i n di c ati o ns  of r e c o v er y  at  v ari o us  l e v els, s u g g esti n g  a n  o n g oi n g r e c o v er y  pr o c ess. 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117126] u d y, t h e  N O A E L  w as  c o nsi d er e d t o  b e  at t h e  a c hi e v e d  d os e l e v el  of 
1 0. 5  m g/ k g/ d a y f or t h e r ats  w h e n  d os e d f or  [ADDRESS_1117127]  a n d l u n gs 
a n d r e pr es e nt e d l o c al irrit ati v e/ a d a pti v e  c h a n g es  e x p e ct e d f oll o wi n g t h e  e x p os ur e t o  hi g h l e v el  of t h e t est  arti cl e.   
[ADDRESS_1117128] er e d,  8 0  m g.  A er o V a n c s h o w e d  a f a v or a bl e  p h ar m a c o ki n eti c  ( P K) pr ofil e,  wit h  a r el ati v el y sl o w  p ul m o n ar y 
a bs or pti o n  p h as e (t
m a x of  1. 3 3  h r –2. 0 8  h r), f oll o w e d  b y  distri b uti o n  a n d  eli mi n ati o n  c o m p ar a bl e t o t h e i ntr a v e n o us 
a d mi nistr ati o n  ( Fi g ur e  2 ) T h e  m e a n  a bs ol ut e  bi o a v ail a bilit y  a cr oss  all  A er o V a n c  d os es  w as  4 9 % ( st a n d ar d 
d e vi ati o n [ S D ] 8 %),  wit h  n o  a p p ar e nt  diff er e n c e  o bs er v e d  b et w e e n t h e  d os es.  T h e  a bs ol ut e  bi o a v ail a bilit y  cl os el y 
c orr es p o n ds  wit h t h e  p ul m o n ar y  a bs or pti o n  of  v a n c o m y ci n,  c o nsi d eri n g t h at  v a n c o m y ci n i s  n ot  a bs or b e d fr o m t h e g astr oi nt esti n al ( GI ) tr a ct.  T h e  m e a n  C
m a x of  A er o V a n c  aft er  a n  8 0  m g  d os e  w as  6 1 8  n g/ m L,  c orr es p o n di n g t o 
a p pr o xi m at el y  1/ 5t h of t h e  d os e  a dj ust e d  C m a x aft er  a  2 5 0  m g  d os e  of I V  v a n c o m y ci n.  T h e  d os e li n e arit y  of 
A er o V a n c i n t er ms  of  C m a x a n d  ar e a  u n d er t h e  c ur v e ( A U C ) v al u es  w as  e x c ell e nt ( R2 >  0. 9 9). I n t h e  C F  c o h orts ,  all 
s u bj e cts  h a d s p ut u m  v a n c o m y ci n  c o n c e ntr ati o ns i n  hi g h  e x c ess  of t h e  m e a n i n hi bit or y  c o n c e ntr ati o n  (MI C ) of 
v a n c o m y ci n f or  M R S A  ( 2 µ g/ m L)  at  1  h r aft er t h e  a d mi nistr ati o n  of  A er o V a n c  wit h  b ot h t h e l o w  a n d t h e  hi g h  d os e 
( m e a n  of  1 0 6  μ g/ m L,  a n d  2 6 1  μ g/ m L, r es p e cti v el y).  At l at er ti m e  p oi nt s, t h e  c o n c e ntr ati o ns  d e cr e as e d,  b ut  o n a v er a g e r e m ai n e d  a b o v e t h e  MI C  v al u es f or  u p t o  [ADDRESS_1117129] e d ( S D f or  C
m a x 1 7 9 -1 9 0 %).    
 
 
Fi g u r e  2 : A e r o V a n c  a n d i nt r a v e n o us  v a n c o m y ci n  pl as m a  c o n c e nt r ati o n  as  a f u n cti o n  of ti m e (s e mi -l o g)  aft e r  a si n gl e 
d os e  a d mi nist r ati o n . 
 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117130] u d y  ar e i n  k e e pi n g  wit h t h e l ar g e  m ol e c ul ar  w ei g ht  of  v a n c o m y ci n, t h e  v a n c o m y ci n l u n g  c o n c e ntr ati o ns  o bs er v e d  aft er  n e b uli z e d  v a n c o m y ci n  a d mi ni str ati o n ( S hir ai  et  al.,  1 9 9 5), t h e a ni m al  P K  i nf or m ati o n ( V all e,  2 0 0 7),  as  w ell  as t h e  p o or  p e n etr ati o n  of  v a n c o m y ci n t o t h e  e pit h eli al li ni n g fl ui d 
( E L F) fr o m t h e  bl o o d  o bs er v e d i n  h u m an st u di es ( Cr u ci a ni  et  al,  1 9 9 6;  L a m er  et  al,  1 9 9 3).    
All  t h e  a d v ers e  e v e nts i n t h e  h e alt h y  v ol u nt e ers  w er e  cl assifi e d  as  mil d,  a n d  all  of t h e  e v e nts t h at  w er e  c o nsi d er e d 
pr o b a bl y  dr u g -r el at e d i n v ol v e d l o c al irrit ati o n  eff e cts  a n d r es ol v e d s p o nt a n e o usl y  a n d r a pi [INVESTIGATOR_2478] y ( 1 5  mi n  –  6 0  mi n). 
S m all r e d u cti o n i n t h e  p ost -d os e  F E V
1 ( 7 % –  1 1 %)  w as  o bs er v e d i n  3  s u bj e cts  aft er t h e  8 0  m g  d os e.  N o n e  of t h e  
s u bj e cts r e q uir e d  br o n c h o dil at or tr e at m e nt,  a n d t h e  c h a n g es  w er e  c o nsi d er e d  b y  t h e D at a  S af et y  M o nit ori n g  B o ar d  
(D S M B ) t o  b e n ot  cli ni c all y si g nifi c a nt. I n  C F  s u bj e cts,  c h est  c o n g esti o n  a n d  c h est ti g ht n ess  w er e r e p ort e d  b y 4  of t h e 7  s u bj e cts,  a n d t h er e  ap p e ar e d t o  b e  a sli g ht tr e n d t o w ar ds  m or e  a d v ers e  e v e nt s  at t h e  hi g h er  d os e ( 8 0  m g).  All 
r e p ort e d r es pir at or y  e v e nts  w er e  mil d,  n o n e  of t h e s u bj e ct s f elt  distr ess e d,  a n d t h e  e v e nt s  eit h er  di d  n ot r e q uir e tr e at m e nt  or r es ol v e d  aft er  air w a y  cl e ar a n c e  a n d/ or al b ut er ol i n h al ati o n.  B as e d  o n t h e r es ult s,  br o n c h o dil at or  pr e -
tr e at m e nt w as  i m pl e m e nt e d i n s u bs e q u e nt cli ni c al tri als .  S h ort-a cti n g  br o n c h o dil at ors  h a v e  b e e n r o uti n el y  us e d  as pr e -tr e at m e nt i n t h e  p u blis h e d  a n d  u n p u bli s h e d st u di es  of  a er os oli z e d I V  v a n c o m y ci n  as  w ell  as i n h al e d t o br a m y ci n a n d  a ztr e o n a m st u di es.  S y m pt o m ati c  br o n c h o c o nstri cti o n is r ar e  w h e n  s u bj e cts ar e  pr e -tr e at e d  wit h  a br o n c h o dil at or.   
3. [ADDRESS_1117131].  Elli ott  D as e n br o o k ( C as e  W est er n  R es er v e U ni v ersit y ,  Cl e v el a n d,  O H),  a n d  Dr.  P atri c k  Fl u m e ( Me di c al  U ni v ersit y  of  S o ut h  C ar oli n a ,  C h arl est o n,  S C). I n s u m m ar y,  A er o V a n c r e d u c e d  M R S A  d e nsit y i n s p ut u m  a n d s h o w e d  e n c o ur a gi n g t r e n ds  of i m pr o v e m e nt i n r es pir at or y s y m pt o ms, l u n g f u n cti o n,  a n d  pr ol o n g ati o n  of t h e ti m e t o  n e e d  of  ot h er  a nti bi oti cs,  a n d ti m e t o p ul m o n ar y  e x a c er b ati o n,  wit h  b est r es p o ns es  o bs er v e d i n  s u bj e cts <  [ADDRESS_1117132] u d y is  d e m o nstr at e d i n T a bl e  1 : 
 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  2 3 T a bl e  1 : P h as e II  D e m o g r a p hi cs  a n d  C h a r a ct e risti cs  at  B as eli n e ( B L) . 
T r e at m e nt  A e r o V a n c  [ADDRESS_1117133] a c e b o   A e r o V a n c  
N 2 0  2 0     2 3   2 4     4 3   4 4  
A g e ( m e a n)  2 4. 6   2 2. 4     2 7. 8   2 7. 8     2 6. 3   2 5. 3  
A g e ( <  2 1/ ≥  2 1  y e a rs)   1 0/ 1 0   1 0/ 1 0     5/ 1 8   4/ 2 0     1 5/ 2 8   1 4/ 3 0  
S e x ( m/f)  1 1/ 9   7/ 1 3     1 5/ 8   1 5/ 9     2 6/ 1 7   2 2/ 2 2  
P.  a e r u gi n os a ( +/ −)   1 2/ 8   1 3/ 7     1 3/ 1 0   1 4/ 1 0     2 5/ 1 8   2 7/ 1 7  M R S A (l o g
1 0 
C F U/ m L)  6. 7 8   7. 3 1     7. 5 4   7. 2 4   7. 1 8   7. 2 7  
C F R S D -C RI S S   3 1. 6   2 9. 1     3 0. 4   2 7. 6   3 1. 0   2 8. 3  F E V
1 p e r c e nt  p r e d. 
( %) [ADDRESS_1117134] a c e b o  c o h orts  w er e  hi g h, r a n gi n g fr o m  6. 7 8 t o  7. 5 4  l o g 1 0 C F U/ m L,  d e p e n di n g  o n t h e  gr o u p ( T a bl e  1 ). A 
r e d u cti o n fr o m  b as eli n e i n  M R S A c ol o n y f or mi n g  u nit s ( C F U ) w as  o bs er v e d i n  b ot h  3 2  m g  a n d  6 4  m g  d os e  c o h orts i n t h e I T T  p o p ul ati o n (
Fi g ur e  3 ), wit h  m e a ns  of  -0. 4 2 l o g  1 0 C F U/ m L ( 3 2  m g)  a n d  -0. 6 0 l o g  1 0 C F U/ m L ( 6 4  m g). 
T h e r e d u cti o ns i n t h e  [ADDRESS_1117135] ati sti c all y si g nifi c a nt 
(l e ast s q u ar es  m e a ns -0. 6 3  v ers us  0. 1 6 l o g  1 0 C F U/ m L;  p = 0. 0 1 4 5,  a n d  -0. 5 2  v ers us  -0. 0 6 l o g  1 0 C F U/ m L;  p = 0. 0 3 1 2, 
r es p e cti v el y). N o l asti n g  er a di c ati o n s  of  M R S A  w er e  o bs er v e d.   
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  2 4  
Fi g u r e  3: C h a n g e i n  M R S A  D e nsit y i n  S p ut u m i n  [ADDRESS_1117136] as m a  a n d  S p ut u m  P h a r m a c o ki n eti cs 
V a n c o m y ci n  p e a k  a n d tr o u g h  c o n c e ntr ati o ns  at  D a y  8  a n d  D a y  2 9 i n s p ut u m  w er e i n  v er y  hi g h  e x c ess  o v er  MI Cs 
( m e a n  C tr o u g h/ MI C r ati o >  3 5 )  aft er  m ulti pl e  d osi n g i n  all s u bj e cts at  b ot h  d os e l e v els , wit h  a p p ar e nt  d os e -
d e p e n d e n c y,  b ut  n o  n ot a bl e  diff er e n c e i n  C  tr o u g h b et w e e n t h e t w o ti m e  p oi nts  ( Fi g ur e  4 ). T h e  g e n er all y  a c c e pt e d 
MI C  of  v a n c o m y ci n f or  M R S A is ill ustr at e d  b y t h e  d ott e d li n e,  at  2  µ g/ m L.  
 p  =  N /A p  <  0 .0 1 p  <  0 .0 0 0 1 p  =  0 .0 3 -1 .4-1 .2-1 .0-0 .8-0 .6-0 .4-0 .20 .00 .20 .40 .6
B a s eli n e D a y  8 D a y  1 5 D a y  2 9C h a n g e i n  M R S A   D e n sit y i n  S p ut u m  ( lo g 1 0C F U /m L )A er o Va n c Pl a c e b o
v al u e s - a n d  p , c o nf i d e n c e i nt er v al s% [ADDRESS_1117137]  s q u ar e  m e a n s
. ar e f r o m  a r e p e at e d  m e a s ur e s li n e ar  mi x e d  m o d el
. 4 3 = n : Pl a c e b o , 4 4 = n : A er o V a n c , MI T T
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  2 5  
Fi g u r e  4 : M e a n  S p ut u m  C o n c e nt r ati o ns  of  V a n c o m y ci n  F oll o wi n g  A e r o V a n c  A d mi nist r ati o n  wit h  Visits  O v e rl ai d  a n d 
S e p a r at e d  b y  T r e at m e nt ( S e mi -l o g  S c al e). 
3. 2. 3. [ADDRESS_1117138] es  w er e  o bt ai n e d f or t h e  m e as ur e m e nt  of  v a n c o m y ci n l e v els i n  a s u bs et  of 
2 4  s u bj e cts ([ADDRESS_1117139] s tr e at e d  at  e a c h  d os e l e v el).  T h e  pr e d os e s a m pl es  w er e  c oll e ct e d  wit hi n 
[ADDRESS_1117140] e d  0. 2 5,  1,  2,  a n d  4  h o urs ( all  ± 1 0  mi n ut e s) P ost d os e  o n  D a ys  1,  8,  a n d  2 9  ( T a bl e  2 ). 
 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  2 6 T a bl e  2 : Pl a s m a  P K  P a r a m et e rs . 
M e a n ( C V  %)  Pl as m a  P K  P a r a m et e rs f o r  A e r o V a n c  
P K  P ar a m et er  Visit  2 ( D a y  1)  Visit  3 ( D a y  7 -8)  Visit  6 ( D a y  2 8 -2 9)  
[ADDRESS_1117141] s  6 6 6 3 2 2 
Cm a x ( µ g/ m L)  0. 2 8 3 ( 6 8. 7)   0. 5 8 9 ( 3 7. 8)   0. 3 1 5 ( 7 0. 5)   0. 4 3 5 ( 1 9. 5)   0. 2 6 6 ( N Cb)  0. 6 9 4 ( N Cb) 
Cm a x/ D o s e 
( µ g/ m L/ m g) 0. 0 0 8 8 4 ( 6 8. 7)   0. 0 0 9 2 0 ( 3 7. 8)   0. 0 0 9 8 5 ( 7 0. 5)   0. 0 0 6 7 9 ( 1 9. 5)   0. 0 0 8 3 3  ( N Cb)  0. 0 1 0 8 ( N Cb) 
Tm a xa ( h)  1. 0 0 ( 1. 0 0 -2. 0 0)  1. 0 0 ( 1. 0 0 - 2. 0 0) 1. 0 0 ( 0. 2 5 -2. 0 0)  1. 0 0 ( 1. 0 0 - 4. 0 0) 1. 0 0 ( 1. 0 0 -1. 0 0)   1. 5 ( 1. 0 0 - 2. 0 0) 
Ctr o u g h 
( µ g/ m L)  - -  0. 1 4 6 ( 1 3 3)   0. 0 5 6 8 ( 4 6. 1)e  0. 0 9 2 0 ( 1 1. 4)   0. 2 1 3 ( N Cb) 
A U C 0- 4 
( h•  µ g/ m L) 0. 9 1 4  ( 78 . 7)  1. 7 3 ( 3 3. 4)   1. 0 4 ( 8 0. 2)  1. 3 4 ( 2 1. 4)   0. 8 8 0 ( N Cb)  2. 1 3 ( N Cb) 
A U C 0- 4/ D o s e 
( h• µ g/ m L/ m g) 0. 0 2 8 6  ( 78. 7 )  0. 0 2 7 1 ( 3 3. 4)   0. 0 3 2 6 ( 8 0. 2)   0. 0 2 1 0 ( 2 1. 4)   0. 0 2 7 5 ( N C
b)  0. 0 3 3 3 ( N Cb) 
Cm a x_ A c cc   - -  1. 1 3 ( 1 6. 7)   0. 6 3 6 ( N Cb)d  1. 2 2 ( N Cb)  0. 9 3 7 ( N Cb) 
A U C _ A c cc   - -  1. 1 5 ( 2 2. 8 )  0. 6 9 5 ( N Cb)d  1. 3 8 ( N Cb)  0. 9 9 1 ( N Cb) 
A b br e vi ati o ns:  A c c:  a c c u m ul ati o n r ati o;  A U C:  ar e a  u n d er t h e  c o n c e ntr ati o n -ti m e  c ur v e;  BI D: t wi c e  d ail y;  C m a x:  m a xi m u m 
c o n c e ntr ati o n;  C tr o u g h:  c o n c e ntr ati o n  at t h e  e n d  of t h e  d osi n g i nt er v al;  h:  h o ur;  P K:  p h ar m a c o ki n eti c(s);  T m a x: tim e  of  m a xi m u m 
c o n c e ntr ati o n.  
a  Tm a x w as r e pr es e nt e d  as  M e di a n ( R a n g e)  
b N C  =  St atisti cs  n ot  c al c ul at e d  w h e n  N < 3  
c  Cm a x_ A c c  a n d  A U C _ A c c  ar e  a c c u m ul ati o n r ati os,  c al c ul at e d  usi n g  P K  p ar a m et ers ( C m a x a n d  A U C 0- 4)  of  Visit  [ADDRESS_1117142]  
d  N u m b er  of  S u bj e cts  =  [ADDRESS_1117143] as m a  v a n c o m y ci n  e x p os ur e ( C m a x a n d  A U C 0- 4)  w as  g e n er all y  d os e-pr o p orti o n al f or t h e  A er o V a n c  [ADDRESS_1117144] u g  a c c u m ul ati o n  o c c urr e d i n s p ut u m. I n  g e n er al, t h er e  w as  a  pr o p orti o n al i n cr e as e i n  v a n c o m y ci n  e x p os ur e ( C
m a x a n d  A U C 0- 4)  wit h i n cr e asi n g  d os e  of  A er o V a n c f or 
si n gl e -d os e ( Visit  2,  B as eli n e,  D a y  1)  a n d  m ulti pl e -d os e  a d mi ni str ati o ns  o n  Visit  3 ( D a y  8).  T h e  e x p os ur e  a p p e ar e d s o m e w h at l ess t h a n  d os e-pr o p orti o n al  o n  Visit  6 ( D a y  2 9),  b ut t h es e  esti m at es  ar e l ess r eli a bl e  b e c a us e  o nl y  [ADDRESS_1117145] at e  s h o ul d  b e  m a d e  wit h c a uti o n.  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  2 7 T a bl e  3 : S p ut u m  P K  P a r a m et e rs . 
M e a n ( C V  %)  S p ut u m  P K  P a r a m et e rs f o r  A e r o V a n c  
P K  P ar a m et er   Visit  2 ( D a y  1)  Visit  3 ( D a y  7 - 8) Visit  6 ( D a y  2 8 - 2 9) 
[ADDRESS_1117146] s  6 5 6 3 2 2 
Cm a x ( µ g/ g)  3 1 6 ( 6 7. 5)   5 3 1 ( 4 8. 4)   7 6 7 ( 6 0. 7)   1 7 9 0 ( 8 4. 1)   1 2 7 0 ( N Cb)  1 4 0 0 ( N Cb) 
Cm a x/ D o s e 
( µ g/ g/ m g) 9. 8 9 ( 6 7. 5)   8. 2 9 ( 4 8. 4)   2 4. 0 ( 6 0. 7)   2 7. 9 ( 8 4. 1)   3 9. 5 ( N Cb)  2 1. 8 ( N Cb) 
Tm a xa ( h)  0. 2 5 ( 0. 2 5 - 0. 2 5) 0. 2 5 ( 0. 2 5 -0. 2 5)  0. 2 5 ( 0. 2 5 - 0. 2 5) 0. 2 5 ( 0. 2 5 -0. 2 5)  0. 2 5  ( 0. 2 5- 0. 2 5) 0. 2 5 ( 0. 2 5 -0. 2 5)  
Ctr o u g h ( µ g/ g)  - -  7 4. 5 ( 1 6 5)   1 1 9 ( 8 0. 8)   8 1. 4 ( 1 1 4)g  9 9. 0 ( N Cb) 
Ctr o u g h / MI C 
(( µ g/ g)/  
( µ g/ m L))f - -  3 7. 3 ( 1 6 5)    5 9. 3 ( 8 0. 8)   4 0. 7 ( 1 1 4)g  4 9. 5 ( N Cb) 
A U C 0- 4 
( h•  µ g/ g) 1 9 4 ( 4 6. 9)   2 8 4 ( 2 6. 1)   6 4 7 ( 6 7. 6)   1 4 3 0 ( 9 1. 3)   8 2 2 ( N Cb)  9 8 8  ( N Cb) 
A U C 0 -
4/ D o s e  ( h•  µ g/ g/ m g) 6. 0 5 ( 4 6. 9)   4. 4 4 ( 2 6. 1)   2 0. 2 ( 6 7. 6)   2 2. 4 ( 9 1. 3)   2 5. 7 ( N C
b)  1 5. 4 ( N Cb) 
A U C 0- 1 2 
( h•  µ g/ g)e - -  1 1 0 0 ( 8 0. 3)   2 4 6 0 ( 9 1. 9)   1 4 8 0 ( N Cb)   1 6 6 0 ( N Cb) 
A U C 0- 1 2/ MI C 
(( h• µ g/ g)/ 
( µ g/ m L))f - -  5 4 9 ( 8 0. 3)   1 2 3 0 ( 9 1. 9)   7 4 1 ( N Cb)  8 2 9 ( N Cb) 
C a v g 0- 4c 
( µ g/ g) 4 8. 4 ( 4 6. 9)   7 1. 0 ( 2 6. 1)   1 6 2 ( 6 7. 6)   3 5 8 ( 9 1. 3)   2 0 6 ( N Cb)  2 4 7 ( N Cb) 
Cm a x_ A c cd   - -  3. 6 0 ( 9 4. 6)   2. 0 9 ( N Cb)  5. 9 6 ( N Cb)  3. 1 4 ( N Cb) 
A U C _ A c cd   - -  3. 8 6 ( 8 2. 2)   2. 2 1  ( N Cb)  6. 4 7 ( N Cb)  3. 1 2 ( N Cb) 
A b br e vi ati o ns:  A c c:  a c c u m ul ati o n r ati o;  A U C:  ar e a  u n d er t h e  c o n c e ntr ati o n -ti m e  c ur v e;  BI D: t wi c e  d ail y;  C a v g:  a v er a g e 
c o n c e ntr ati o n;  C m a x:  m a xi m u m  c o n c e ntr ati o n;  C tr o u g h:  c o n c e ntr ati o n  at t h e  e n d  of t h e  d osi n g i nt er v al;  h:  h o ur;  MI C:  mi ni m u m 
i n hi bit or y  c o nc e ntr ati o n;  P K:  p h ar m a c o ki n eti c(s);  T m a x: ti m e  of  m a xi m u m  c o n c e ntr ati o n. 
a    Tm a x w as r e pr es e nt e d  as  M e di a n ( R a n g e)  
b  N C  =  St atisti cs  n ot  c al c ul at e d  w h e n  N  <  3  
c  C a v g 0- 4 is t h e  a v er a g e  c o n c e ntr ati o n  of t h e 4- h o ur  s a m pli n g  p eri o d,  c al c ul at e d  b y  A U C 0- 4/ 4 
d    Cm a x_ A c c  a n d  A U C _ A c c  ar e  a c c u m ul ati o n r ati os,  c al c ul at e d  usi n g  P K  p ar a m et ers ( C m a x a n d  A U C 0- 4)  of  Visit  [ADDRESS_1117147] e -d os e  a d mi nistr ati o n 
( Visits 3  a n d  6).  ( A U C 0- [ADDRESS_1117148] at e  c a n  b e 
pr es u m e d,  ot h er wis e  A U C 0- 1 2 is  u n d er esti m at e d,  a n d t h er ef or e  A U C/ MI C is  a  c o ns er v ati v e  esti m at e) 
f  MI C  =  Mi ni m u m i n hi bit or y  c o n c e ntr ati o n ( MI C)  of  v a n c o m y ci n f or  m et hi cilli n -r esist a nt  St a p h yl o c o c c us  a ur e us ( M R S A) 
( 2 µ g/ m L)  
g  N u m b er  of  S u bj e cts  =  [ADDRESS_1117149] a c e b o i n t h e  o c c urr e n c e, s e v erit y  or r el at e d n ess  of tr e at m e nt-e m er g e nt  a d v ers e  e v e nt s ( T E A Es ).  H o w e v er, 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117150] u g  dis c o nti n u ati o ns, s u g g esti n g t h e  hi g h er  d os e is  n ot  w ell t ol er at e d. I n  s u bj e cts <  [ADDRESS_1117151] a c e b o  at  b ot h  d os e l e v els.  
T h e i n ci d e n c e  of  T E A Es  wit h  o ns et  d uri n g t h e  Tr e at m e nt  P eri o d  w as si mil ar  b et w e e n tr e at m e nt  gr o u ps i n  e a c h 
c o h ort (r a n g e,  8 2. 6 % t o  9 0. 0 %).  T h e  m ost  c o m m o n  T E A E  w as  c o u g h,  wit h  n o  n ot a bl e  diff er e n c e  b et w e e n t h e  d os e c o h orts  or  b et w e e n  a cti v e  a n d  pl a c e b o.  Si g ns  a n d s y m pt o ms  c o nsi st e nt  wit h  p ot e nti al  br o n c h o c o nstri cti o n  w er e 
o bs er v e d sli g htl y  m or e  oft e n i n t h e  a cti v e tr e at m e nt  gr o u ps,  b ut  wit h  n o  n ot a bl e  diff er e n c e  b et w e e n t h e t w o  d os e 
c o h orts.  T h es e  e v e nts i n cl u d e d  d ys p n e a,  c h est  dis c o mf ort,  br o n c h o c o nstri cti o n,  a n d  F E V
1 d e cr e as e  (T a bl e  4 ). 
N o  d e at hs  w er e r e p ort e d  d uri n g t h e  st u d y.  S eri o us  a d v ers e  e v e nt s ( S A Es)  w er e  e x p eri e n c e d  b y  [ADDRESS_1117152] a c e b o  gr o u ps, r es p e cti v el y.   
T h e  m aj orit y  of  all  a d v ers e  e v e nt s  ( A Es) w er e  mil d  or  m o d er at e,  a n d t h er e  w as  a s hift fr o m  mil d t o  m o d er at e  A Es  i n 
t h e  [ADDRESS_1117153] a c e b o  gr o u ps.  T h er e  w as  n o n ot a bl e  diff er e n c e  b et w e e n t h e tr e at m e nt  gr o u ps i n t h e  o c c urr e n c e  of s e v er e  T E A Es.
 T h e i n ci d e n c e  of tr e at m e nt -
r el at e d  T E A Es ( T E A Es  c o nsi d er e d  p ossi bl y,  pr o b a bl y,  or r el at e d t o st u d y  dr u g)  w as si mil ar ( 2 1. 7  % t o  2 5. 0  %) i n 
t h e  A er o V a n c  [ADDRESS_1117154] a c e b o  gr o u ps,  w h er e as it  w as  hi g h er ( 5 8. 3  %) i n t h e  A er o V a n c  [ADDRESS_1117155] a c e b o  gr o u p. 
T h e  m aj orit y  of  s u bj e cts, 1 9 / [ADDRESS_1117156] u g  pri or t o  d a y  2 9  d u e t o  a  T E A E  w as  5. 0  %,  2 5. 0  %,  4 1. 7  %,  a n d  0  % i n t h e  A er o V a n c 
[ADDRESS_1117157] a c e b o  gr o u ps,  r es p e cti v el y (T a bl e  5 ). 
T h e r es ult s  of  p ost -h o c  a n al ys es s u g g est e d t h at  s u bj e cts <  [ADDRESS_1117158] a c e b o  s u bj e cts. I n s u bj e cts ≥  [ADDRESS_1117159] a c e b o  gr o u ps ( 1. 56  a n d  1. 8 4 f or t h e  A er o V a n c  3 2  m g  a n d  A er o V a n c  6 4  m g  gr o u ps, r es p e cti v el y).  N o  c o nsist e nt  or tr e a t m e nt-
r el at e d  c h a n g es i n  a n y  h e m at ol o g y,  c h e mi str y,  or  uri n al ysis l a b or at or y  p ar a m et er  v al u es,  vit al si g ns  m e as ur e m e nt, or  E C G  p ar a m et er  v al u es  w er e  n ot e d.  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  2 9 T a bl e  4 : I n ci d e n c e  of  a d v e rs e  e v e nts  o c c u r ri n g i n  ≥ [ADDRESS_1117160] e m  O r g a n  Cl ass  
  P r ef e r r e d  T e r m  C o h o rt  1  C o h o rt  2   P o ol e d  C o h o rts  
A e r o V a n c  
3 2  m g  
( N = 2 0) Pl a c e b o  
 
( N = 2 0) A e r o V a n c  
6 4  m g  
( N = 2 4) Pl a c e b o  
 
( N = 2 3) A e r o V a n c  
3 2 & 6 4  m g  
( N = 4 4) Pl a c e b o  
 
( N = 4 3) 
 n ( %)   n ( %)   n ( %)   n ( %)   n ( %)   n ( %)  
S u bj e ct s r e p orti n g  ≥  1  T E A E  Wit h  O ns et 
D uri n g t h e  Tr e at m e nt  P eri o d  1 8 ( 9 0. 0)   1 8 ( 9 0. 0)   2 0 ( 8 3. 3)   1 9 ( 8 2. 6)   3 8 ( 8 6. 4)   3 7 ( 8 6. 0)  
 C o u g h  9 ( 4 5. 0)   7 ( 3 5. 0)   9 ( 3 7. 5)   1 0 ( 4 3. 5)   1 8 ( 4 0. 9)   1 7 ( 3 9. 5)  
 R es pir at or y tr a ct  c o n g esti o n  8 ( 4 0. 0)   4 ( 2 0. 0)   7 ( 2 9. 2)   7 ( 3 0. 4)   1 5 ( 3 4. 1)   1 1 ( 2 5. 6)  
 F ati g u e  5 ( 2 5. 0)   4 ( 2 0. 0)   8 ( 3 3. 3)   3 ( 1 3. 0)   1 3 ( 2 9. 5)   7 ( 1 6. 3)  
 S p ut u m i n cr e as e d  6 ( 3 0. 0)   7 ( 3 5. 0)   6 ( 2 5. 0)   5 ( 2 1. 7)   1 2 ( 2 7. 3)   1 2 ( 2 7. 9)  
 P ar a n as al si n us  h y p ers e cr eti o n  6 ( 3 0. 0)   3 ( 1 5. 0)   4 ( 1 6. 7)   1 ( 4. 3)   1 0 ( 2 2. 7)   4 ( 9. 3)  
 D ys p n o e a  e x erti o n al  4 ( 2 0. 0)   2 ( 1 0. 0)   5 ( 2 0. 8)   3 ( 1 3. 0)   9 ( 2 0. 5)   5 ( 1 1. 6)  
 I nf e cti v e  p ul m o n ar y  e x a c er b ati o n  of  c ysti c fi br o sis  3 ( 1 5. 0)   5 ( 2 5. 0)   5 ( 2 0. 8)   2 ( 8. 7)   8  ( 1 8. 2)  7 ( 1 6. 3)  
 E x er cis e t ol er a n c e  d e cr e a s e d  5 ( 2 5. 0)   1 ( 5. 0)   2 ( 8. 3)   2 ( 8. 7)   7 ( 1 5. 9)   3 ( 7. 0)  
 F or c e d  e x pir at or y  v ol u m e  d e cr e as e d   4 ( 2 0. 0)   2 ( 1 0. 0)   3 ( 1 2. 5)   1 ( 4. 3)   7 ( 1 5. 9)   3 ( 7. 0)  
 C h e st  dis c o mf ort  2 ( 1 0. 0)   0   4 ( 1 6. 7)   0   6 ( 1 3. 6)   0  
 Si n u s  h e a d a c h e  4  ( 2 0. 0)  1 ( 5. 0)   2 ( 8. 3)   3 ( 1 3. 0)   6 ( 1 3. 6)   4 ( 9. 3)  
 W ei g ht  d e cr e as e d  4 ( 2 0. 0)   1 ( 5. 0)   2 ( 8. 3)   1 ( 4. 3)   6 ( 1 3. 6)   2 ( 4. 7)  
 D ys p n o e a  3 ( 1 5. 0)   1 ( 5. 0)   2 ( 8. 3)   0   5 ( 1 1. 4)   1 ( 2. 3)  
 I n cr e as e d  vis c o sit y  of  br o n c hi al  s e cr eti o n  1 ( 5. 0)   3 ( 1 5. 0)   3 ( 1 2. 5)   2 ( 8. 7)   4  ( 9. 1)  5 ( 1 1. 6)   D e cr e as e d  a p p etit e  0   2 ( 1 0. 0)   3 ( 1 2. 5)   4 ( 1 7. 4)   3 ( 6. 8)   6 ( 1 4. 0)  
 Di arr h o e a  0  0   3 ( 1 2. 5)   0   3 ( 6. 8)   0  
 Br o n c h o s p as m  0  0   2 ( 8. 3)   0   2 ( 4. 5)   0  
 D ys g e u si a  2 ( 1 0. 0)   0   0   0   2 ( 4. 5)   0  
 H a e m o pt ysis  1 ( 5. 0)   0   1 ( 4. 2)   4 ( 1 7. 4)   2 ( 4. 5)   4 ( 9. 3)  
 Or o p h ar y n g e al  p ai n  2 ( 1 0. 0)   0   0   0   2 ( 4. 5)   0  
 S p ut u m  dis c ol o ur e d  0   1 ( 5. 0)   2 ( 8. 3)   1 ( 4. 3)   2 ( 4. 5)   2 ( 4. 7)  
 W h e e zi n g  1 ( 5. 0)   2 ( 1 0. 0)   1 ( 4. 2)   0   2 ( 4. 5)   2 ( 4. 7)  
 
  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  3 0 T a bl e  5 : S u bj e ct  E a rl y  Dis c o nti n u ati o ns . 
S u bj e ct  E a rl y  Dis c o nti n u ati o n  
 C o h o rt  1   C o h o rt  2   C o h o rts  1 & [ADDRESS_1117161] a c e b o  
 A e r o V a n c  
3 2 & [ADDRESS_1117162] a c e b o  
 
 n ( %)   n ( %)   n ( %)   n ( %)   n ( %)   n ( %)   n ( %)  
S af et y  P o p ul ati o n  2 0 ( 1 0 0)   2 0 ( 1 0 0)   2 4 ( 1 0 0)   2 3 ( 1 0 0)   4 4 ( 1 0 0)   4 3 ( 1 0 0)   8 7 ( 1 0 0)  
Dis c o nti n u e d  St u d y  Dr u g  Pri or t o 
D a y  2 9 ( Visit  6)  3 ( 1 5. 0)   6 ( 3 0. 0)   1 3 ( 5 4. 2)   1 ( 4. 3)   1 6 ( 3 6. 4)   7 ( 1 6. 3)   2 3 ( 2 6. 4)  
P ri m a r y  R e a s o n f o r  Dis c o nti n u ati o n  of  St u d y  D r u g ( All  S u bj e cts ) 
 A d v ers e  E v e nt  1 ( 5. 0)   5 ( 2 5. 0)   1 0 ( 4 1. 7)   0  1 1 ( 2 5. 0)   5 ( 1 1. 6)   1 6 ( 1 8. 4) 
 St u d y  Dr u g I nt ol er a n c e  0   1 ( 5. 0)   2 ( 8. 3)   0   2 ( 4. 5)   1 ( 2. 3)   3 ( 3. 4)  
 S u bj e ct  Wit h dr e w 
C o ns e nt/ Ass e nt  1 ( 5. 0)   0   0   0   1 ( 2. 3)   0   1 ( 1. 1)  
 I n v e sti g at or  D e cisi o n 1 ( 5. 0)   0   0   0   1 ( 2. 3)   0   1 ( 1. 1)  
Ot h er  0   0   1 ( 4. 2)   1 ( 4. 3)   1 ( 2. 3)   1 ( 2. 3)   2 ( 2. 3)  
3. 2. 4. [ADDRESS_1117163] u d y.  El e v e n  s u bj e cts e x p eri e n c e d  a t ot al  of  1 5  S eri o us  A d v ers e  E v e nt s 
(S A Es ), i n cl u di n g  [ADDRESS_1117164] u g.  All  of t h e  S A Es r e q uir e d  h os pit ali z ati o n  wit h t h e  e x c e pti o n  of  1  S A E  of i nf e cti v e  p ul m o n ar y  e x a c er b ati o n  of  c ysti c fi br osis.  All  S A Es r es ol v e d ( 1 1 wit h o ut  s e q u el a e ). S A Es  w er e 
e x p eri e n c e d  b y  [ADDRESS_1117165] u di es  usi n g i n h al e d t o br a m y ci n ( T O BI  or  T O BI  P o d h al er ®) f or t h e 
tr e at m e nt  of P.  a er u gi n os a  i nf e cti o n i n  C F,  w h er e  a n i m pr o v e m e nt i n  F E V 1 is  pr e d o mi n a ntl y s e e n i n  y o u n g er 
s u bj e cts ( W e ers,  2 0 1 5) . I n  or d er t o s el e ct  a n  a p pr o pri at e  a g e  c ut off f or t h e  A er o V a n c s u b gr o u p  a n al ys es,  g ui d a n c e 
w as s o u g ht fr o m  a l ar g e r e tr os p e cti v e st u d y  b y  D as e n br o o k ( D as e n br o o k  E C  M.  C.-W.,  2 0 0 8) ,  w hi c h s h o w e d t h at p ersist e nt  M R S A i nf e cti o n i n  C F  s u bj e cts  8 –[ADDRESS_1117166] s  <  2 1  y e ars  of  a g e i n  F E V
1,  C F R S D-C RI S S, ti m e t o  n e e d  of  ot h er 
a nti bi oti cs,  a n d ti m e t o  e x a c er b ati o n.   
A  m e a n r e d u cti o n  of  0. 7 l o g 1 0 C F U/ m L fr o m  b as eli n e i n  M R S A  C F U s, t h e  pri m ar y  e n d p oi nt,  w as  o bs er v e d  aft er  2 8 
d a ys  of  A er o V a n c  a d mi nistr ati o n i n s u bj e cts  b el o w  2 1  y e ars  of  a g e  ( Fi g ur e  5 ),  al b eit  n ot st atisti c all y  si g nifi c a nt  d u e 
t o t h e li mit e d  n u m b er  of s u bj e ct s. 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  3 1   
Fi g u r e  5 : C h a n g e i n  M R S A  D e nsit y i n  S p ut u m i n  S u bj e cts l ess t h a n  [ADDRESS_1117167] s  2 1  y e ars  of  a g e  or  y o u n g er  a cr oss  all 
ti m e  p oi nts  d uri n g t h e tr e at m e nt  p eri o d ( Fi g ur e  6 ). T h e  m e a n   abs ol ut e  c h a n g e i n  F E V [ADDRESS_1117168] e d  o bs er v e d 
i n t h e  A er o V a n c  3 2  m g  bi d  ar m is  c o nsi d er e d  cli ni c all y  m e a ni n gf ul,  wit h  a n i m pr o v e m e nt r a n gi n g  b et w e e n  4 %  a n d 
6  % ( or  6  %  a n d  1 0  %  o n  a r el ati v e  c h a n g e  b asis),  al b eit  n ot st atisti c all y  si g nifi c a nt  d u e t o t h e li mit e d  n u m b er  of 
s u bj e cts.  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  3 2   
Fi g u r e  6 : A bs ol ut e  C h a n g e f r o m  B as eli n e i n  F E V [ADDRESS_1117169] a c e b o  ( Fi g ur e  7 ).  W h er e as i n t his si n gl e  c y cl e st u d y 
s e v er al s u bj e ct s i n t h e  A er o V a n c  ar m  w er e  pr es cri b e d  ot h er  a nti bi oti cs  at t h e s c h e d ul e d  o n e -m o nt h  p ost -tr e at m e nt 
visit ( a p pr o xi m at el y  D a y  5 6), s u c h tr e at m e nt  w o ul d  n ot  b e  e x p e ct e d t o  b e  pr es cri b e d  d uri n g  c hr o ni c  A er o V a n c tr e at m e nt,  or i n  a  m ulti pl e-c y cl e st u d y,  b e c a us e t h e ti mi n g  w o ul d  c oi n ci d e  wit h t h e  st art  of  a  n e w  A er o V a n c 
tr e at m e nt  p eri o d
.  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  3 3   
Fi g u r e  7 : Ti m e t o  Us e  of  Ot h e r  A nt i bi oti cs f o r  R es pi r at o r y I nf e cti o n i n  S u bj e cts l ess t h a n  [ADDRESS_1117170] u d y  ( S A V 0 0 5-0 2),  A er o V a n c  d e m o nstr at e d  a r e d u cti o n i n  M R S A  d e nsit y i n s p ut u m  al o n g  wit h 
i m pr o v e m e nt i n r es pir at or y s y m pt o ms, l u n g f u n cti o n, pr ol o n g ati o n  of t h e ti m e t o  n e e d  of  ot h er  a nti bi oti cs,  a n d ti m e 
t o  p ul m o n ar y  e x a c er b ati o n. S u bj e cts  <  [ADDRESS_1117171] s (P F Ts ). I n  a d diti o n t o s af et y  e v al u ati o n, t h e l att er  will  b e m e as ur e d t o  ass ess  c o nti n u e d  effi c a c y  of t h e tr e at m e nt  b ut  will  n ot  b e  us e d  as  p art  of t h e f or m al  effi c a c y  e v al u ati o n.  
[ADDRESS_1117172] u d y i s t o  e v al u at e t h e  effi c a c y  of  A er o V a n c i n i m pr o vi n g l u n g f u n cti o n  of  C F 
p ati e nts  ≤  [ADDRESS_1117173] e nt  M R S A l u n g i nf e cti o n.  N u m b er  at ri s k :H a z ar d  R ati o  (9 5  %  CI ): 0 .5 8  (0 .1 7 , 1 .9 7 )
P -v al u e : [ADDRESS_1117174] a c e b o
1 0 = n : Pl a c e b o , 1 0 = n : A er o V a n c , y e ar s  of   a g e2 1 ,  < MI T T
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117175] u d y  ar e : 
•   T o  e v al u at e t h e t i m e t o first p ul m o n ar y  e x a c er b ati o n  r e q uiri n g us e  of  a n ot h er  a nti bi oti c  m e di c ati o n ( or al, 
i ntr a v e n o us,  a n d/ or i n h al e d) a n d t h e fr e q u e n c y  of  p ul m o n ar y  e x a c er b ati o ns .  
•   T o  e v al u at e t h e  effi c a c y  of  A er o V a n c i n t h e r e d u cti o n  of r es pir at or y s y m pt o ms  a n d i m pr o v e m e nt i n  q u alit y 
of lif e . 
•   T o  e v al u at e t h e s af et y  a n d t ol er a bilit y  of  A er o V a n c  d uri n g  3 tr e at m e nt  c y cl es ( 2 4  w e e ks) . 
[ADDRESS_1117176] e d ( 2 0 0)  s u bj e ct s  ar e  e x p e ct e d t o  b e 
e nr oll e d i n t h e st u d y  at  a p pr o xi m at el y  [ADDRESS_1117177] at es ( U S)  a n d  C a n a d a.  S u bj e ct s  will  b e r a n d o mi z e d 
t o r e c ei v e  A er o V a n c ( n = 1 0 0);  or  pl a c e b o ( n = 1 0 0). It is  a nti ci p at e d t h at  u p t o  [ADDRESS_1117178] e nt  M R S A l u n g i nf e cti o n i n  p ati e nts  di a g n os e d  wit h c ysti c fi br osis.  
Aft er  a  S cr e e ni n g  p eri o d ( u p t o  4 2  d a ys)  t o  c o nfir m  eli gi bilit y f or st u d y  p arti ci p ati o n, s u bj e cts will  b e r a n d o m l y 
assi g n e d i n  a  bli n d e d f as hi o n  t o r e c ei v e  eit h er  A er o V a n c 3 0  m g t wi c e  d ail y ( BI D ),  or  pl a c e b o BI D  ( 1: [ADDRESS_1117179] a c e b o)  b y i n h al ati o n f or  2 4  w e e ks  or  3  d osi n g  c y cl es ( P eri o d  1).  U p o n  c o m pl eti o n  of  P eri o d  1, s u bj e cts  will 
r e c ei v e  o p e n-l a bel  A er o V a n c  3 0  m g  BI D  f or  a n  a d diti o n al  2 4  w e e ks  or  3  d osi n g  c y cl es ( P eri o d  2), t o  e v al u at e l o n g-t er m s af et y  of  A er o V a n c.  A  d osi n g  c y cl e is  d efi n e d  b y  [ADDRESS_1117180] u d y will  b e  str atifi e d  u p o n r a n d o mi z ati o n  o n t h e  b asis  of 
( a)  a g e ( 6– 2 1;  >  2 1), ( b)  B as eli n e  F E V
1 ( ≥ 6 0 %;  < 6 0 %), ( c)  pri or  e x a c er b ati o ns tr e at e d  wit h  a nti bi oti cs  d uri n g t h e 
pr e vi o us  1 2  m o nt hs ( 1 -2;  ≥  3 )  a n d ( d) P.  a er u gi n os a  tr e at m e nt ( n ot tr e at e d; tr e at e d).  
S u bj e cts  o n  a  2 8 -d a y  c y cli c al  o n/ off  a nti -Ps e u d o m o n al  a nti bi oti c r e gi m e n  will  e nt er t h e  S cr e e ni n g  p eri o d  at  a ti m e 
s u c h t h at t h e  B as eli n e  visit  c oi n ci d es  wit h t h e  e n d  of t h eir  a nti -Ps e u d o m o n as  a nti bi oti c  c y cl e.  St u d y  dr u g  will 
t h er e b y b e  a d mi nist er e d  d uri n g t h e  off -c y cl e,  a n d s u bj e cts  c a n t h e n r es u m e  a nti -Ps e u d o m o n al t h er a p y  d uri n g t h e  2 8 -
d a y  o bs er v ati o n  p eri o d ( W e e k  5 t hr o u g h  W e e k  8).  S u bj e cts  c o nti n ui n g  alt er n ati n g  a nti -Ps e u d o m o n al t h er a p y  c a n 
c o nti n u e t h eir tr e at m e nt  d uri n g t h e st u d y  dr u g  a d mi nistr ati o n  a n d  o bs er v ati o n  p eri o d s.  
T h e  pri m ar y  effi c a c y  a n d s af et y  p ar a m et ers  will  b e  m e as ur e d  d uri n g t h e  [ADDRESS_1117181] u d y ( P eri o d  1).  U p o n  c o m pl eti o n  of t h e  d o u bl e-bli n d  p orti o n, s u bj e cts  will  h a v e t h e  o pti o n  t o  c o nti n u e i nt o  a n 
o p e n -l a b el  p orti o n i n  w hi c h  s u bj e cts  will r e c ei v e  A er o V a n c 3 0  m g  BI D  f or  3,  2 8-d a y  d osi n g  c y cl es ( P eri o d  2).  S e e 
Fi g ur e  8  b el o w.  
 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  3 5  
Fi g u r e  8 :  St u d y  D esi g n. 
6. 3   Effi c a c y  a n d  S af et y  E v al u ati o ns 
Effi c a c y  ass ess m e nt s  will i n cl u d e  p ul m o n ar y f u n cti o ns t ests ( P F T),  p ul m o n ar y  e x a c er b ati o ns,  p ati e nt  r e p ort e d 
o ut c o m es  a n d  s p ut u m mi cr o bi ol o g y i n cl u di n g  M R S A  d e nsit y,  v a n c o m y ci n s us c e pti bilit y,  a n d  e m er g e n c e  of a d diti o n al  p at h o g e ns.  S af et y  ass ess m e nts  will i n cl u d e  all  a d v ers e  e v e nt s ( A Es),  as  w ell  as st a n d ar d  h e m at ol o g y, 
bi o c h e mistr y,  a n d  uri n e  a n al ys es,  vit al si g ns,  p h ysi c al  e x a mi n ati o n,  a n d  el e ctr o c ar di o gr a m ( E C G).  
6. [ADDRESS_1117182] u d y:   
1.   S u bj e cts  ≥  6  y e ars  of  a g e  at ti m e  of I nf or m e d  C o ns e nt  F or m (I C F)  or  Ass e nt  F or m si g ni n g.   
2.   C o nfir m e d  di a g n osis  of  C F,  d et er mi n e d  b y  h a vi n g  cli ni c al f e at ur es  c o nsist e nt  wit h t h e  C F  p h e n ot y p e,  pl us  1 
of t h e f oll o wi n g:  
a.   P ositi v e s w e at  c hl ori d e t est ( v al u e  ≥  6 0  m E q/ L),   b.   G e n ot y p e  wit h  [ADDRESS_1117183] e nt  wit h  C F ( i. e.,  a  m ut ati o n i n  e a c h  of t h e  c ysti c fi br osis 
tr a ns m e m br a n e  c o n d u ct a n c e r e g ul at or [ C F T R]  g e n es). 
3.   P ositi v e s p ut u m  c ult ur e  or  a t hr o at s w a b  c ult ur e f or  M R S A  at  S cr e e ni n g.   4.   I n  a d diti o n t o t h e S cr e e ni n g s a m pl e,  h a v e  at l e ast  [ADDRESS_1117184]  5 0 %  of  all  M R S A  c ult ur es 
(s p ut u m  or t hr o at s w a b  c ult ur e)  c oll e ct e d fr o m t h e ti m e  of t h e first  p ositi v e  c ult ur e (i n t h e  pr e vi o us 1  y e ar ) 
m ust  h a v e  t est e d p ositi v e f or  M R S A.  (N ot e:  S cr e e ni n g s a m pl e  m a y  c o u nt t o w ar ds  5 0 %  p ositi v e  c o u nt)  
5.   F or c e d  e x pir at or y  v ol u m e i n  1 s e c o n d ( F E V
1)  ≥ 3 0 %  a n d  ≤   90 %  of  pr e di ct e d t h at is  n or m al f or  a g e,  g e n d er, 
r a c e,  a n d  h ei g ht,  usi n g t h e Gl o b al  L u n g  F u n cti o n I niti ati v e ( G LI ) e q u ati o n.  
6.   At l e ast  1  e pis o d e  of  a c ut e  p ul m o n ar y i nf e cti o n tr e at e d  wit h  n o n -m ai nt e n a n c e  a nti b i oti cs  wit hi n  1 2  m o nt hs 
pri or t o  t h e  B as eli n e v isit. (I niti ati o n  of tr e at m e nt  wit h i nt er mitt e nt i n h al e d  a nti-Ps e u d o m o n al t h er a p y  will 
n ot  q u alif y  as tr e at m e nt  wit h  n o n -m ai nt e n a n c e  a nti bi oti cs).  
7.   If f e m al e  of  c hil d b e ari n g  p ot e nti al,  a n  a c c e pt a bl e  m et h o d  of  c o ntr a c e pti o n  m ust  b e  us e d  d uri n g t h e  c o urs e 
of t h e st u d y  a n d  m ust  b e  c o m bi n e d  wit h  a  n e g ati v e  pr e g n a n c y t est  o bt ai n e d  d uri n g  S cr e e ni n g;  s e x u all y 
a cti v e  m al e s u bj e ct s  of r e pr o d u cti v e  p ot e nti al  w h o  ar e  n o n -st eril e (i. e.,  m al e  w h o  h as  n ot  b e e n st erili z e d  b y 
v as e ct o m y f or  at l e ast  [ADDRESS_1117185] e  a n d/ or  a bs e n c e  of  v as  d ef er e ns t hr o u g h  ultr as o u n d )  m ust  b e  willi n g t o  us e  a b arri er  m et h o d  of  c o ntr a c e pti o n ,  or t h eir f e m al e  p art n er  m ust  us e  a n  a c c e pt a bl e  m et h o d  of  c o ntr a c e pti o n, 
d uri n g t h e  c o urs e  of t h e st u d y.  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117186] u d y, t h e  S p o ns or  d efi n es  “ a c c e pt a bl e  m et h o ds  of  c o ntr a c e pti o n ”  as:  
a.   Or al  birt h  c o ntr ol  pi[INVESTIGATOR_4382] s  a d mi ni st er e d f or  at l e ast  [ADDRESS_1117187] a nt e d r o d ( e g, I m pl a n o n ® ) f or  at l e ast  [ADDRESS_1117188] u g  a d mi ni str ati o n  b ut  n ot  b e y o n d t h e  4 t h s u c c essi v e  y e ar f oll o wi n g i ns erti o n 
c.   I ntr a ut eri n e  d e vi c es (I U Ds), i ns ert e d  b y a  q u alifi e d cli ni ci a n f or at l e ast  [ADDRESS_1117189] er o n e  a c et at e ( e g,  D e p o -Pr o v er a®)  a d mi ni st er e d f or  a  mi ni m u m  of  [ADDRESS_1117190] erili z ati o n  
f.  A bsti n e n c e  
g.   D o u bl e  b arri er  m et h o d ( di a p hr a g m  wit h s p er mi ci d al  g el  or  c o n d o ms  wit h  c o ntr a c e pti v e f o a m)  
N O T E :  F or s u bj e cts  pr es cri b e d  Or k a m bi:  Or k a m bi  m a y s u bst a nti all y  d e cr e as e  h or m o n al  c o ntr a c e pti v e 
e x p os ur e, r e d u ci n g t h e  eff e cti v e n ess  a n d i n cr e asi n g t h e i n ci d e n c e  of  m e nstr u ati o n -ass o ci at e d  a d v ers e 
r e a cti o ns.  H or m o n al  c o ntr a c e pti v es, i n cl u di n g  or al, i nj e ct a bl e, tr a ns d er m al,  a n d i m pl a nt a bl e, s h o ul d  n ot  b e 
r eli e d  u p o n  as  a n  eff e cti v e  met h o d  of  c o ntr a c e pti o n  w h e n  c o -a d mi nist er e d  wit h  Or k a m bi.  
8.   A bl e  a n d  willi n g t o  c o m pl y  wit h t h e  pr ot o c ol, i n cl u di n g  a v ail a bilit y f or  all s c h e d ul e d st u d y  visit s  a n d  b e 
a bl e t o  p erf or m  all t e c h ni q u es  n e c ess ar y t o  us e t h e  A er o V a n c i n h al er  a n d  m e as ur e l u n g f u n ct i o n. 
9.   A gr e e  n ot t o s m o k e  d uri n g  a n y  p art  of t h e  cli ni c al tri al ( S cr e e ni n g  vi sit t hr o u g h  e n d  of st u d y).  
[ADDRESS_1117191] u d y:   
1.   Us e  of  a nti -M R S A tr e at m e nts  pr es cri b e d  as  m ai nt e n a n c e t h er a p y  (I V  or i n h al e d tr e at m e nt wit hi n  2 8  d a ys; 
or al  tr e at m e nt wit hi n  1 4  d a ys)  pri or t o t h e  B as eli n e  vi sit.     
2.   Us e  of  n o n -m ai nt e n a n c e  a nti bi oti c  f or  p ul m o n ar y i nf e cti o n  or  e xtr a p ul m o n ar y  M R S A i nf e cti o n (I V  or 
i n h al e d  a nti bi oti c  wit hi n  2 8  d a ys;  or al  a nti bi oti c  wit hi n  1 4  d a ys)  pri or t o t h e  Bas eli n e  vi sit.     
3.   Hist or y  of  pr e vi o us  all er gi es  or s e nsiti vit y t o  v a n c o m y ci n,  or  ot h er  c o m p o n e nt(s)  of t h e st u d y  dr u g  or 
pl a c e b o  e x c e pt f or  a  hist or y  of r e d -m a n s y n dr o m e.  
4.   I n a bilit y t o t ol er at e i n h al e d  pr o d u cts. 
5.   First ti m e  s p ut u m  c ult ur e  or t hr o at s w a b  c ult ur e  yi el di n g  B.  c e p a ci a ,  or  n o nt u b er c ul o us  M y c o b a ct eri a i n t h e 
pr e vi o us  [ADDRESS_1117192] a n c e t o  v a n c o m y ci n  at  S cr e e ni n g ( v a n c o m y ci n r esi st a nt  St a p h yl o c o c c us  a ur e us  [ V R S A],  or 
v a n c o m y ci n i nt er m e di at e r esist a nt  St a p h yl o c o c c us  a ur e us  [ VI S A],  wit h  mi ni m u m i n hi bit or y  c o n c e ntr ati o n 
[ MI C]  ≥  8  µg/ m L).  
8.   Or al  c orti c ost er oi ds i n  d os es  e x c e e di n g  [ADDRESS_1117193] or y  at  S cr e e ni n g t h at, i n t h e I n v esti g at or's 
o pi [INVESTIGATOR_9384] o n,  w o ul d  c o m pr o mis e t h e s af et y  of t h e s u bj e ct  or t h e  q u alit y  of t h e st u d y  d at a.  
[ADDRESS_1117194]. 
1 2.  S p O 2  <9 0 %  at  S cr e e ni n g . 
[ADDRESS_1117195] r es ult  d uri n g  S cr e e ni n g ,  pr e g n a nt ( or i nt e n ds t o  b e c o m e  pr e g n a nt), 
la ct ati n g  or i nt e n ds t o  br e astf e e d  d uri n g t h e  c o urs e  of t h e st u d y . 
1 6.  R e n al i ns uffi ci e n c y,  d efi n e d  as  cr e ati ni n e  cl e ar a n c e  <  5 0  m L/ mi n  usi n g t h e  C o c k cr oft -G a ult  e q u ati o n f or 
a d ults  or  S c h w art z  e q u ati o n  f or c hil dr e n  at t h e  S cr e e ni n g  vi sit.  
1 7.  A b n or m al li v er f u n cti o n,  d efi n e d  as  ≥  4 x  u p p er li mit  of  n or m al ( U L N),  of s er u m  as p art at e  a mi n otr a nsf er as e 
( A S T)  or s er u m  al a ni n e  a mi n otr a nsf er as e ( A L T),  or  k n o wn  cirr h osi s  at  S cr e e ni n g.  
[ADDRESS_1117196] or y  of  p ositi v e r es ult  f or  h u m a n i m m u n o d efi ci e n c y  vir us ( HI V),  h e p atitis  B  vir us ( H B V)  or  h e p atitis  C 
vir us ( H C V).  
[ADDRESS_1117197] a n n e d  h os pit ali z ati o ns f or  pr o p h yl a xis  a nti bi oti c tr e at m e nt  wit hi n  2 8  d a ys  pri or t o  B as eli n e  visit  or  d uri n g 
t h e  o p e n-l a b el  p eri o d ( P eri o d  1). 
6. [ADDRESS_1117198]  s af et y  a n d/ or  s ci e ntifi c  v al u e  of  t h e  st u d y  a n d/ or  q u alit y  of  t h e  st u d y  dr u gs  h a v e  b e e n 
c o m pr o mis e d, t h e  st u d y  s h o ul d  b e  h alt e d , or t h e  st u d y  c e nt er’s  p arti ci p ati o n  s h o ul d  b e t er mi n at e d.  C o n diti o ns t h at 
m a y  w arr a nt t er mi n ati o n  of t h e st u d y i n cl u d e,  b ut  ar e  n ot li mit e d t o, t h e f oll o wi n g:  
•   T h e  dis c o v er y  of  a n  u n e x p e ct e d, s eri o us,  or  u n a c c e pt a bl e ris k t o t h e s u bj e cts  e nr oll e d i n t h e st u d y;  
•   A  d e cisi o n  o n t h e  p art  of t h e  S p o ns or t o  s us p e n d  or  dis c o nti n u e t esti n g,  e v al u ati o n,  or  d e v el o p m e nt  of t h e 
pr o d u ct f or  a n y r e as o n;  
•   F ail ur e  of t h e I n v esti g at or t o  e nr oll s u bj e cts i nt o t h e st u d y  at  a n  a c c e pt a bl e r at e;  
•   F ail ur e  of t h e I n v esti g at or t o  c o m pl y  wit h  p erti n e nt  g o v er ni n g  b o d y r e g ul ati o ns;  
•   S u b missi o n  of  k n o wi n gl y f als e i nf or m ati o n fr o m t h e r es e ar c h f a cilit y t o t h e  S p o ns or, st u d y  m o nit or,  m e di c al 
offi c er,  or r e g ul at or y  offi ci al;  a n d,  
•   I ns uffi ci e nt  a d h er e n c e t o  pr ot o c ol r e q uir e m e nt s.  
St u d y t er mi n ati o n  a n d  foll o w -u p s h o ul d  b e  p erf or m e d i n  c o m pli a n c e  wit h  a p pli c a bl e  g o v er ni n g  b o d y r e g ul ati o ns.  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  3 8 If  a n  I nstit uti o n al   R e vi e w   B o ar d  (I R B),  I n d e p e n d e nt   Et hi cs   C o m mitt e e  (I E C),  or   R es e ar c h   Et hi cs   B o ar d  ( R E B)  
wit h dr a ws  a p pr o v al f or  a st u d y sit e  d u e t o s u bj e ct  s af et y  c o n c er ns r el at e d t o t h e i n v esti g ati o n al  pr o d u ct,  al l sit es  will 
b e  n otifi e d  a n d  n o f urt h er tr e at m e nts  will  b e  gi v e n  u ntil r es ol uti o n  of t h e iss u e  or  d et er mi n ati o n  b y t h e r e vi e w ers t h at 
n o  u n d u e ris k  e xists.  
If t h e st u d y is t er mi n at e d f or s af et y  c o n c er ns,  all s u bj e cts  will  b e f oll o w e d f or  at l e ast  [ADDRESS_1117199]’s fi n al 
tr e at m e nt,  u nl ess  a l o n g er f oll o w-u p  p eri o d is  w arr a nt e d t o  a d dr ess t h e s af et y  c o n c er n.  S u bj e cts  wit h si g nifi c a nt s af et y e v e nt s  will  b e f oll o w e d  u ntil r es ol uti o n  or  st a bili z ati o n  of t h e  e v e nt  as  st at e d  i n S e cti o n  [ADDRESS_1117200]  2 8  d a ys  pri or t o t h e  B as eli n e  vi sit , 
a n d/ or  us e  of  or al  a nti -M R S A tr e at m e nt s  at l e ast  [ADDRESS_1117201] a bl e  a nti bi oti cs  wit h  p ot e nti al  a cti vit y t o  M R S A ( e. g. 
v a n c o m y ci n, t el a v a n ci n, li n e z oli d, t etr a c y cli n es s u c h  as  d o x y c y cli n e  or  mi n o c y cli n e,  
tri m et h o pri m/s ulf a m et h o x a z ol e,  M R S A-a cti v e  c e p h al os p ori ns  ( e. g. c eft ar oli n e ),  cli n d a m y ci n,  d a pt o m y ci n, 
g e nt a mi ci n , or rif a m pi n) . 
7. 2   A nti - Ps e u d o m o n as  A nti bi oti c  T r e at m e nt 
F or  s u bj e cts o n  a  2 8 -d a y  c y cli c al  o n/ off  a nti -P s e u d o m o n al  a nti bi oti c r e gi m e n, t h e y  will  e nt er t h e  S cr e e ni n g  p eri o d 
at  a ti m e  s u c h t h at t h e  B as eli n e  visit  c oi n ci d es  wit h t h e  e n d  of t h eir  a nti -Ps e u d o m o n as  a nti bi oti c  c y cl e.  St u d y  dr u g 
will t h er e b y  b e  a d mi ni st er e d  d uri n g t h e  off -c y cl e ,  a n d s u bj e cts c a n t h e n r es u m e  a nti -Ps e u d o m o n al t h er a p y  d uri n g 
t h e 4- w e e k  o bs er v ati o n  p eri o d s ( W e e k  5 t hr o u g h  W e e k  8,  W e e k  13  t hr o u g h  W e e k  1 6,  W e e k  21  t hr o u g h  W e e k  2 4). 
S u bj e cts  o n  c o nti n ui n g  alt er n ati n g  a nti -Ps e u d o m o n al t h er a p y  ( C A T) c a n  c o nti n u e t h eir tr e at m e nt  d uri n g t h e st u d y 
dr u g  a d mi ni str ati o n  a n d  F oll o w -u p  p eri o d s,  b ut t h e s u bj e ct’s i niti al  d os e  of st u d y  m e di c ati o n  m ust  c oi n ci d e  wit h t h e 
i niti al  d os e  of a ztr e o n a m ( C a yst o n )/ c oli sti m et h at e ( C olisti n) .  
[ADDRESS_1117202] y  p o w d er f or m ul ati o n  of t h e  a cti v e 
p h ar m a c e uti c al i n gr e di e nt ( A PI)  v a n c o m y ci n  h y dr o c hl ori d e,  d e v el o p e d  b y  S a v ar a  P h ar m a c e uti c als.  As s h o w n i n T a bl e  [ADDRESS_1117203].  E a c h  cl e ar , ( H y dr o x y pr o p yl) m et h yl  c ell ul os e (H P M C ), si z e  [ADDRESS_1117204] u d y l a b el  cl ai m  is l o w er e d fr o m  1 6  m g ( P h as e II  d os e) t o 
[ADDRESS_1117205] u al  c o nt e nt  of  v a n c o m y ci n i n t h e  c a ps ul e  will  b e  c o m p ar a bl e  b et w e e n t h e  P h as e II  a n d  P h as e III  b at c h es . 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  3 9 T a bl e  6 : F o r m ul ati o n  of  A e r o V a n c . 
I n g r e di e nt  P u r p os e/ R ol e  
V a n c o m y ci n  H y dr o c hl ori d e  U S P  A cti v e  p h ar m a c e uti c al i n gr e di e nt  
L -L e u ci n e  U S P  Dis p ersi o n  a n d st a bilit y  e n h a n c e m e nt  
P urifi e d  W at er  U S P  M a n uf a ct uri n g  pr o c essi n g  ai d  
8. [ADDRESS_1117206] a c e b o . 
T a bl e  7 : F o r m ul ati o n  of  Pl a c e b o . 
I n g r e di e nt  P u r p os e/ R ol e  
Tr e h al os e  Di h y dr at e  N F  B ul ki n g  a g e nt  
L -L e u ci n e  U S P  Dis p ersi o n  a n d  st a bilit y  e n h a n c e m e nt  
P urifi e d  W at er  U S P  M a n uf a ct uri n g  pr o c essi n g  ai d  
8. [ADDRESS_1117207] u g is s u p pli e d  i n  a  4-w e e k  cli ni c al  kit.  E a c h  cli ni c al  kit  c o nt ai ns  4  w e e kl y  b o x es  c o nt ai ni n g  8  d ail y  d osi n g  c ar ds. 
E a c h  d ail y  d osi n g  c ar d  will  c o nt ai n  4  c a ps ul es.  T w o  ( 2) c a ps ul es  will  b e  us e d f or t h e  m or ni n g  d os e  a n d  2  c a ps ul es f or t h e  e v e ni n g  d os e.  
  
 
 
L a b eli n g:  E a c h  4 -w e e k  cli ni c al  kit,  a n d  c o nt e nts  wit hi n t h e  kit (i . e.,  w e e kl y  b o x es  a n d  d osi n g  c ar ds),  will  b e l a b el e d 
wit h  pr o d u ct  n a m e,  t h e  pr ot o c ol  n u m b er, t h e  n a m e  of t h e S p o ns or  a n d  a d dr ess ,  a n d  dir e cti o ns f or t h e us e  a n d 
st or a g e ( 4-w e e k  cli ni c al  a n d  w e e kl y  kit)  a n d  t h e r e q uir e d a p pli c a bl e r e g ul at or y  a g e n c y  w ar ni n g st at e m e nt s 
( "C a uti o n:  N e w  Dr u g  - Li mit e d  b y  F e d er al  L a w t o I n v esti g ati o n al  Us e. ") . 
8. [ADDRESS_1117208] u d y  D r u g  at t h e  Sit e  
T h e  S p o ns or ( or  d esi g n e e)  will s hi p  St u d y  Dr u g t o t h e i n v esti g ati o n al sit es  pri or t o  e nr oll m e nt  of t h e  first s u bj e ct. 
T h e i niti al st u d y  dr u g s hi p m e nt  will  b e s hi p p e d  aft er sit e  a cti v ati o n ( i. e.,  all r e q uir e d r e g ul at or y  d o c u m e nt ati o n, 
i n cl u di n g  et hi c’s  a p pr o v al, a n d  a n  e x e c ut e d tri al  c o ntr a ct)   has  b e e n r e c ei v e d  b y t h e  S p o ns or.  S u bs e q u e nt  st u d y  dr u g 
s hi p m e nts  will  b e  m a d e  as  n e c ess ar y  b as e d  u p o n  s u bj e ct r e cr uit m e nt. 
A er o V a n c  will  b e s hi p p e d t o t h e  cli ni c al sit e i n  a n i ns ul at e d  c o nt ai n er  c o ntr oll e d t o  2 -8 ° C.  E a c h s hi p m e nt  will  b e 
e q ui p p e d  wit h  a  T e m p T al e  [ADDRESS_1117209] o p t e m p er at ur e r e c or di n g,  d o w nl o a d  d at a  a n d e m ail  d at a  will  b e  pr o vi d e d  wit h  e a c h s hi p m e nt.  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  4 0 8. 5   D os a g e/ D os a g e  R e gi m e n 
T h e i n h al ati o n  p o w d er is  p a c k a g e d i nt o  c a ps ul es,  e a c h  c a ps ul e  c o nt ai ni n g  [ADDRESS_1117210] u d y i s  3 0  m g ( 2  c a ps ul es)  BI D  ( at l e ast  6 h o urs  a p art) .  Alt er n ati v el y,  a s u bj e ct m a y  b e r a n d o mi z e d t o r e c ei v e  a 
m at c hi n g  pl a c e b o,  wit h  e q ui v al e nt  n u m b ers  of  c a ps ul es.  
8. [ADDRESS_1117211] will  b e  dis p e ns e d  a  4 -w e e k  kit  c o nt ai ni n g  4  w e e kl y  b o x es.  E a c h  b o x  will 
c o nt ai n  8  d ail y  d osi n g  c ar ds  ( 7  +  1  e xtr a). E a c h  d ail y  d osi n g  c ar d  c o nt ai n s [ADDRESS_1117212] eti o n  of t h e  S cr e e ni n g  p eri o d  ( u p t o  4 2  d a ys) t o  c o nfir m i n cl usi o n/ e x cl usi o n  crit eri a, eli gi bl e 
s u bj e cts  will  b e r a n d o mi z e d t o r e c ei v e  eit h er  A er o V a n c  [ADDRESS_1117213] a c e b o BI D  ( 1: [ADDRESS_1117214] a c e b o)  b y 
i n h al ati o n f or t hr e e 4- w e e k l y  c y cl es. A  c e ntr al r a n d o mi z ati o n  s c h e m e  will  b e  pr o d u c e d  wit h  f o ur str atifi c ati o n 
f a ct ors  o n t h e  b asis of  ( a)  a g e ( 6– 2 1;  >  2 1), ( b)  B as eli n e  F E V 1 ( ≥ 6 0 %;  < 6 0 %), ( c)  pri or  e x a c er b ati o ns tr e at e d  wit h 
a nti bi oti cs  d uri n g t h e  pr e vi o us  1 2  m o nt hs ( 1 -2;  ≥  3 )  a n d ( d) P.  a er u gi n os a  tr e at m e nt ( n ot tr e at e d; tr e at e d). 
R a n d o mi z ati o n  will  b e  c arri e d  o ut  vi a I nt er a cti v e  W e b  R es p o ns e (I W R).  
8. [ADDRESS_1117215]  b e  n otifi e d  of t h e  u n bli n di n g,  a n d t h e I n v esti g at or  or  d esi g n e e  will  d o c u m e nt t h e r e as o n(s) 
n e c ess ar y t o  br e a k t h e  bli n d f or  a n y  s u bj e ct. S u bj e ct s  will  b e  d is c o nti n u e d fr o m t h e st u d y if t h e  bli n d is  br o k e n.  
8. 9   I n h al e r  D e vi c e 
T h e  A er o V a n c i n h al er ( M o n o d os e  R S [ADDRESS_1117216] a n d ar d i n h al er) is  a  u nit  d os e,  dr y  p o w d er i n h al er  d e vi c e t h at 
utili z es si z e  [ADDRESS_1117217] er  Fil e ( D M F ) h as 
b e e n fil e d.  Fi v e  ( 4  +  1  e xtr a  { w e e kl y }) i n h al ers  will  b e  pr o vi de d  wit hi n  e a c h  [ADDRESS_1117218] at e m e nt, " C a uti o n:  N e w  D e vi c e  - Li mit e d  b y  F e d er al 
L a w t o I n v esti g ati o n al  Us e. "  T h e  A er o V a n c i n h al er  s h o ul d  b e st or e d  u n d er t h e s a m e  c o n diti o ns  as t h e  dr u g s u p pli es 
(i. e. r efri g er at e d  pri or t o  dis p e nsi n g  a n d  a m bi e nt r o o m t e m p er at ur e  c o n diti o ns  aft er  dis p e nsi n g).  
F or  d et ail e d i nstr u cti o ns  of  us e, s e e  A p p e n di x  [ADDRESS_1117219] a c e b o ( 2  c a ps ul es)  BI D  will  b e  a d mi ni st er e d  usi n g t h e r el o a d a bl e,  c a ps ul e i n h al er. 
S u bj e cts  will  b e i nstr u ct e d t o t a k e  a s h ort -a cti n g  br o n c h o dil at or  a g e nt  pr e -tr e at m e nt (2  p uffs  of  t h e s h ort  a cti n g 
br o n c h o dil at or  al b ut er ol ,  or  e q ui v al e nt) n o l ess t h a n  [ADDRESS_1117220] or a g e i n t h e  cli ni c/ p h ar m a c y  e x c e e ds  or f alls  b el o w t his r a n g e, t his  s h o ul d  b e 
r e p ort e d t o t h e  S p o ns or  or  d esi g n e e pri or t o  dis p e nsi n g st u d y  dr u g . T h e  S u bj e cts  will  b e i nstr u ct e d t o st or e t h e 
m e di c ati o n i n  ori gi n al  p a c k a gi n g ( al u mi n u m  f oil blist er  p a c ks  a n d  pr ot e ct e d fr o m li g ht)  at r o o m t e m p er at ur e 
a c c or di n g t o t h e i nstr u cti o ns  o utli n e d  in  t h e I nstr u cti o ns f or  Us e of  A er o V a n c I n h al er li st e d i n  A p p e n di x  [ADDRESS_1117221]  mi sses  a s c h e d ul e d 
d os e  ( m or ni n g  or  e v e ni n g)  a n d  h as at l e ast  [ADDRESS_1117222] u d y ( C o d e  of  F e d er al  R e g ul ati o ns,  Titl e  2 1,  P art  3 1 2. 5 7 ). R e c or ds will  b e  k e pt  o n  pr o d u ct  a c c o u nt a bilit y  a n d i n v e nt or y f or ms.  All  pr o d u ct,  w h et h er  us e d  or  u n us e d,  will  b e  d o c u m e nt e d o n  dr u g  a c c o u nt a bilit y f or ms.  A c c o u nt a bilit y  of t h e i n v esti g ati o n al  a g e nt  will  b e  v erifi e d  b y t h e st u d y  m o nit or  d uri n g 
o n -sit e  m o nit ori n g  vi sit s.  
If t h e i n v esti g ati o n i s t er mi n at e d, s us p e n d e d,  dis c o nti n u e d,  or  c o m pl et e d  u p o n i nstr u cti o n fr o m  S a v ar a, t h e 
In v esti g a t or s h all r et ur n  all  us e d  a n d u n us e d s u p pli es  ( blist ers,  c a ps ul es,  a n d i n h al ers) t o  S a v ar a’s  cli ni c al r et ur n v e n d or .  T h e s hi p m e nt  m ust  c o nt ai n fi n al dr u g  a c c o u nt a bilit y f or ms,  w hi c h  c o m pl et e t h e  a c c o u nt a bilit y  of t h e  e ntir e 
st u d y  a n d r e c o n cil e  a n y  dis cr e p a n ci es.
 
[ADDRESS_1117223]’s l e g al r e pr es e nt ati v e. 
If a p pr o pri at e,  ass e nt  m ust  a ls o  b e  o bt ai n e d  pri or t o  c o n d u cti n g  a n y st u d y-r el at e d  a cti viti es. 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117224] u d y.  D os e, r o ut e,  u nit fr e q u e n c y  of  a d mi nistr ati o n,  a n d i n di c ati o n f or 
a d mi nistr ati o n  a n d  d at es  of  m e di c ati o n  will  b e  c a pt ur e d.  
9. 1. 2   D e m o g r a p hi cs   
D e m o gr a p hi c i nf or m ati o n ( d at e  of  birt h,  s e x, r a c e a n d  et h ni cit y )  will  b e r e c or d e d  at t h e  S cr e e ni n g  visit. 
9. 1. [ADDRESS_1117225]’s 
g e n er al  a p p e ar a n c e,  h e a d,  e y es,  e ars,  n os e,  a n d t hr o at ( H E E N T),  n e c k,  h e art, l u n gs,  a b d o m e n,  e xtr e miti es, s ki n,  a n d g e n er al  n e ur ol o gi c al  s yst e m.   
S y m pt o m -ori e nt e d  or  bri ef  p h ysi c al  e x a mi n ati o ns  will  b e  p erf or m e d  at ti m e  p oi nts  n ot e d i n t h e  S c h e d ul e  of  E v e nts 
a n d  as  cli ni c all y i n di c at e d.  N e w  a b n or m al  p h ysi c al  e x a m fi n di n gs  n ot  pr es e nt  d uri n g t h e  b as eli n e  vi sit s s h o ul d  b e 
r e c or d e d  as A Es  a n d  f oll o w e d d uri n g s u bs e q u e nt  visit s. 
9. 1. [ADDRESS_1117226] r o c a r di o g r a m ( E C G) 
A  [ADDRESS_1117227] u d y as i n di c at e d  o n t h e  S c h e d ul e  of  E v e nts.  All  E C G s will  b e  
tr a ns mitt e d t o t h e  C R O fr o m t h e l a pt o p ( C P S/ B E A M S). T h e tr a ci n g s will  b e  pr o c ess e d  a n d  a  c o nfir m e d  E C G ( o v er -
r e a d  b y  a c e ntr ali z e d  C ar di ol o gist)  will  b e  r et ur ne d  t o t h e sit e, g e n er all y  wit hi n  2  b usi n ess  d a ys . A s u m m ar y  of t h e 
re a di n gs  will  b e  pr o vi d e d t o t h e sit e f or t h eir  r e c or ds. It  will  b e t h e r es p o nsi bilit y  of t h e In v esti g at or  or  a  S u b -
In v esti g at or  t o r e vi e w t h e tr a ci n gs f or s af et y. Cli ni c all y si g nifi c a nt fi n di n gs,  n ot  pr es e nt  d uri n g t h e  B as eli n e  visit , 
s h o ul d  b e r e c or d e d  as  a n  A E .  
9. 1. 7   C F R S D -C RI S S  
T h e  C ysti c  Fi br osi s  R es pir at or y  S y m pt o m  Di ar y  –  C hr o ni c  R es pir at or y I nf e cti o n  S y m pt o m  S c or e ( C F R S D -C RI S S), 
is  a n  8-it e m  p ati e nt-r e p ort e d  o ut c o m e ( P R O) s y m pt o m  m e as ur e t h at is  p art  of t h e  C ysti c  Fi br osis  R es pir at or y S y m pt o m  Di ar y ( C F R S D).  T h e  C F R S D -C RI S S  is  d esi g n e d t o  e v al u at e t h e  eff e ct  of tr e at m e nt  o n t h e  s e v erit y  of 
s y m pt o ms  of r es pir at or y i nf e cti o n i n  s u bj e cts  wit h  C ysti c  Fi br osis ( C F).  Ass ess m e nt s i n t h e  C F R S D -C RI S S 
c o m pris e t h e  8 s y m pt o m it e ms  of  t h e  C F R S D:  diffi c ult y br e at hi n g,  c o u g h,  c o u g h  u p  m u c us,  c h est ti g ht n ess,  w h e e z e, 
f e eli n g f e v eris h, tir e d,  a n d  c hill s/s w e at s.  
T h e  ass ess m e nt s  s h o ul d  b e  c o m pl et e d  w e e kl y  b y  t h e  s u bj e ct  at  h o m e  at  b e dti m e.    T h e    C F R S D -C RI S S   will  b e 
a d mi nist er e d  usi n g  a n  e -Di ar y  ( h a n d  h el d  d e vi c e) t h at will  b e  pr o vi d e d t o  e a c h s u bj e ct . 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  4 3 9. 1. 8   C F Q - R 
T h e  C ysti c  Fi br osis  Q u esti o n n air e -R e vis e d  ( C F Q -R) is  a  dis e as e -s p e cifi c  h e alt h-r el at e d  q u alit y  of lif e  m e as ur e  f or 
c hil dr e n,  a d ol es c e nt s ,  a n d  a d ults    wit h    C F.   T h e    C F Q -R    m e as ur es  f u n cti o ni n g  i n  a  v ari et y  of  d o m ai ns,  i n cl u di n g 
P h ysi c al  F u n cti o ni n g,   Vit alit y,   H e alt h  P er c e pti o ns,   R es pir at or y  S y m pt o ms,   Tr e at m e nt   B ur d e n,   R ol e  F u n cti o ni n g, 
E m oti o n al  F u n cti o ni n g , a n d  S o ci al  F u n cti o ni n g.  T h e   C R Q -R    will  b e  a d mi ni st er e d  usi n g  a n  e -Di ar y  t h at  will  b e 
pr o vi d e d t o  e a c h s u bj e ct  e v er y t w o  w e e ks . 
9. 1. 9   E Q- 5 D- 5 L  &  E Q- 5 D y  
T h e  E ur o Q ol -5 D ( E Q -5 D) is  a  m or e  g e n er al  q u esti o n n air e  w hi c h is  wi d el y  us e d t o  m e as ur e  h e alt h  o ut c o m e i n t er ms 
of  m o bilit y, s elf -c ar e,  us u al  a cti viti es,  p ai n/ dis c o mf ort,  a n xi et y/ d e pr essi o n.  T h e  5- l e v el i nstr u m e nt ( E Q-5 D -5 L) 
w hi c h  us es  a  5 -p oi nt s c al e ( n o  pr o bl e ms, sli g ht  pr o bl e ms,  m o d er at e  pr o bl e ms, s e v er e  pr o bl e ms,  a n d  e xtr e m e 
pr o bl e ms)  will  b e  us e d i n t h e l o c al l a n g u a g e . F or s u bj e cts  1 5  y e ars  or  y o u n g er t h e  E Q -5 D  Y o ut h ( E Q -5 D y)  will  b e us e d.  T his i nstr u m e nt  will  b e  us e d t o  m e as ur e  o v er all s elf -r at e d  h e alt h st at us. T h e  q u esti o n n air e  will  b e  c o n d u ct e d 
i n t h e  cli ni c  d uri n g t h e  vi sit. 
9. 1. 1 0   P ul m o n a r y  F u n cti o n  T ests  ( P F T) 
All s u bj e cts  will  u n d er g o st a n d ar di z e d  p ul m o n ar y f u n cti o n t esti n g  as i n di c at e d i n t h e  S c h e d ul e  of  E v e nts t o 
d et er mi n e t h eir f or c e d  vit al  c a p a cit y ( F V C ), p e a k  e x pir at or y fl o w r at e ( P E F R ), f or c e d  e x pir at or y fl o w ( F E F) b et w e e n  2 5 %  a n d  7 5 %  of  F V C ( F E F
2 5 -7 5) a n d  F E V 1.  P ul m o n ar y f u n cti o n t esti n g  will  b e  p erf or m e d  a c c or di n g t o 
A m eri c a n  T h or a ci c  S o ci et y ( A T S ) g ui d eli n es ( 2 0 0 5).  S u bj e ct s  will  b e t est e d  usi n g t h e  s a m e  s pir o m etr y  e q ui p m e nt 
pr o vi d e d  b y t h e  S p o ns or .  U p t o  [ADDRESS_1117228] ’s  C R Fs  a n d a  c o p y  of t h e s pir o m etr y r e p orts  will  b e r et ai n e d  wit h t h e  s u bj e ct’s s o ur c e  d o c u m e nts.  
P r e -d os e  P F Ts  will  b e  p erf or m e d  at  all  visits  pri or t o t h e  s u bj e ct a d mi ni st eri n g t h e  br o n c h o dil at or  pr e -tr e at m e nt  a n d 
st u d y  dr u g ( A er o V a n c/ pl a c e b o).  T h e  B as eli n e  P F T  m ust  b e  p erf or m e d  a n d  m e et i n cl usi o n  crit eri a,  pri or t o  b ei n g 
r a n d o mi z e d t o st u d y  m e di c ati o n,  aft er  w hi ch  a d mi nistr ati o n  of  br o n c h o dil at or  a n d st u d y  dr u g  will  b e  d o n e  as d es cri b e d  b el o w.  
 
T h e s e q u e n c e  of  e v e nt s  o n t h e  d a ys  of st u d y  dr u g  a d mi nistr ati o n  will  b e  p erf or m e d  as f oll o ws:   
•   S u bj e cts  will  p erf or m t h eir  m or ni n g  air w a y  cl e ar a n c e  at  h o m e i n  a  n or m al f as h i o n (e g ,  a d mi nist eri n g  a 
s h ort-a cti n g  br o n c h o dil at or, f oll o w e d  b y  h y p ert o ni c s ali n e,  v est,  P ul m o z y m e
®,  a n d  p ot e nti all y  a l o n g-a cti n g 
br o n c h o dil at or/ c orti c ost er oi d i n h al ati o n).  A s  a r e mi n d er,  all s u bj e ct s s h o ul d  b e  m ai nt ai n e d  o n t h e  s a m e m e di c ati o ns t hr o u g h o ut t h e  e ntir e st u d y  p eri o d,  as  m e di c all y f e asi bl e,  wit h t h e  e x c e pti o n  of t h os e s p e cifi e d 
i n S e cti o n  7. 1 . 
•   S u bj e cts  will t h e n  c o m e t o t h e  cli ni c  d uri n g t h e  m or ni n g.  T h e  s u bj e cts ar e  n ot  all o w e d t o  us e  al b ut er ol ( or 
ot h er s h ort -a cti n g  br o n c h o dil at or) f or  [ADDRESS_1117229] u g ( A er o V a n c  or  Pl a c e b o)  u n d er s u p er vi si o n.   
•   T h e  s u bj e cts s h o ul d f oll o w t his  e x a ct s a m e  pr o c e d ur e  at  all tr e at m e nt  vi sit s,  a n d t h er e b y, t h e y s h o ul d  n ot 
t a k e t h eir  m or ni n g st u d y  dr u g  u ntil t h e y  h av e  c o m e t o t h e  cli ni c,  c o m pl et e d  P F Ts, t h e n  pr e -tr e at e d  wit h  a 
s h ort-a cti n g  br o n c h o dil at or, f oll o w e d  b y st u d y  dr u g  a d mi nistr ati o n.  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117230] es  will  i n cl u d e i d e ntifi c ati o n  a n d  q u a ntifi c ati o n  of  M R S A a n d  s us c e pti bilit y t o 
v a n c o m y ci n ( MI C)  at  all  ti m e p oi nts, a n d  s us c e pti bilit y t o  a st a n d ar d  p a n el  of  a nti bi oti cs  at  B as eli n e,  W e e k  [ADDRESS_1117231]  s p ut u m ( aft er t h e  S cr e e ni n g  visit)  will  n ot  b e  c o nsi d er e d  a  pr ot o c ol  d e vi ati o n.  
S u bj e cts  wit h  a  n e g ati v e  c ult ur e (s p ut u m  or  t hr o at s w a b)  at  S cr e e ni n g  will  h a v e t h e  o p p ort u nit y t o  pr o vi d e  a s e c o n d  
s a m pl e  d uri n g t h e  S cr e e ni n g  p eri o d t o  c o nfir m  a  p ositi v e  c ult ur e.   
9. 1. [ADDRESS_1117232] e d.  T h e  pr es e n c e  of t h e f oll o wi n g  p at h o g e ns  will  b e 
d et er mi n e d  at  B as eli n e,  W e e k  2 0,  a n d  W e e k  4 4 : Ps e u d o m o n as  a er u gi n os a , A c hr o m o b a ct er  x yl os o xi d a ns , 
As p er gill us f u mi g at us , B ur k h ol d eri a  c e p a ci a  c o m pl e x,  a n d  St e n otr o p h o m o n as  m alt o p hili a . 
9. 1. [ADDRESS_1117233]’s  C R F (s e e  als o  S e cti o n  1 2  f or r e p orti n g  of  A Es r el at e d t o l a b or at or y 
a b n or m aliti es).  T h e I n v esti g at or  will  ass ess  a n y  cli ni c all y si g nifi c a nt  v al u es r el e v a nt t o t h e  s u bj e ct  p o p ul ati o n t o 
d et er mi n e if t er mi n ati o n  of t h e st u d y  dr u g is r e q uir e d . 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  4 5 N ot e: I n t h e  e v e nt  of  a b n or m al l a b or at or y t est s, f oll o w -u p l a b or at or y t ests  m a y  b e  c o n d u ct e d.  A n y  cli ni c all y 
si g nifi c a nt  a b n or m aliti es  n ot e d i n l a b or at or y t est s s h o ul d  b e  dis c uss e d  wit h t h e  S p o ns or  or  d esi g n e e.  Cr e ati ni n e 
cl e ar a n c e f or  ki d n e y f u n cti o n  ass ess m e nt  at  S cr e e ni n g  will  b e  d et er mi n e d  b y  C o c kr oft -G a ult  c al c ul ati o n i n  a d ults  or 
S c h w art z  e q u ati o n i n  c hil dr e n.  
9. 2. [ADDRESS_1117234] e 
c oll e cti o n  a n d  k e pt  fr o z e n at  -7 0  ° C  u ntil s hi p m e nt .  P h ar m a c o ki n eti c s p ut u m s a m pl es  will  b e  c oll e ct e d i n s p e ci m e n 
c oll e cti o n  c u ps  a n d  k e pt  fr o z e n at  -2 0  ° C  u ntil s hi p m e nt.  S u bj e cts  will  b e  as k e d t o  att e m pt t o  pr o d u c e  a s a m pl e  at 
t h e ti m es  n ot e d i n  A p p e n di x I , S c h e d ul e  of  E v e nts . If  a s u bj e ct m a k es  a n  att e m pt  b ut is  u n a bl e t o  pr o d u c e  a s a m p l e 
wit hi n t h e s p e cifi e d  wi n d o w, t h e f ail e d  att e m pt  will  n ot  b e  c o nsi d er e d  a  pr ot o c ol  d e vi ati o n. If  n o  bl o o d is  c oll e ct e d 
d u e t o  b a d  a c c essi bilit y  of  v ei ns,  n o  ot h er  v e ni p u n ct ur e  will  b e  m a d e  at t h at  vi sit.  T h e l a c k  of  bl o o d  c oll e cti o n, if it w as  att e m pt e d,  will  n ot  b e  c o u nt e d  as  a  pr ot o c ol  d e vi ati o n.  
9. 4   U ns c h e d ul e d  Visit(s)  
Visits  o c c urri n g  o utsi d e  of t h e s c h e d ul e d  vi sit s list e d i n  A p p e n di x I ,  S c h e d ul e  of  E v e nts s h o ul d  c o m pl et e t h e 
pr o c e d ur es  n ot e d  u n d er  W e e k  4 4 / Earl y  T er mi n ati o n  visit , t o  ass ess  a  p ot e nti al e x a c er b ati o n  or  ot h er  cli ni c al  e v e nt 
aft er st u d y tr e at m e nt  a d mi nistr ati o n.  
Ass ess m e nts t o  b e  c o m pl et e d f or  a n  u ns c h e d ul e d  visit, f or  a n y  ot h er r e as o n,  will  b e  at t h e  In v esti g at or ’s  dis cr eti o n. 
1 0   P R E C A U TI O N  
1 0. 1   P r e g n a n c y  
Alt h o u g h  pr e g n a n c y  i s n ot  c o nsi d er e d  a n  A E,  t h e I n v esti g at or ( or his  or  h er  d esi g n e e)  is  r es p o nsi bl e  f or  r e c or di n g 
i n  t h e  s u bj e ct’s  s o ur c e  d o c u m e nt   a n y   pr e g n a n c y   d uri n g   or   wit hi n   [ADDRESS_1117235] ( or s u bj e ct’s  p art n er)  w h o  b e c o m es  pr e g n a nt  d uri n g t h e st u d y s h o ul d  b e f oll o w e d t hr o u g h  d eli v er y  or t er mi n ati o n  of t h e  pr e g n a n c y. I n  a d diti o n, s u bj e ct s  w h o  b e c o m e  pr e g n a nt  d uri n g t h e st u d y  m ust  dis c o nti n u e st u d y 
dr u g  a d mi ni str ati o n  im m e di at el y.   
I n  pr e g n a n ci es t h at  pr o gr ess t o t er m,  a n y  c o n g e nit al  a b n or m aliti es/ birt h  d ef e cts i n t h e  offs pri n g  of  a s u bj e ct  w h o 
r e c ei v e d st u d y  m e di c ati o n s h o ul d  b e r e p ort e d  as  a n  S A E.  T h e  o ut c o m e  of t h e  pr e g n a n c y  a n d t h e  pr es e n c e  or a bs e n c e  of  a  c o n g e nit al  a b n or m alit y  will  b e  d o c u m e nt e d  b y  c o m pl eti o n  of  a  Pr e g n a n c y  Q u esti o n n air e  a n d  a 
Pr e g n a n c y  O ut c o m e  F or m i n  a c c or d a n c e  wit h  G C P  a n d I C H  g ui d eli n es  a n d  St a n d ar d  O p er ati n g  Pr o c e d ur es ( S O Ps ).  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117236] u d y, s af et y will  b e  e v al u at e d  t hr o u g h A E  m o nit ori n g,  cli ni c al  e v al u ati o ns ( i. e.,  vit al si g ns,  p h ysi c al 
e x a mi n ati o ns,  E C Gs),  a n d  l a b or at or y t est s (i. e.,  h e m at ol o g y,  s er u m  c h e mi stri es,  a n d  uri n al ysi s)  fr o m t h e si g ni n g 
of  i nf or m e d c o ns e nt  u ntil  t h e l ast st u d y vi sit.  
D efi niti o ns  a n d  r e p orti n g pr o c e d ur es  pr o vi d e d  i n t his pr ot o c ol  c o m pl y  wit h  c urr e nt  I C H  E [ADDRESS_1117237] ess e d t o t h e  M e di c al  M o nit or.  
C e cili a  G a nsl a n dt,  M. D   
M e di c al  M o nit or  S a v ar a,  A p S   
Sl ots m ar k e n  1 7,  2.t v.  
D K -2 9 7 0  H ors h ol m , D e n m ar k  C ell:  + 4 6  7 0 5  7 9 7 0 7 5  E m ail:  C e cili a. G a nsl a n dt @s a v ar a p h ar m a. c o m  
 
[ADDRESS_1117238] will  b e  r e c or d e d 
i n t h e a p pr o pri at e  s e cti o n of  t h e C R F  a n d  e v al u at e d  b y t h e I n v esti g at or.  Mi ni m u m  i nf or m ati o n r e q uir e d f or e a c h  
A E  i n cl u d es  d es cri pti o n  of  t h e e v e nt,  d ur ati o n   (st art a n d  e n d  d at es),  s e v erit y, ass ess m e nt  of  s eri o us n ess,  a n d  
c a us al  r el ati o ns hi p t o st u d y  dr u g.   
A n  a d v ers e  e v e nt ( A E) is  a n y  u nf a v or a bl e  or  u ni nt e n d e d si g n, s y m pt o m,  or  dis e as e t e m p or all y  ass o ci at e d  wit h t h e 
us e  of st u d y tr e at m e nt,  w h et h er  or  n ot  c o nsi d er e d r el at e d t o t h e st u d y tr e at m e nt.  Cli ni c al  c h a n g es  pri or t o t h e first d os e  of st u d y  dr u g  will  n o t  b e  c o nsi d er e d  a d v ers e  e v e nt s b ut  will  b e i n cl u d e d i n t h e  s u bj e ct’s  m e di c al  hist or y.  All A Es  m ust  b e r e c or d e d i n t h e s o ur c e  d o c u m e nt s  a n d  o n t h e  A d v ers e  E v e nt  C R F, r e g ar dl ess  w h et h er  t h e  e v e nt is 
c o nsi d er e d r el at e d t o st u d y  m e di c ati o n.   
T hi s  d efi niti o n i n cl u d es  a n  e x a c er b ati o n  of  pr e -e xisti n g  m e di c al  c o n diti o ns  or  e v e nts,  hist ori c al  c o n diti o n  n ot 
pr es e nt  pri or t o st u d y tr e at m e nt,  w hi c h r e a p p e ar f oll o wi n g  st u d y tr e at m e nt, i nt er c urr e nt ill n ess es,  h y p ers e nsiti vit y 
r e a cti o ns,  dr u g i nt er a cti o n,  or t h e si g nifi c a nt  w ors e ni n g  of t h e  dis e as e  u n d er i n v esti g ati o n t h at i s  n ot r e c or d e d 
els e w h er e i n t h e  C R F.  A nti ci p at e d  d a y -t o-d a y fl u ct u ati o ns  of  pr e -e xisti n g  c o n diti o ns t h at  d o  n ot r e pr es e nt  a 
cli ni c all y si g nifi c a nt  e x a c er b ati o n  or  w ors e ni n g  n e e d  n ot  b e  c o nsi d er e d  A Es.  
F or  all  A Es, t h e  In v esti g at or  m ust  p urs u e  a n d  o bt ai n i nf or m ati o n  a d e q u at e  b ot h t o  d et er mi n e t h e  n at ur e  a n d  o ut c o m e 
of t h e  a d v ers e  e v e nt  a n d t o  ass ess  w h et h er it  m e ets t h e  crit eri a f or  cl assifi c ati o n  as  a s eri o us  a d v ers e  e v e nt ( S A E) 
r e q uiri n g i m m e di at e  n otifi c ati o n  of t h e M e di c al   Mo nit or.  F oll o w -u p  of  cli ni c all y  si g nifi c a nt  A Es  of  at l e ast  a  gr a d e 
3  (s e e S e cti o n  1 2. 2  f or  d efi niti o n),  e v e n  aft er t h e  d at e  of t h er a p y  dis c o nti n u ati o n, i s r e q uir e d  u ntil r es ol uti o n  or 
st a bili z ati o n is j u d g e d  a c c e pt a bl e  b y t h e  In v esti g at or.  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117239] e d s h o ul d  b e 
pr o m ptl y r e p ort e d t o t h e  S p o ns or’s   Me di c al   Mo nit or.  A n y  cli ni c all y si g nifi c a nt l a b or at or y  a b n or m alit y  will  b e 
r e c or d e d  as  a n  a d v ers e  e v e nt o n t h e  C R F, i n cl u di n g t h e  di a g n osi s, if  a n y,  ass o ci at e d  wit h t h e l a b  a b n or m alit y.  T h e 
A E s h o ul d  b e r e c or d e d  as t h e  u n d erl yi n g  a b n or m alit y  or  di a g n osis ( e g , r e n al i ns uffi ci e n c y), if  o n e is  d et er mi n e d,  as 
o p p os e d t o t h e  o bs er v e d  d e vi ati o n i n t h e l a b or at or y  r es ult (e g ,  el e v at e d  cr e ati ni n e). 
I n  a d diti o n t o r e c or di n g  cli ni c all y si g nifi c a nt l a b or at or y  a b n or m aliti es,  c h a n g es t o  cli ni c al si g ns  a n d s y m pt o ms  will 
als o  b e  ass ess e d  at  b as eli n e  a n d  at  all  pl a n n e d  a n d  u n pl a n n e d st u d y  visits  at  w hi c h  ot h er  cli ni c al  ass ess m e nts  ar e t o b e  c arri e d  o ut.   
A d diti o n al t est s  a n d  ot h er  e v al u ati o ns r e q uir e d t o  est a blis h t h e si g nifi c a n c e  or  eti ol o g y  of  a  cli ni c all y si g nifi c a nt 
a b n or m al r es ult  or t o  m o nit or t h e  c o urs e  of  a n  A E  ar e t o  b e  o bt ai n e d  w h e n  cli ni c all y i n di c at e d. I n  p arti c ul ar, if  a 
cli ni c all y si g nifi c a nt  a b n or m al r es ult is  o bs er v e d t h at i s  n ot r es ol v e d  b y t h e fi n al st u d y  vi sit, r e p e at e d t est s s h o ul d  b e p erf or m e d  a n d f oll o w  u p  c o nti n u e d  u ntil r es ol uti o n  or st a bili z ati o n  of t h e  A E.  
F or  all  A Es r es ulti n g i n  dis c o nti n u at i o n  of t h e st u d y  dr u g, t h e  e v e nt  m ust  b e  ass ess e d  b y t h e  s af et y  c o m mitt e e t o 
d et er mi n e if t h e  e v e nt  m e ets t h e  d efi niti o n  of  a  d os e li miti n g t o xi cit y ( D L T).  T h e  c o m mitt e e  will  ass ess t h e  e v e nt 
t y p e, t e m p or al r el ati o ns hi p  of t h e  e v e nt t o  d osi n g,  a n d s e v erit y of t h e  e v e nt . 
1 2. 2   S e v e rit y  
S e v erit y  will  b e  gr a d e d  utili zi n g T a bl e  8  b el o w.  
T a bl e  8 : A E  S e v e rit y  G r a di n g .  
S e v e rit y ( T o xi cit y  G r a d e)   D es c ri pti o n  
Mil d ( 1)  Tr a nsi e nt  or  mil d  dis c o mf ort;  n o li mit ati o n i n  a cti vit y;  n o  m e di c al i nt er v e nti o n  or t h er a p y r e q uir e d.  T h e s u bj e ct m a y  b e  a w ar e  of t h e si g n 
or s y m pt o m  b ut t ol er at es it r e as o n a bl y  w ell.  
M o d er at e ( 2)  Mil d t o  m o d er at e li mit ati o n i n  a cti vit y,  n o  or  mi ni m al  m e di c al i nt er v e nti o n/t h er a p y r e q uir e d. 
S e v er e ( 3)  M ar k e d li mit ati o n i n  a cti vit y,  m e di c al i nt er v e nti o n/t h er a p y r e q uir e d, h os pit ali z ati o ns  p ossi bl e.  
Lif e -t hr e at e ni n g ( 4) T h e  s u bj e ct is  at ri s k  of  d e at h  d u e t o t h e  a d v ers e  e x p eri e n c e  as it o c c urr e d.  T hi s  d o es  n ot r ef er t o  a n  e x p eri e n c e t h at  h y p ot h eti c all y 
mi g ht  h a v e  c a us e d  d e at h if it  w er e  m or e s e v er e.  
[ADDRESS_1117240] u d y tr e at m e nt,  w hi c h i n cl u d es  pr o c ur e m e nt  pr o c e d ur es, s h o ul d  b e s p e cifi e d  b y t h e  In v esti g at or  usi n g t h e f oll o wi n g  d efi niti o ns:  
T a bl e  9 : R el at e d n ess . 
R el at e d n ess   D es c ri pti o n  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V [ADDRESS_1117241] u gs  or  c h e mi c al s   
1 2. 4   S e ri o us  A d v e rs e  E v e nts ( S A E) 
A n  S A E is  d efi n e d  as  a n y  A E  o c c urri n g  at  a n y  d os e t h at r es ult s i n  a n y  of t h e f oll o wi n g  o ut c o m es:  
1.   Is f at al: a p pli es  if t h e s u bj e ct’s d e at h  is a  dir e ct  o ut c o m e  of   a n A E . 
2.   Is lif e t h r e at e ni n g:  a p pli es if t h e  s u bj e ct, i n t h e  vi e w  of  t h e I n v esti g at or, is  at  s u bst a nti al ris k  of  d yi n g fr o m 
t h e  A E  as it  o c c urs. It  d o es  n ot  a p pl y if t h e  A E  c o ul d  h y p ot h eti c all y  h a v e  c a us e d  d e at h  h a d it  b e e n  m or e s e v er e. 
3.   R e q ui r es  o r  p r ol o n gs  i n -p ati e nt  h os pit ali z ati o n:  a p pli es  if  t h e   A E  r e q uir es  at  l e ast  a  2 4 -h o ur  i n -p ati e nt 
h os pit ali z ati o n  or, if i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e I n v esti g at or,  pr ol o n gs  a n  e xisti n g  h os pit ali z ati o n.  A  h os pit ali z ati o n f or 
a n  el e cti v e  pr o c e d ur e  or  a r o uti n el y s c h e d ul e d tr e at m e nt is  n ot  a n  S A E  b y t his  crit eri o n  b e c a us e  a  “ pr o c e d ur e ”  or 
a  “tr e at m e nt ” is  n ot  a n  u nt o w ar d  m e di c al  o c c urr e n c e.  A n  e m er g e n c y r o o m  visit  of l ess t h a n  2 4  h o urs  b y its elf  d o es 
n ot  c o nstit ut e  a  S A E.   
4.   R es ults i n  p e r m a n e nt  o r si g nifi c a nt  dis a bilit y/i n c a p a cit y:  a p pli es if t h e  “ dis a bilit y ”  c a us e d  b y t h e r e p ort e d 
A E r es ults i n  a s u bst a nti al  disr u pti o n  of t h e s u bj e ct’s  a bilit y t o  c arr y  o ut  n or m al lif e f u n cti o ns.   
5.   Is  a  c o n g e nit al  a n o m al y/ bi rt h  d ef e ct:  a p pli es if  a  s u bj e ct  e x p os e d t o  a  m e di ci n al  (i n v esti g ati o n al)  pr o d u ct 
gi v es  birt h t o  a  c hil d  wit h  c o n g e nit al  a n o m al y  or  birt h  d ef e ct.   
M e di c al  a n d s ci e ntifi c j u d g m e nt s h o ul d  b e  e x er ci s e d i n  d et er mi ni n g s eri o us n ess i n  ot h er  sit u ati o ns, s u c h  as i m p ort a nt  m e di c al  e v e nts t h at  m a y  n ot  b e i m m e di at el y lif e- t hr e at e ni n g, r es ult i n  d e at h,  or  h os pit ali z ati o n,  b ut  m a y 
j e o p ar di z e t h e s u bj e ct  or m a y r e q uir e i nt er v e nti o n t o  pr e v e nt  o n e  of t h e  ot h er  o ut c o m es list e d i n t h e  d efi niti o n a b o v e.  T h es e  e v e nts  s h o ul d  b e  c o nsi d er e d s eri o us  a n d s u bj e ct t o r e p orti n g  pr o c e d ur es s p e cifi e d  b el o w.  
Ot h er i m p ort a nt  m e di c al  e v e nts  m a y  als o  b e  c o nsi d er e d  a n  S A E  w h e n,  b as e d  o n  a p pr o pri at e  m e di c al j u d g m e nt, t h e y 
j e o p ar di z e t h e s u bj e ct or r e q uir e i nt er v e nti o n t o  pr e v e nt  o n e  of t h e  o ut c o m es list e d.   
1 2. 4. 1   S e ri o us  A d v e rs e  E v e nt  R e p o rti n g  
Wit hi n   2 4  h o u rs   of  b e c o mi n g  a w ar e   of  a n y  S A E   (r e g ar dl ess  of its  r el ati o ns hi p  t o  i n v esti g ati o n al  pr o d u ct) t h at  
o c c urs   d uri n g  t h e  cli ni c al   st u d y,  t h e st u d y p ers o n n el  at  t h e sit e m ust  c o m pl et e  t h e S A E  R e p ort   F or m  ( e v e n if all  
i nf or m ati o n r e g ar di n g t h e S A E  is u n k n o w n  or  i n c o m pl et e), a n d  f a x  or e m ail  it t o t h e  S af et y  Offi c er list e d  b el o w. 
S h o ul d  y o u  n ot  b e  a bl e t o  c o nt a ct t h e  S af et y  Offi c er,  y o u  m ust r e a c h  o ut t o t h e  S p o ns or  M e di c al  M o nit or.  T hi s 
e ns ur es ti m el y r e p orti n g  of  a p pli c a bl e   r e p orts t o all  R e g ul at or y  A ut h oriti es.  T h e  f or m m ust  b e  si g n e d  b y  t h e 
Pri n ci p al   I n v esti g at or or  d esi g n e e,  a n d  if n ot  a v ail a bl e,  t h e u nsi g n e d  r e p ort s h o ul d  b e  f a x e d or  e m ail e d  f or 
i niti al  pr o c essi n g  a n d r es u b mitt e d  aft er t h e I n v esti g at or’s si g n at ur e  h as  b e e n  o bt ai n e d. Aft er s u b missi o n, t h e st u d y 
p ers o n n el s h o ul d  a w ait  a  c o nfir m ati o n  of r e c ei pt fr o m t h e  S af et y  O ffi c er a n d/ or t h e  S p o ns or; if  n ot r e c ei v e d t h e 
r e p ort  m ust  b e r es u b mitt e d. 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  4 9  
S af et y  Offi c e r  S p o ns o r -M e di c al  M o nit o r  S p o ns o r -Cli ni c al  O p e r ati o ns  
F a x:  [ADDRESS_1117242] u g S af et y @i n cr es e ar c h. c o m 
 C e cili a  G a nsl a n dt,  M. D   
Sl ots m ar k e n  1 7,  2.t v.  
D K -2 9 7 0  H ors h ol m , D e n m ar k  C ell:  + 4 6  7 0 5  7 9 7 0 7 5  C e cili a. G a nsl a n dt @s a v ar a p h ar m a. c o m   
 J essi c a J a c ks o n  
Dir e ct or  of  Cli ni c al  O p er ati o ns  
6 8 3 6  B e e  C a v es  R d,  B uil di n g III, S uit e  2 0 0  A usti n,  T e x as  7 8 7 4 6,  U S A  
C ell:  8 3 2 -2 3 1 -6 2 8 3  
j essi c a.j a c ks o n @s a v ar a p h ar m a. c o m  
 
 
T h e  i niti al writt e n  r e p ort s h o ul d  b e f oll o w e d  b y f ull  writt e n s u m m ar y  d et aili n g r el e v a nt  as p e cts  of t h e  S A E i n q u esti o n  usi n g t h e  pr o vi d e d  S A E r e p ort f or m.  W h er e  a p pli c a bl e, i nf or m ati o n fr o m r el e v a nt  h os pit al  c as e r e c or ds 
a n d  a ut o ps y r e p orts s h o ul d  b e  o bt ai n e d.  T h e  S A E s h o ul d  al s o  b e r e c or d e d  o n t h e  A E  p a g e  of t h e s u bj e ct’s  C R F.  T h e  
S af et y  Offi c er  a n d  M e di c al   M o nit or   will   r e vi e w  t h e  S A E   d o c u m e nt ati o n   r e c ei v e d  f or  a c c ur a c y   a n d  
c o m pl et e n ess  a n d  f oll o w-u p  wit h  t h e I n v esti g at or t o o bt ai n  missi n g  i nf or m ati o n, if  r e q uir e d. 
If  a n  A E d o es  n ot  m e et t h e r e g ul at or y  d efi niti o n  of  “s eri o us ”  b ut is  c o nsi d er e d  b y t h e I n v esti g at or t o  b e r el at e d t o 
t h e st u d y  m e di c ati o n  a n d  of s u c h  cli ni c al  c o n c er n  as t o i nfl u e n c e t h e  o v er all  ass ess m e nt  of s af et y, it  m ust  b e 
r e p ort e d  as  d efi n e d f or  a n  S A E. 
All  A Es  a n d  S A Es  will  b e f oll o w e d  u ntil t h e  e v e nt  h as r es ol v e d, t h e  e v e nt  h as r e a c h e d  a  n e w  b as eli n e,  a n d f or  a 
mi ni m u m  of  [ADDRESS_1117243] u d y.  F oll o w -u p  S A E i nf or m ati o n 
s h o ul d  b e s u b mitt e d  as  n e w i nf or m ati o n  b e c o m es  a v ail a bl e  b y  usi n g t h e f oll o w -u p  S A E r e p ort f or m  a n d 
f a xi n g/ e m aili n g t his f or m t o t h e S af et y  Offi c er  a n d  M e di c al  M o nit or  or  d esi g n e e. If t h e f oll o w -u p i nf or m ati o n c h a n g es t h e I n v esti g at or’s  ass ess m e nt  of s eri o us n ess  or  c a us alit y  or r el ati o ns hi p t o t h e st u d y  dr u g, t hi s  c h a n g e s h o ul d  b e  n ot e d  o n t h e f oll o w-u p  S A E f or m.  T h e i niti al  a n d  a n y f oll o w -u p  S A E r e p orts s h o ul d  b e  pl a c e d i n t h e 
s u bj e ct’s fil e.  U p o n r e c ei vi n g  a n y  u p d at es, t h e I n v esti g at or  m ust r e vi e w  a n d r et ai n t h e  u p d at es  a n d i m m e di at el y s u b mit  a  c o p y  of t his i nf or m ati o n t o t h e I R B/I E C/R E B.  T h e I n v esti g at or s h o ul d  als o  c o m pl y  wit h I R B/ I E C/R E B pr o c e d ur es f or r e p orti n g  a n y  ot h er  s af et y i nf or m ati o n.   
I n  a d diti o n, if t h e In v esti g at or l e ar ns  of  a n  S A E  o c c urri n g  aft er t h e l ast f oll o w -u p  visit,  b ut  wi t hi n  [ADDRESS_1117244] u d y tr e at m e nt,  h e/ s h e s h o ul d r e p ort t h e  e v e nt  wit hi n  [ADDRESS_1117245] e d  S e ri o us  A d v e rs e  R e a cti o ns ( S U S A Rs)  
T h e  F D A  a n d/ or  ot h er  a p pli c a bl e  R e g ul at or y  A ut h oriti es  a n d  all  p arti ci p ati n g I n v esti g at ors  will  b e  n otifi e d  b y  a writt e n I n v esti g ati o n al  N e w  Dr u g  A p pli c ati o n (I N D) s af et y r e p ort  a n d/ or  ot h er  a p pli c a bl e r e g ul at or y r e p ort ( e g , 
e x p e dit e d  c as e r e p ort)  of  a n y s us p e ct e d  a d v ers e r e a cti o n t h at is  b ot h s eri o us  a n d  u n e x p e ct e d  (i. e.  a  S U S A R),  n o l at er 
t h a n  1 5  c al e n d ar  d a ys fr o m t h e  “ d at e l e ar n e d ”  of t h e  e v e nt. I n  a d diti o n,  all  a p pli c a bl e r e g ul at or y  b o di es  will  b e 
n otifi e d  wit hi n  [ADDRESS_1117246]’s  b est i nt er est t o  c o nti n u e.  T h e f oll o wi n g is  a list  of  p ossi bl e r e as o ns f or 
st u d y tr e at m e nt  dis c o nti n u ati o n:   
•   S u bj e ct  wit h dr a w al  of  c o ns e nt  ( or  ass e nt) 
•   S u bj e ct is  n ot  c o m pli a nt  wit h st u d y  pr o c e d ur es  
•   E x a c er b ati o n ( us e  of  a nti mi cr o bi al  m e di c ati o n t o tr e at r es pir at or y s y m pt o ms)  - aft er  c o m pl eti o n  of 
a nti mi cr o bi al tr e at m e n t st u d y  dr u g  m a y  b e r est art e d  at t h e  dis cr eti o n  of t h e I n v esti g at or. 
•   A d v ers e  e v e nt t h at i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e  In v esti g at or  w o ul d  b e i n t h e  b est i nt er est  of t h e s u bj e ct t o 
dis c o nti n u e st u d y tr e at m e nt  
•   Pr ot o c ol  vi ol ati o n r e q uiri n g  dis c o nti n u ati o n  of st u d y tr e at m e nt  
•   L ost t o f oll o w -u p  
•   S p o ns or r e q u est f or  e arl y t er mi n ati o n  of st u d y  
•   P ositi v e  pr e g n a n c y t est (f e m al es)  
S u bj e cts  w h o  ar e  dis c o nti n u e d fr o m st u d y tr e at m e nt  b ef or e  c o m pl eti n g t h e  e ntir e  d ur ati o n  of t h e  Tr e at m e nt  P eri o d 
s h o ul d  c o nti n u e  cli ni c  vi sit s  a c c or di n g t o t h e st u d y s c h e d ul e i n  A p p e n di x I , S c h e d ul e  of  E v e n t f or  P eri o d  1; this 
i n cl u d es t h e r e p orti n g  of  a n y  A Es, i n cl u di n g  S A Es. S u bj e ct s  w h o  dis c o nti n u e  st u d y  m e di c ati o n i n  P eri o d  [ADDRESS_1117247] u d y tr e at m e nt,  a n d  w h o  ar e  n ot  willi n g t o  c o nti n u e  cli ni c  visits ( e g ,  wit h dr a w al  of c o ns e nt) s h o ul d  b e  e n c o ur a g e d t o  c o m pl et e t h e  W e e k  4 8/  E n d  of  St u d y ( E O S)  ass ess m e nts  as i d e ntifi e d i n t h e S c h e d ul e  of  E v e nts.  
T h e  d at e t h e s u bj e ct  dis c o nti n u es st u d y tr e at m e nt, t h e  pri m ar y r e as o n f or st u d y tr e at m e nt  dis c o nti n u ati o n, st u d y 
t er mi n ati o n,  a n d/ or t er mi n ati o n  of  p arti ci p ati o n (e g ,  wit h dr a w al  of  c o ns e nt),  will  b e  c a pt ur e d  wit hi n t h e  C R F. 
W h e n s u bj e cts  wit h dr a w  c o ns e nt fr o m st u d y  p arti ci p ati o n, it  m ust  b e r e c or d e d  o n t h e  C R F  w h et h er t h e  wit h dr a w al of  c o ns e nt  a p pli es t o s p e cifi c  as p e cts  of t h e st u d y s u c h  as  dis c o nti n u ati o n  of st u d y tr e at m e nt,  p arti ci p ati o n i n st u d y 
visits,  c o nt a ct  b y st u d y  p ers o n n el,  or  a c c ess t o i nf or m ati o n  a b o ut  p ot e nti al  S A Es. If s p e cifi c  c o ns e nt  h as  n ot  b e e n 
wit h dr a w n, st u d y  p ers o n n el  s h o ul d  c o nt a ct t h e s u bj e ct ( or  a  pr e vi o usl y  a p pr o v e d  d esi g n e e s u c h  as  a  c ar e gi v er, p art n er,  or f a mil y  m e m b er)  at t h e s c h e d ul e d  F oll o w -u p  vi sit t o i n q uir e  a b o ut  h e alt h st at us.   
[ADDRESS_1117248] u d y 
i n cl u d e,  b ut  ar e  n ot li mit e d t o, t h e f oll o wi n g: 
•   F ail ur e t o  m e et i n cl usi o n/ e x cl usi o n  crit eri a  
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  5 1 •   Us e  of  a  pr o hi bit e d  c o n c o mit a nt  m e di c ati o n  
•   F ail ur e t o  c o n d u ct  pr ot o c ol r e q uir e d  pr o c e d ur es  
•   N o n -c o m pli a nt  wit h st u d y  dr u g r e gi m e n  
•   F ail ur e t o  c o m pl y  wit h  G o o d  Cli ni c al  Pr a cti c e ( G C P)  g ui d eli n es.   
T h e  S p o ns or  will  d et er mi n e if  a  pr ot o c ol  vi ol ati o n  will r es ult i n  wit h dr a w al  of  a  s u bj e ct. 
W h e n  a  pr ot o c ol  vi ol ati o n  o c c urs, it  will  b e  di s c uss e d  wit h t h e  In v esti g at or  a n d  a  Pr ot o c ol  Vi ol ati o n  F or m  d et aili n g 
t h e  vi ol ati o n  will  b e  g e n er at e d.  T his f or m  will  b e si g n e d  b y  a  S p o ns or r e pr es e nt ati v e  a n d t h e I n v esti g at or.  A  c o p y  of 
t h e f or m  will  b e fil e d i n t h e sit e’s r e g ul at or y  bi n d er  a n d  S p o ns or’s fil es.  T h e  Et hi cs  C o m mitt e e s h o ul d  b e i nf or m e d 
of t h e  vi ol ati o n.  
[ADDRESS_1117249] e d  b y t h e  C ysti c  Fi br osi s  F o u n d ati o n  T h er a p e uti cs ( C F F T)  D at a  a n d S af et y  M o nit ori n g  B o ar d ( D S M B).  A s u b c o m mitt e e  of t h e  D S M B,  a  D at a  M o nit ori n g  C o m mitt e e ( D M C),  will 
s er v e as t h e r e vi e w  b o ar d f or t his tri al.  T h e  D M C  will  c o nsist  of  at l e ast  [ADDRESS_1117250] ati sti ci a n  wit h  e x p ertis e i n  cli ni c al tri al  s af et y m o nit ori n g.  T h e  D M C  m e m b ers  will  all  b e i n d e p e n d e nt t o 
S a v ar a  a n d t o t h e  cli ni c al i n v esti g at ors.  
 S p e cifi c all y, t h e  D M C is r es p o nsi bl e f or:  
 
•   R e vi e wi n g  cli ni c al tri al  d esi g n (i n cl u di n g r el e v a nt  d at a fr o m  pri or  cli ni c al tri als  a n d  In v esti g at or  B r o c h ur es 
r e g ar di n g t h e  dr u g  b ei n g st u di e d); 
•   R e vi e wi n g  S A Es  a n d t o xi cit y  d at a;  
•   E x a mi ni n g  u n bli n d e d  a c c u m ul at e d  o ut c o m e  a n d  s af et y  d at a i n  or d er t o  m a k e r e c o m m e n d ati o ns  c o n c er ni n g 
c o nti n u ati o n, t er mi n ati o n  or  m o difi c ati o n  of t h e tri al,  b as e d  o n t h e  eff e cts  of t h e i nt er v e nti o ns  u n d er  st u d y . 
T er mi n ati o n  or  m o difi c ati o n  will  o nl y  b e f or  n e c ess ar y s af et y r e as o ns;  
•   R e vi e wi n g  cli ni c al tri al  d esi g n  m o difi c ati o ns  pr o p os e d  b y t h e  T h er a p e u ti cs  D e v el o p m e nt  N et w or k (T D N ) or 
S p o ns or  a n d  a n y f ut ur e  a m e n d m e nts  pri or t o i m pl e m e nt ati o n;   
•   R e vi e wi n g  t h e  g e n er al  pr o gr ess  of  t h e  cli ni c al  tri al    wit h  r e g ar d  t o  a c cr u al/ wit h dr a w als  or  dr o p -o ut  r at es, 
pr ot o c ol  vi ol ati o ns  a n d/ or  d e vi ati o ns,  a n d tri al  c o n d u ct  
[ADDRESS_1117251] a n ( S A P)  will  b e  writt e n  d es cri bi n g  all  a n al ys es t h at  will  b e  p erf or m e d.  T h e  S A P  will  c o nt ai n  a n y  m o difi c ati o ns  or  cl arifi c ati o ns  t o t h e  a n al ysis  pl a n 
d es cri b e d  b el o w  t h at  m a y  b e  n e c ess ar y.  
[ADDRESS_1117252] a n d ar d  d e vi ati o ns,  m e di a ns,  mi ni m u ms,  a n d  m a xi m u ms.   
T h e f oll o wi n g  p o p ul ati o ns  will  b e  us e d f or  effi c a c y  a n al ys es:   - I nt e nt-t o-Tr e at ( I T T)  p o p ul ati o n  will i n cl u d e  all r a n d o mi z e d s u bj e cts ≤  2 1  y e ars  of  a g e . 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  5 2 - T h e  P er -Pr ot o c ol ( P P)  p o p ul ati o n  will i n cl u d e  I T T s u bj e ct s  w h o  a d h er e t o  all  k e y  pr ot o c ol  pr o c e d ur es, t o  b e 
s p e cifi e d i n  a s e p ar at e  St atist i c al  A n al ysis  Pl a n ( S A P).  
Pri m ar y  effi c a c y  a n al ys es, f or  w hi c h f ull  c o ntr ol  of  T y p e I  err or  will  b e i m pl e m e nt e d,  will  b e i n t h e  gr o u p  of 
p ati e nts  w h o  ar e  ≤  2 1  y e ars  of  a g e.  
S u p p orti n g  a n al ys es i n  p ati e nt s  w h o  ar e  >  [ADDRESS_1117253] e risti cs  
T h e  esti m at e d r es p o ns e r at e  a n d its  c o nfi d e n c e i nt er v al  will  b e  esti m at e d  a n d  ass ess e d  b y t h e f o ll o wi n g a  pri ori  
s u b gr o u ps:  
•   A g e  gr o u p  ( 6 –2 1  y e ars  ol d  a n d  >  2 1 ) 
•   B as eli n e  F E V 1 ( ≥ 6 0 %;  < 6 0 %) 
•  P ri or  e x a c er b ati o ns tr e at e d  wit h  a nti bi oti cs  d uri n g t h e  pr e vi o us  1 2  m o nt hs ( 1-2;  ≥  3 )  
•  P.  a er u gi n os a  tr e at m e nt ( n ot tr e at e d; tr e at e d)  
[ADDRESS_1117254] e d  i n  p ati e nts  w h o 
ar e  ≤  2 1  y e ars  of  a g e .  T h e e n d p oi nt  will  b e  a n al y z e d s e q u e nti all y  at  W e e k  4 ( e n d  of  C y cl e  1) ,  W e e k  1 2 ( e n d  of 
C y cl e  2),  a n d  at  W e e k  2 0 ( e n d  of  C y cl e  3). If  a st atisti c all y si g nifi c a nt  diff er e n c e i s  o bs er v e d i n f a v or  of  A er o V a n c 
c o m p ar e d t o  pl a c e b o  aft er  C y cl e  1, t h e n t h e  m e a n  c h a n g e i n t h e  F E V [ADDRESS_1117255] ors  as fi x e d  eff e cts.  
A li n e ar r e gr essi o n  m o d el  will  b e fitt e d  usi n g  s u bj e cts  wit h  o bs er v e d  v al u es f or t h e  e n d p oi nt ( W e e k  4,  1 2  a n d  2 0, r es p e cti v el y), t h e  c o v ari at es  B as eli n e  F E V
[ADDRESS_1117256] e d t h at  ar e  a v ail a bl e (if  a n y),  a n d t h e str atifi c ati o n f a ct ors.   F ull  d et ails  will  b e i n cl u d e d i n t h e  S A P.  
F or  c o nfir m ati o n  of t h e  pri m ar y  e n d p oi nt , a s e nsiti vit y  a n al ysis  will  b e  c o n d u ct e d  w h er e  missi n g  d at a  will  b e 
i m p ut ed  i n  diff er e nt  w a ys.   T h es e  will i n cl u d e: 
•   W o rst  r e as o n a bl e  c as e  a n al ysis : s u bj e ct s i n t h e  A er o V a n c  gr o u p  wit h  a  missi n g  F E V [ADDRESS_1117257] e d  will  b e  assi g n e d t h e  m e di a n f or t h e  A er o V a n c  gr o u p.  
•   B est  r e as o n a bl e  c as e  a n al ysis : s u bj e cts  i n t h e  A er o V a n c  gr o u p  wit h  a  missi n g  F E V [ADDRESS_1117258] a c e b o  gr o u p.  
•   Ti p pi n g  p oi nt  a n al ysis :  I n t h e  e v e nt t h at  st atisti c al  si g nifi c a n c e i n f a v o ur  of  A er o V a n c is  d et er mi n e d fr o m t h e 
pri m ar y  a n al ysis,  s u bj e cts  i n  eit h er  gr o u p  wit h  a  missi n g  F E V [ADDRESS_1117259]  (i. e. t h e  2 -si d e d  P -v al u e  b e c o m es 
gr e at er t h a n  0. 0 5).  
[ADDRESS_1117260]  a c hi e v es  o v er t h e  3  c y cl es  of t h er a p y  will  b e  us e d t o  cr e at e 
a  2  ×  4  c o nti n g e n c y t a bl e  c o nsisti n g  of t h e  2 tr e at m e nts ( A er o V a n c  a n d  Pl a c e b o)  a n d t h e  c o u nts  of  all  p ati e nts a cr oss t h e  4 l e v el s  of r es p o ns e ( 0,  1,  2,  or  3 s u c c essf ul tr e at m e nt  c y cl es).  A r es p o ns e i n  a  c y cl e i s  d efi n e d  b y  at l e ast a  5  % r el ati v e i m pr o v e m e nt i n  F E V
[ADDRESS_1117261] e d  at t h e  e n d  of  e a c h  c y cl e ( W e e k  4,  W e e k  1 2,  a n d  W e e k  2 0). If 
t h e r el ati v e  F E V 1 i m pr o v e m e nt is l ess t h a n  5  %, t h e s u bj e ct is  c o nsi d er e d  a f ail ur e i n t h at  c y cl e,  b ut t h e f ail ur e  d o es 
n ot  pr e cl u d e  s u c c ess i n f ut ur e  c y cl es.  If  a s u bj e ct r e c ei v es  c o n c o mit a nt  n o n-m ai nt e n a n c e  a nti bi oti c t h er a p y  f or p ul m o n ar y i nf e cti o n  ( e. g. f or  p ul m o n ar y  e x a c er b ati o n), t h e s u bj e ct is  c o nsi d er e d  a f ail ur e i n t h at  c y cl e b ut t h e f ail ur e  d o es  n ot  pr e cl u d e s u c c ess i n f ut ur e  c y cl es. A n  a p pr o pri at e  pr o p orti o n al  o d ds  m o d el f or  or d er e d  c at e g ori es will  b e  us e d t o  a n al y z e  t h es e  d at a. 
Fr e q u e n c y  of  p ul m o n ar y  e x a c er b ati o ns  will  b e  c o m p ar e d  b et w e e n t h e  gr o u ps  usi n g  a  n e g ati v e  bi n o mi al  m o d el f or 
c o u nt  d at a,  a dj usti n g f or  e a c h  s u bj e ct’s l e n gt h  of f oll o w-u p.   T h e r a n d o mi z ati o n str atifi c ati o n f a ct ors  will  b e 
i n cl u d e d i n t h e  m o d el  as fi x e d  eff e cts. 
Ar e a  u n d er t h e  F E V
1– ti m e  pr ofil e  will  b e  a n al y z e d  usi n g  a n al ysi s  of  c o v ari a n c e i n cl u di n g t h e s u bj e ct’s  b as eli n e 
F E V [ADDRESS_1117262] ors.  
1 6. 5   M ulti pli cit y /  C o nt r ol  of  T y p e I  e r r o r  r at e  
T h e s e q u e n c e  of st atisti c al t esti n g  will  b e  as f oll o ws:  
•   A g e  gr o u p  6 – 2 1:  
o   Pri m ar y  e n d p oi nt ( m e a n  a bs ol ut e  c h a n g e fr o m  B as eli n e i n  F E V [ADDRESS_1117263] e d)  at  4  w e e ks, t h e n  1 2 
w e e ks, t h e n  2 0  w e e ks.  
o   S e c o n d ar y  e n d p oi nts:  
   ti m e t o first p ul m o n ar y  e x a c er b ati o n  
   c h a n g e i n  C F Q - R at  4  w e e ks, t h e n  1 2  w e e ks, t h e n  2 0  w e e ks  
   c h a n g e i n  C F R S D -C RI S S  s c or e  at  4  w e e ks, t h e n  1 2  w e e ks, t h e n  2 0  w e e ks  
   r el ati v e  c h a n g e fr o m  b as eli n e i n  F E V [ADDRESS_1117264] e d  at  4  w e e ks, t h e n  1 2  w e e ks, t h e n  2 0 
w e e ks.  
   n u m b er  of s u c c essf ul r es p o ns e  c y cl es.  
   fr e q u e n c y  of p ul m o n ar y  e x a c er b ati o ns.  
   A U C  of  F E V 1-ti m e  pr ofil e. 
T h e st atisti c al  d e ci si o n r ul e f or  m o vi n g t o  e a c h  a n al ysis  will  b e  b as e d  o n t h e s e q u e n c e list e d  a b o v e  a n d  m e eti n g  a 
t hr es h ol d  of  P  < 0. [ADDRESS_1117265] ors ( ot h er t h a n  a g e  gr o u p)  ar e f or  d es cri pti v e  a n d s u p p orti v e p ur p os es  a n d  will  n ot i m p a ct t h e  d e cisi o n t o  m o v e f or w ar d  or st o p t esti n g.  
Alt h o u g h t h e  a b o v e s e q u e n c e i s i m pl e m e nt e d t o  c o ntr ol t y p e I  err or, r es ult s  of  all t h e  a n al ys es  will  b e i n cl u d e d i n 
t h e fi n al r e p ort. 
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  5 4 I n  a d diti o n t o t h e  a b o v e,  all  a n al ys es  will  b e r e p e at e d i n t h e  gr o u p  of p ati e nt s   > 2 1  y e ars  of  a g e.   Esti m at es  of 
tr e at m e nt eff e cts  a n d  9 5 %  c o nfi d e n c e i nt er v al s  will  b e  pr o d u c e d.   N o mi n al  p -v al u es  will  al s o  b e  pr o d u c e d  b ut  o nl y 
f or  d es cri pti v e  p ur po s es.  N o  T y p e I  err or  c o ntr ol  will  b e i m pl e m e nt e d f or t h e  p ati e nt s  > 2 1  y e ars  of  a g e.  
1 6. 6   S af et y  A n al y sis 
A si n gl e s et  of s af et y  a n al ys es  will  b e  pr o d u c e d i n cl u di n g  all  p ati e nt s  (t h os e ≤  2 1  y e ars  ol d  a n d t h os e  > 2 1  y e ars  ol d, 
c o m bi n e d).   Sel e ct e d  a n al ys es  will  b e r e p e at e d f or t h e t w o  gr o u ps s e p ar at el y (s u bj e ct  ≤  2 1  y e ars  ol d  a n d  s u bj e cts 
> 2 1  y e ars  ol d, r es p e cti v el y ).   
E xt e nt  of  e x p os ur e  a n d  d osi n g  c o m pli a n c e  will  b e s u m m ari z e d  b y tr e at m e nt  gr o u p.  A d v ers e  e v e nt s  will  b e  m a p p e d 
t o  pr ef err e d t er ms  a n d s yst e m  or g a n  cl ass es  usi n g t h e  M e di c al  Di cti o n ar y f or  R e g ul at or y A cti viti es ( M e d D R A).  
T h e i n ci d e n c e  of  A Es ( e v er  h a vi n g)  a n d t h e fr e q u e n c y  of  A Es (t ot al  n u m b er)  a n d  9 5 %  c o nfi d e n c e i nt er v als  will  b e t a b ul at e d  b y tr e at m e nt  gr o u p, s yst e m  or g a n  cl ass,  a n d  pr ef err e d t er m.  S eri o us  a d v ers e  e v e nt s ( S A Es)  will  b e 
s u m m ari z e d i n  a  si mil ar f as hi o n.  A d v ers e  e v e nt s u m m ari es  b y s e v erit y  a n d r el ati o ns hi p t o st u d y  dr u g  will  al s o  b e 
pr o vi d e d.  T h e  A E s u m m ari es  will  b e  pr es e nt e d f or  all s u bj e cts  a n d  b y t h e t w o  a g e  gr o u ps.  
L a b or at or y  p ar a m et ers  will  b e s u m m ari z e d  usi n g  d es cri pti v e st atisti cs  at  B as eli n e  a n d  at  e a c h  p ost -b as eli n e  visit. 
C h a n g es fr o m  B as eli n e  will  als o  b e s u m m ari z e d. I n  a d diti o n, s hift t a bl es (i. e., l o w -n or m al -hi g h  at  B as eli n e  v ers us 
l o w-n or m al -hi g h  at  e a c h  p ost -b as eli n e  vi sit i n  a  3 -b y -3  c o nti n g e n c y t a bl e)  will  b e  pr o vi d e d t o  ass ess  c h a n g es fr o m 
B as eli n e i n l a b or at or y  v al u es.   
Vit al si g ns  will  b e s u m m ari z e d  usi n g  d es cri pti v e st ati sti cs  at  B as eli n e  a n d  at  e a c h  p ost -B as eli n e  visit.  C h a n g es fr o m 
B as eli n e  will  al s o  b e s u m m ari z e d.  
El e ctr o c ar di o gr a m  p ar a m et ers  will  b e s u m m ari z e d  usi n g  d es cri pti v e st atisti cs  at  B as eli n e  a n d  at  e a c h  p ost -b as eli n e 
visit  w h er e  a n  E C G  ass ess m e nt  w as  m a d e.  C h a n g es fr o m  B as eli n e  will  als o  b e s u m m ari z e d. I n  a d diti o n, s hift t a bl es (i. e.,  n or m al,  n ot  cli ni c all y si g nifi c a nt [ N C S],  cli ni c all y si g nifi c a nt [ C S])  at  B as eli n e  v ers us  n or m al,  N C S,  C S  at e a c h  p ost -b as eli n e  vi sit i n  a   3-b y -3  c o nti n g e n c y t a bl e)  will  b e  pr o vi d e d t o  ass ess  c h a n g es fr o m  B as eli n e . 
[ADDRESS_1117266] u d y ( [ADDRESS_1117267] s  ≤  2 1  y e ars  ol d,  5 0 s u bj e cts  >  2 1  y e ars  ol d).  T h e 
pri m ar y  a n al ysis  p o p ul ati o n  will  b e t h e s u bj e cts   ≤ [ADDRESS_1117268] e d  of  4.  3  %  a n d  a r o ot  m e a n s q u ar e  d e vi ati o n  of  6. 3  %  w er e  o bs er v e d  b et w e e n t h e tr e at m e nt  ar ms i n 
s u bj e cts  <  [ADDRESS_1117269] s  p er  ar m  w o ul d  pr o vi d e  8 9  % 
p o w er t o  d et e ct  a st atisti c all y  si g nifi c a nt  diff er e n c e  at  al p h a l e v el  of  0. [ADDRESS_1117270] o p  o uts  a n d/ or s m all er eff e ct si z e i n  a t hr e e -c y cl e st u d y,  a s a m pl e si z e  of  [ADDRESS_1117271] et e d  w o ul d  pr o vi d e  9 0 %  p o w er t o  d et e ct  a  diff er e n c e  of  3. 4 %  at  [ADDRESS_1117272] a n d ar d  d e vi ati o n  of  6. 3%.  I n  a d diti o n,  a p pr o xi m at el y  [ADDRESS_1117273]’s  visit i nt o t h e 
pr ot o c ol -s p e cifi c  C as e  R e p ort  F or m ( C R F  w h e n t h e i nf or m ati o n  c orr es p o n di n g t o t h at  visit is  a v ail a bl e ). S u bj e cts  
will  n ot  b e i d e ntifi e d  b y  n a m e i n t h e st u d y  d at a b as e  or  o n  a n y st u d y  d o c u m e nt s t o  b e  c oll e ct e d  b y t h e  S p o ns or ( or 
d esi g n e e),  b ut  will  b e i d e ntifi e d  b y  a sit e  n u m b er,  s u bj e ct n u m b er  a n d i niti als.  
If  a  c orr e cti o n is r e q uir e d f or a n  e C R F, t h e ti m e  a n d  d at e st a m ps tr a c k t h e  p ers o n  e nt eri n g  or  u p d ati n g  e C R F  d at a 
a n d  cr e at es  a n  el e ctr o ni c  a u dit tr ail.  T h e I n v esti g at or is r es p o nsi bl e f or  all i nf or m ati o n  c oll e ct e d  o n s u bj e ct s  e nr oll e d i n t his st u d y. All  d at a  c oll e ct e d  d uri n g  t hi s st u d y m ust  b e r e vi e w e d  a n d  v erifi e d f or  c o m pl et e n ess  a n d  a c c ur a c y  b y 
t h e I n v esti g at or,  vi a  el e ctr o ni c si g n at ur e. A  c o p y  of t h e  C R F  will r e m ai n  at t h e I n v esti g at or’s sit e  at t h e  c o m pl eti o n of t h e st u d y . 
[ADDRESS_1117274] a n d ar d  O p er ati n g 
Pr o c e d ur es ( S O Ps), f or  h a n dli n g  a n d  a n al ysis  of  d at a f or  cli ni c al tri al s. 
[ADDRESS_1117275] a blis h e d s e c urit y  pr o c e d ur es;  a p pr o pri at e  b a c k u p c o pi [INVESTIGATOR_11960] t h e  d at a b as e  a n d r el at e d s oft w ar e fil es  will  b e  m ai nt ai n e d.  D at a b as es  ar e  b a c k e d  u p  b y t h e  d at a b as e 
a d mi nistr at or i n  c o nj u n cti o n  wit h  a n y  u p d at es  or  c h a n g es t o t h e  d at a b as e.   
At  criti c al j u n ct ur es  of t h e  pr ot o c ol,  d at a f or  a n al ysi s is l o c k e d  a n d  cl e a n e d  p er  est a blis h e d  pr o c e d ur es.  
[ADDRESS_1117276] u d y  d at a  a c c essi bl e t o t h e  m o nit or,  ot h er  a ut h ori z e d r e pr es e nt ati v es  of t h e  S p o ns or ( or 
d esi g n e e), I R B/I E C ,  a n d  R e g ul at or y  A g e n c y (e g ,  F D A) i ns p e ct ors  u p o n r e q u est. A fil e f or  e a c h  s u bj e ct m ust  b e 
m ai nt ai n e d t h at i n cl u d es t h e si g n e d I nf or m e d  C o ns e nt,  HI P A A  A ut h ori z ati o n  a n d  Ass e nt  F or m  a n d  c o pi [INVESTIGATOR_166769] s o ur c e  d o c u m e nt ati o n r el at e d t o t h at  s u bj e ct. T h e I n v esti g at or  m ust  e ns ur e t h e r eli a bilit y  a n d  a v ail a bilit y  of s o ur c e 
d o c u m e nts fr o m  w hi c h t h e i nf or m ati o n  o n t h e  C R F  w as  d eri v e d.  
All st u d y  d o c u m e nts ( s u bj e ct fil es, si g n e d i nf or m e d  c o ns e nt f or ms,  c o pi [INVESTIGATOR_11960]  C R Fs,  St u d y  Fil e  N ot e b o o k,  et c.)  m ust 
b e  k e pt s e c ur e d f or  a  p eri o d  of  [ADDRESS_1117277] e d  b y r e pr es e nt ati v es  of t h e  S p o ns or  a c c or di n g t o t h e  U. S.  C F R  Titl e  2 1  P arts  5 0, 
5 6,  a n d  3 1 2  a n d I C H  G ui d eli n es f or  G C P ( E 6).  B y si g ni n g t hi s  pr ot o c ol, t h e I n v esti g at or  gr a nts  p er mi ssi o n t o t h e 
S p o ns or ( or  d esi g n e e),  a n d  a p pr o pri at e r e g ul at or y  a ut h oriti es t o  c o n d u ct  o n -sit e  m o nit ori n g  a n d/ or  a u diti n g  of  all 
a p pr o pri at e st u d y  d o c u m e nt ati o n.  
[ADDRESS_1117278] e d  a c c or di n g t o t h e  D e cl ar ati o n  of  H elsi n ki,  Pr ot e cti o n  of  H u m a n  V ol u nt e ers ( 2 1  C F R 
5 0), I nstit uti o n al  R e vi e w  B o ar ds ( 2 1  C F R  5 6),  a n d  O bli g ati o ns  of  Cli ni c al I n v esti g a t ors ( 2 1  C F R  3 1 2). 
T o  m ai nt ai n  c o nfi d e nti alit y,  all l a b or at or y s p e ci m e ns,  e v al u ati o n f or ms, r e p orts  a n d  ot h er r e c or ds  will  b e i d e ntifi e d 
b y  a  c o d e d  n u m b er  a n d i niti al s  o nl y.  All st u d y r e c or ds  will  b e  k e pt i n  a l o c k e d r o o m  wit h li mit e d  a c c ess.  Cli ni c al 
i nf or m ati o n  will  n ot  b e r el e as e d  wit h o ut  writt e n  p er missi o n  of t h e s u bj e ct,  e x c e pt  as  n e c ess ar y f or  m o nit ori n g  b y t h e F D A.  T h e I n v esti g at or  m ust  als o  c o m pl y  wit h  all  a p pli c a bl e  pri v a c y r e g ul ati o ns ( e g ,  H e alt h I ns ur a n c e  P ort a bilit y 
a n d  A c c o u nt a bilit y  A ct  of  1 9 9 6,  E U  D at a  Pr ot e cti o n  Dir e cti v e  9 5/ 4 6/ E C).  
[ADDRESS_1117279] e m e nt e d 
wit h o ut  pri or  writt e n I R B/I E C  a p pr o v al  e x c e pt  as  n e c ess ar y t o  eli mi n at e i m m e di at e s af et y  h a z ar ds t o  s u bj e cts. A 
pr ot o c ol  a m e n d m e nt i nt e n d e d t o  eli mi n at e  a n  a p p ar e nt i m m e di at e  h a z ar d t o  s u bj e cts m a y  b e i m pl e m e nt e d 
i m m e di at el y,  pr o vi d e d t h e I R Bs  ar e  n otifi e d. 
1 8. 2   I nstit uti o n al  R e vi e w  B o a r ds  a n d  I n d e p e n d e nt  Et hi cs  C o m mitt e es 
T h e  pr ot o c ol  a n d  c o ns e nt  f or m  will  b e r e vi e w e d  a n d  a p pr o v e d  b y t h e I R B/I E C  of  e a c h  p arti ci p ati n g  c e nt er  pri or t o 
st u d y i niti ati o n. S eri o us  a d v ers e  e v e nts  will  b e r e p ort e d t o t h e I R B/I E C i n  a c c or d a n c e  wit h t h e st a n d ar d  o p er ati n g pr o c e d ur es  a n d  p oli ci es  of t h e I R B/I E C,  a n d t h e I n v esti g at or  will  k e e p t h e I R B/I E C i nf or m e d  as t o t h e  pr o gr ess  of 
t h e st u d y. T h e I n v esti g at or  will  o bt ai n  ass ur a n c e  of I R B/I E C  c o m pli a n c e  wit h r e g ul ati o ns.  
A n y  d o c u m e nt s t h at t h e I R B/I E C  m a y  n e e d t o f ulfill its r es p o nsi biliti es (s u c h  as  pr ot o c ol,  pr ot o c ol  a m e n d m e nts, 
I n v esti g at or’s  Br o c h ur e,  c o ns e nt f or ms, i nf or m ati o n  c o n c er ni n g s u bj e ct r e cr uit m e nt,  p a y m e nt  or  c o m p e ns ati o n 
pr o c e d ur es,  or  ot h er  p erti n e nt i nf or m ati o n)  will  b e s u b mitt e d t o t h e I R B/I E C.  T h e I R B/I E Cs  writt e n  a p pr o v al  of t h e 
st u d y  pr ot o c ol  a n d t h e i nf or m e d  c o ns e nt f or m  will  b e i n t h e  p oss essi o n  of t h e I n v esti g at or  b ef or e t h e st u d y i s i niti at e d. T h e I R B/I E Cs  a p pr o v al st at e m e nt  will  b e tr a ns mitt e d  b y t h e I n v esti g at or t o t h e  S p o ns or  or  d esi g n e e  pri or t o t h e s hi p m e nt  of st u d y s u p pli es t o t h e sit e. T his  a p pr o v al  m ust r ef er t o t h e st u d y  b y  e x a ct  pr ot o c ol titl e  a n d  n u m b er 
a n d s h o ul d i d e ntif y t h e  d o c u m e nt s r e vi e w e d  a n d t h e  d at e  of r e vi e w.  
Pr ot o c ol  a n d/ or i nf or m e d  c o ns e nt  m o difi c ati o ns  or  c h a n g es  m a y  n ot  b e i niti at e d  wit h o ut  pri or  writt e n I R B/I E C 
a p pr o v al  e x c e pt  w h e n  n e c ess ar y t o  eli mi n at e i m m e di at e  h a z ar ds t o t h e  s u bj e cts or  w h e n t h e  c h a n g e(s) i n v ol v es  o nl y l o gisti c al  or  a d mi nistr ati v e  as p e cts  of t h e st u d y. S u c h  m o difi c ati o ns  will  b e s u b mitt e d t o t h e I R B/I E C  a n d  writt e n 
v erifi c ati o n t h at t h e  m o difi c ati o n  w as s u b mitt e d  a n d s u bs e q u e ntl y  a p pr o v e d s h o ul d  b e  o bt ai n e d.   
S a v ar a  P h ar m a c e uti c al s   Pr ot o c ol  S A V 0 0 5 -0 4  
1 8- A P R - 2 0 1 8 C o nfi d e nti al  5 7 T h e I R B/I E C  m ust  b e i nf or m e d  of r e visi o ns t o  ot h er  d o c u m e nts  ori gi n all y s u b mitt e d f or r e vi e w; s eri o us  a n d/ or 
u n e x p e ct e d  a d v ers e  e x p eri e n c es  o c c urri n g  d uri n g t h e st u d y i n  a c c or d a n c e  wit h t h e st a n d ar d  o p er ati n g  pr o c e d ur es 
a n d  p oli ci es  of t h e I R B;  n e w i nf or m ati o n t h at  m a y  aff e ct  a d v ers el y t h e s af et y  of t h e  s u bj e ct s  of t h e  c o n d u ct  of t h e 
st u d y;  a n  a n n u al  u p d at e  a n d/ or r e q u est f or r e -a p pr o v al;  a n d  w h e n t h e st u d y  h as  b e e n  c o m pl et e d.  
[ADDRESS_1117280] s ( 2 1  C F R  5 0. 2 5[ a,  b],  C F R  5 0. 2 7,  a n d  C F R  P art  5 6,  S u b p art  A), t h e 
H e alt h I ns ur a n c e  P ort a bilit y  a n d  A c c o u nt a bilit y  A ct ( HI P A A, if  a p pli c a bl e),  a n d l o c al r e g ul ati o ns.  
T h e I n v esti g at or  will  pr e p ar e t h e i nf or m e d  c o ns e nt f or m,  ass e nt  a n d  HI P A A  a ut h ori z ati o n  a n d  pr o vi d e t h e 
d o c u m e nts t o t h e  S p o ns or  or  d esi g n e e f or  a p pr o v al  pri or t o s u b missi o n t o t h e I R B/I E C.  T h e  c o ns e nt f or m  g e n er at e d 
b y t h e I n v esti g at or  m ust  b e  a c c e pt a bl e t o t h e  S p o ns or  a n d  b e  a p pr o v e d  b y t h e I R B/I E C.  T h e  writt e n  c o ns e nt d o c u m e nt  will  e m b o d y t h e  el e m e nts  of i nf or m e d  c o ns e nt  as  d es cri b e d i n t h e I nt er n ati o n al  C o nf er e n c e  o n 
H ar m o ni z ati o n  a n d  will  als o  c o m pl y  wit h l o c al r e g ul ati o ns.  T h e I n v esti g at or  will s e n d  a n I R B/I E C -a p pr o v e d  c o p y 
of t h e I nf or m e d  C o ns e nt  F or m t o t h e  S p o ns or ( or  d esi g n e e) f or t h e st u d y fil e.  
A  pr o p erl y  e x e c ut e d,  writt e n, i nf or m e d  c o ns e nt  will  b e  o bt ai n e d fr o m  e a c h  s u bj e ct pri or t o  e nt eri n g t h e  s u bj e ct i nt o 
t h e tri al. I nf or m ati o n s h o ul d  b e  gi v e n i n  b ot h  or al  a n d  writt e n f or m  a n d s u bj e cts ( or t h eir l e g al r e pr es e nt ati v es)  m ust 
b e  gi v e n  a m pl e  o p p ort u nit y t o i n q uir e  a b o ut  d et ails  of t h e st u d y.  If  a p pr o pri at e  a n d r e q uir e d  b y t h e l o c al I R B/I E C, 
ass e nt fr o m t h e  s u bj e ct will  al s o  b e  o bt ai n e d.  If  a s u bj e ct is  u n a bl e t o si g n t h e i nf or m e d  c o ns e nt f or m (I C F)  a n d t h e 
HI P A A  a ut h ori z ati o n,  a l e g al r e pr es e nt ati v e  m a y si g n f or t h e  s u bj e ct.  A  c o p y  of t h e si g n e d  c o ns e nt f or m ( a n d 
ass e nt)  will  b e  gi v e n t o t h e  s u bj e ct or l e g al r e pr es e nt ati v e  of t h e  s u bj e ct a n d t h e  ori gi n al  will  b e  m ai nt ai n e d  wit h t h e 
s u bj e ct’s r e c or ds. 
[ADDRESS_1117281]  of  1 9 9 6.  
It is t h e  S p o ns or’s i nt e nt t o  e v e nt u all y  p u blis h t h e r es ults  of t his st u d y.  T h e  S p o ns or  will  s e p ar at el y  a gr e e  wit h t h e 
C o or di n ati n g I n v esti g at or  a n d t h e  P ri n ci p al I n v esti g at ors  o n  a  p u bli c ati o n  str at e g y,  w hi c h  will i n cl u d e t h e  n a m es  of t h e  a ut h ors  of t h e  p u bli c ati o n(s).  T h e  S p o ns or  m ust r e vi e w  a n d  a p pr o v e  a n y  m a n us cri pts  or  a bstr a cts  pr e p ar e d f or 
s u b missi o n t o s ci e ntifi c j o ur n als  or f or  pr of essi o n al  m e eti n g s.  D at a fr o m i n di vi d u al st u d y  c e nt ers s h all  n ot  b e 
p u blis h e d s e p ar at el y.  
1 8. 5   I n v esti g at o r  R es p o nsi biliti es  
B y si g ni n g t h e  A gr e e m e nt  of I n v esti g at or f or m, t h e I n v esti g at or  a gr e es t o:  
1.   C o n d u ct t h e st u d y i n  a c c or d a n c e  wit h t h e  pr ot o c ol  a n d  o nl y  m a k e  c h a n g es  aft er  n otif yi n g t h e  S p o ns or ( or 
d esi g n e e),  e x c e pt  w h e n t o  pr ot e ct t h e s af et y, ri g hts  or  w elf ar e  of s u bj e ct s.  
2.   P ers o n all y  c o n d u ct  or s u p er vi s e t h e st u d y ( or i n v esti g ati o n).  3.   E ns ur e t h at t h e r e q uir e m e nt s r el ati n g t o  o bt ai ni n g i nf or m e d  c o ns e nt  a n d I R B r e vi e w  a n d  a p pr o v al  m e et f e d er al 
g ui d eli n es,  as  st at e d i n  §  [ADDRESS_1117282] u d y, i n  a c c or d a n c e  wit h  § [ADDRESS_1117283] u d y  ar e i nf or m e d  a b o ut 
t h eir  o bli g ati o ns i n  m e eti n g t h e  a b o v e  c o m mit m e nts. 
6.   M ai nt ai n  a d e q u at e  a n d  a c c ur at e r e c or ds i n  a c c or d a n c e  wit h  § 2 1  C F R  3 1 2. 5 7  a n d t o  m a k e t h os e r e c or ds 
a v ail a bl e f or i ns p e cti o n  wit h t h e  S p o ns or ( or  d esi g n e e).  
7.   E ns ur e t h at  a n I R B t h at  c o m pli es  wit h t h e r e q uir e m e nt s  of  § [ADDRESS_1117284] u d y.  
8.   Pr o m ptl y r e p ort t o t h e I R B  a n d t h e  S p o ns or ( or  d esi g n e e)  all  c h a n g es i n t h e r es e ar c h  a cti vit y  a n d  al l 
u n a nti ci p at e d  pr o bl e ms i n v ol vi n g ris ks t o s u bj e ct s  or  ot h ers (t o i n cl u d e  a m e n d m e nts  a n d I N D s af et y r e p orts).  
9.   S e e k I R B  a p pr o v al  b ef or e  a n y  c h a n g es  ar e  m a d e i n t h e r es e ar c h st u d y,  e x c e pt  w h e n  n e c ess ar y t o  eli mi n at e 
h a z ar ds t o t h e  p ati e nts/s u bj e ct s.  
[ADDRESS_1117285] e d i n  §  [ADDRESS_1117286] a p h yl o c o c c us  a ur e us ( M R S A) i nf e cti o n i n  c ysti c fi br osis.  Mi all  L S,  M c Gi nl e y  N T, 
Br o w nl e e  K G,  C o n w a y  S P. s.l.  :  Ar c h  Dis  C hil d,  [ADDRESS_1117287] a p h yl o c o c c us  a ur e us  L u n g I nf e cti o n i n 
P ati e nts  wit h  C ysti c  Fi br osis.  Eli z ur  A,  Ors c h el n  R C,  F er k ol  T W,  et  al. s.l.  :  C h est,  [ADDRESS_1117288] a p h yl o c o c c us  a ur e us ( M R S A) 
c ol o ni ati o n i n  p ati e nts  wit h  C ysti c  Fi br osi s:  A si n gl e -c e nt er  c as e  c o ntr ol st u d y  of  [ADDRESS_1117289] 
E,  D e  M eirl eir  L,  V er b a n c k  S.  et  al. s.l.  : J  C ysti c  Fi br osis,  [ADDRESS_1117290]  M,  et.  al. s.l.  :  A m J  R es pir  Crit  C ar e  M e d,  [ADDRESS_1117291] a p h yl o c o c c us  a ur e us  a n d  S ur vi v al i n  C ysti c 
Fi br osis.  D a s e n br o o k  E C,  C h e c kl e y  W,  M erl o  C A,  et  al. s.l.  : J A M A,  [ADDRESS_1117292] a p h yl o c o c c us  a ur e us i nf e cti o n i n  c ysti c fi br osis.  Z o b ell 
J T,  E p ps  K L,  Y o u n g  D C,  M o nt a g u e  M,  Ols o n J,  A m p of o  K,  C hi n  MJ,  M ars h all  B C,  D as e n br o o k  E.  6, s.l.  : 
P e di atri c  P ul m o n ol o g y,  2 0 1 5,  V ol.  5 0,  p p.  5 5 2 – [ADDRESS_1117293] a p h yl o c o c c us  a ur e us (i n  J a p a n es e). 
S hir ai  M, I d e  K,  S at o  M,  T a n a k a  Y,  S at o  A,  C hi d a  K. s.l.  :  Ni h o n  K y o b u  S hi k k a n  G a k k ai  Z ass hi,  [ADDRESS_1117294] e mi c  d eli v er y  of  a nti bi oti cs:  c o m -p aris o n  of  v a n c o m y ci n  dis p ositi o n i n t h e is ol at e d r at 
l u n g. V all e,  MJ.,  L o p e z,  F G,  H url e,  A.,  a n d  N a v arr o,  A.  1 0, s.l.  :  A nti mi cr o b.  A g e nt s  C h e m ot h er. ,  2 0 0 7, 
V ol.  5 1,  p p.  3 7 7 1 -3 7 7 4.  
1 0.  P e n et r ati o n  of  v a n c o m y ci n i nt o  h u m a n l u n g tiss u e.  Cr u ci a ni  M,  G atti  G,  L a z z ari ni  L,  et  al. s.l.  : J 
A nti mi cr o b  C h e m ot h er,  1 9 9 6,  V ol.  3 8,  p p.  8 6 5 -8 6 9.  
1 1.  A n al ysis  of  v a n c o m y ci n  e ntr y i nt o  p ul m o n ar y li ni n g fl ui d  b y  br o n c h o al v e ol ar l a v a g e i n  criti c all y ill 
p ati e nts.  L a m er  C  et  al.  2, s.l.  :  A nti mi cr o b  A g e nts  C h e m ot h er,  1 9 9 3,  V ol.  3 7,  p p.  2 8 1-6.  
1 2.  I n h al e d  a nti mi cr o bi al t h er a p y –  B arri ers t o  eff e cti v e tr e at m e nt.  J.,  W e ers. s.l. :  A d v a n c e d  Dr u g  D eli v er y 
R e vi e ws,  [ADDRESS_1117295] e  v ol u m e 
( m L) N u m b e r  of  s a m pl es  Esti m at e d t ot al  v ol u m e 
( m L) 
C B C ( h e m at ol o g y)  3  9  2 7  
Bl o o d  C h e mistr y  2. 5  4  1 0  
S er u m  Pr e g n a n c y    4    5 *  [ADDRESS_1117296] e  6 1 6 
Esti m at e d  T ot al  ( m L)   
                                                                                      6 3  
*I n cl u d es  Bl o o d C h e mistr y  c oll e cti o n.  
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           6 2 A P P E N DI X   3.  C Y S TI C   FI B R O SI S    R E S PI R A T O R Y   S Y M P T O M    DI A R Y  ( C F R S D ©) 
S E L F - R E P O R T  – W E E K L Y  V E R SI O N  2 . 0 
( O nl y t h e first [ADDRESS_1117297] u d y t o  pr o vi d e t h e  C F R S D-
C RI S S .)  
 
 
  
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           6 3  
  
C y sti c  Fi br o si s  R e s pir at or y  
S y m pt o m  Di ar y  –  ( C F R S D ©) 
 
 
S elf- R e p ort  –  V er si o n  2. 0 
 
7- D a y  R e c all  
 
 
U ni v er sit y  Of  W a s hi n gt o n  
S e attl e  Q u alit y  of  Lif e  Gr o u p  a n d  D e p art m e nt  of  M e di ci n e  
 
 
 
  
 
 
 
 
 
 
 
 
©  U ni v er sit y  of  W a s hi n gt o n  
 
D o  n ot r e pr o d u c e  or  cir c ul at e  wit h o ut  p er mi s si o n  of  t h e  a ut h or s. 
 
T hi s  w or k  h a s  b e e n  s u p p ort e d  wit h  a  gr a nt fr o m t h e  C y sti c  Fi br o si s  
F o u n d ati o n  
 
   
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           6 4  
 
                     
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           6 5  
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           6 6  
 
 
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           6 7  
 
   
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           6 8  
 
 
  
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           6 9  
A P P E N DI X   4. C ysti c  Fi br osis  q u esti o n n air e  -  re vis e d  ( C F Q -R)  S elf - R e p ort  –  T w o  W e e k 
R e c all ;  v ersi o n  2 
  
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           7 0 T E E N/ A D U L T  V E R SI O N  F O R  A G E S  1 4  T H R O U G H  A D U L T H O O D  
 
 
 
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           7 1  
 
 
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           7 2  
 
  
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           7 3 P A R E N T  V E R SI O N  F O R  C HI L D R E N  A G E S  6 -1 3 ( P A R E N T S  R E P O R TI N G  O N  T H E 
C HI L D’ S  H R Q O L)  
 
 
 
 
  
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           7 4  
 
 
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           7 5  
 
   
 
   
 
   
  
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           7 6 A P P E N DI X   5.  E Q- 5 D-5 L  &  E Q- [ADDRESS_1117298] e as e r e a d t h e f oll o wi n g i nstr u cti o ns  c ar ef ull y t o l e ar n  h o w t o  us e  a n d  c ar e f or  y o ur 
A er o V a n c  i n h al er. 
•   O nl y  us e t h e  A er o V a n c i n h al er  pr o vi d e d.  D o  n ot  us e  A er o V a n c  or  Pl a c e b o 
c a ps ul es  w it h  a n y  ot h er i n h al er,  a n d  d o  n ot  us e t h e  A er o V a n c i n h al er t o t a k e 
a n y  ot h er  c a ps ul e  m e di ci n e.  
•   D o  n ot s w all o w t h e  c a ps ul es.   T h e  p o w d er i n t h e  c a ps ul es is f or  y o u t o i n h al e. 
T h e  A er o V a n c  i n h al er  e n a bl es  y o u t o i n h al e t h e  pr o d u ct  c o nt ai n e d i n  a n A er o V a n c  or Pl a c e b o  c a ps ul e.  
A er o V a n c  a n d  Pl a c e b o  c a ps ul es  ar e s u p pli e d i n  al u mi n u m f oil  p e el a bl e l a mi n at e d  blist ers . 
E a c h  blist er stri p   c o nt ai ns  [ADDRESS_1117299] art s h e et,  a n d  a r et ur ns  b a g  ar e i n cl u d e d i n  e a c h  2 8-d a y cli ni c al  kit.   
H o w t o  us e  y o u r i n h al e r  1.   P ull  off t h e  c a p.  2.    O p e n  t h e i n h al er: H ol d t h e  b as e  of t h e i n h al er fir ml y  a n d t wist t h e  m o ut h pi e c e i n t h e  dir e cti o n  of t h e  arr o w. 
T his  o p e ns t h e i n h al er.  
3.   Pr e p ar e  t h e  c a ps ul e: I m m e di at el y  b ef or e  us e,  wit h  dr y  h a n ds,  c ar ef ull y t e ar  a n d r e m o v e t h e  e n d  of t h e  blist er 
stri p.  P e el   o p e n t h e f oil  blist er fr o m  o n e  of t h e  h al v es  o nl y, t a ki n g  c ar e t o  o nl y  e x p os e  o n e of t h e t w o  c a ps ul es fr o m t h at  h alf.  R e m o v e  o n e  c a ps ul e.  D o  n ot  o p e n  b y  p us hi n g t h e c a ps ul e t hr o u g h t h e f oil si n c e t his  c a n  d a m a g e t h e  c a ps ul e.  
4.   I ns ert  t h e  c a ps ul e: 
Pl a c e t h e  c a ps ul e i nt o t h e  c a ps ul e  c h a m b er.  N e v e r  pl a c e  a  c a ps ul e  di r e ctl y i nt o t h e  m o ut h pi e c e.  5.  Cl os e t h e i n h al er:  Cl os e t h e i n h al er  u ntil  y o u  h e ar  a  “ cli c k ”.  6.  Pi [INVESTIGATOR_3694] c e t h e  c a ps ul e:  H ol d t h e i n h al er  u pri g ht  wit h t h e  m o ut h pi e c e  p oi nti n g  u p.  Pi [INVESTIGATOR_3694] c e t h e  c a ps ul e  b y fir ml y  pr essi n g t o g et h er  b ot h si d e  b utt o ns  at t h e s a m e ti m e.  D o t his 
o nl y  o n c e.  
Y o u s h o ul d  h e ar  a  “ cli c k ”  as t h e  c a ps ul e is  b ei n g  pi [INVESTIGATOR_3694] c e d.  
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V 0 0 5 -0 4  
 
1 8- A P R - 2 0 1 8                                                        C o nfi d e nti al                                                           7 9 7.  R el e as e t h e si d e  b utt o ns f ull y.  
8.  Br e at h e  o ut:  B ef or e  pl a ci n g t h e  m o ut h pi e c e i n  y o ur  m o ut h,  br e at h e  o ut f ull y. D o  n ot  bl o w i nt o t h e  m o ut h pi e c e. 9.  I n h al e t h e  m e di ci n e:  T o  br e at h e t h e  m e di ci n e  d e e pl y i nt o  y o ur  air w a ys:  
•   H ol d t h e i n h al er i n  a  h ori z o nt al  ori e nt ati o n.  T h e si d e  b utt o ns s h o ul d  b e f a ci n g 
l eft  a n d ri g ht.  D o  n ot  pr ess t h e si d e  b utt o ns. 
•   Pl a c e t h e   m o ut h pi e c e i n  y o ur  m o ut h  a n d  cl os e  y o ur li ps fir ml y  ar o u n d t h e 
m o ut h pi e c e.  
•   Br e at h e i n  q ui c kl y   a n d  d e e pl y. 
As  y o u  br e at h e i n t hr o u g h t h e i n h al er, t h e  c a ps ul e s pi [INVESTIGATOR_808346] o u n d i n t h e  c h a m b er  a n d  y o u 
s h o ul d  h e ar  a  w hirri n g  n ois e. If  y o u  d o  n ot  h e ar  a  w hirri n g  n o is e, th e  c a ps ul e  m a y  b e st u c k i n t h e  c a ps ul e  c h a m b er. If t his  h a p p e ns: 
•   O p e n t h e i n h al er  a n d  c ar ef ull y l o os e n t h e  c a ps ul e  b y t a p pi n g t h e  b as e  of t h e 
i n h al er.  Cl os e t h e i n h al er.  D o  n ot  pr ess t h e si d e  b utt o ns  a g ai n. 
•   I n h al e t h e  m e di ci n e  a g ai n  b y r e p e ati n g  St e ps  [ADDRESS_1117300] t h e s cr e e n  a n d  e nt er  y o ur 
m o ut h. If t his  h a p p e ns,  y o u  m a y  b e  a bl e t o f e el t h es e  pi e c es  o n  y o ur t o n g u e. It is  n ot h ar mf ul if t h es e  pi e c es  ar e s w all o w e d  or i n h al e d.  T h e  c h a n c es  of t h e  c a ps ul e s h att eri n g  will b e i n cr e as e d if t h e  c a ps ul e is  a c ci d e nt all y  pi [INVESTIGATOR_3694] c e d  m or e t h a n  o n c e ( St e p  6).  
1 0.  H ol d   y o ur br e at h:   Aft er  y o u  h a v e i n h al e d t h e  m e di ci n e:  
•   H ol d  y o ur  br e at h f or  at l e ast  5- 1 0 s e c o n ds  or  as l o n g  as  y o u  c o mf ort a bl y  c a n 
w hil e t a ki n g t h e i n h al er  o ut  of  y o ur  m o ut h. 
•   T h e n  br e at h e  o ut. 
•   O p e n t h e i n h al er t o s e e if  a n y  p o w d er is l eft i n t h e  c a ps ul e.  
If t h er e is  p o w d er l eft i n t h e  c a ps ul e: 
•   Cl os e t h e i n h al er. 
•   R e p e at  St e ps  8,  [ADDRESS_1117301] e  ar e  a bl e t o  e m pt y t h e  c a ps ul e  wit h  o n e  or t w o i n h al ati o ns.  
A d diti o n al i nf or m ati o n: S o m e  p e o pl e  m a y  o c c asi o n all y  c o u g h  bri efl y s o o n  aft er i n h ali n g t h e  m e di ci n e. If  y o u  d o, 
d o n’t  w orr y.  As l o n g  as t h e  c a ps ul e is  e m pt y,  y o u  h a v e r e c ei v e d  e n o u g h  of  y o ur  m e di ci n e. 
 
S a v ar a  P h ar m a c e uti c al s                  Pr ot o c ol  S A V [ADDRESS_1117302] u g: 
O p e n t h e  m o ut h pi e c e  a g ai n  a n d r e m o v e t h e  e m pt y  c a ps ul e  b y ti p pi n g it  o ut  of t h e  c a ps ul e 
c h a m b er.  P ut t h e  e m pt y  c a ps ul e i n t h e  pl asti c  w ast e  b a g  pr o vi d e d f or r et ur n t o t h e  cli ni c al sit e. 
R e p e at  St e ps  [ADDRESS_1117303] o r e t h e  c a ps ul es i n t h e  A e r o V a n c  i n h al e r.     R E M E M B E R:  
•   D o  n ot s w all o w  A er o V a n c  or  Pl a c e b o  c a ps ul es.  
•   O nl y  us e t h e  A er o V a n c i n h al er  pr o vi d e d. •   A er o V a n c  a n d  Pl a c e b o  c a ps ul es  m ust  al w a ys  b e st or e d i n t h e s e al e d f oil  blist er, 
a n d  o nl y r e m o v e d i m m e di at el y  b ef or e  us e.  
•   N e v er  pl a c e  a n  A er o V a n c  or  Pl a c e b o  c a ps ul e  dir e ctl y i nt o t h e  m o ut h pi e c e  of t h e 
A er o V a n c  i n h al er. 
•   D o  n ot  pr ess t h e si d e  b utt o ns  m or e t h a n  o n c e. •   N e v er  bl o w i nt o t h e  m o ut h pi e c e  of t h e  A er o V a n c i n h al er. 
•   Al w a ys r el e as e t h e  p us h  b utt o ns  b ef or e i n h al ati o n.  
•   D o  n ot  cl e a n t h e  A er o V a n c i n h al er. •   N e v er t a k e t h e  A er o V a n c  i n h al er  a p art. •   D o  n ot st or e t h e  c a ps ul es i n t h e  A er o V a n c  i n h al er. 
•   Al w a ys  k e e p t h e  A er o V a n c i n h al er  a n d  A er o V a n c  a n d  Pl a c e b o  c a ps ul es i n  a  dr y 
pl a c e.  
 